CXCR4 as a target for preclinical Positron Emission Tomography of cancer by Stevens, Elizabeth
1 
 
  
CXCR4 as a target for preclinical 
Positron Emission Tomography of 
cancer  
 
 
Elizabeth Stevens 
Supervised by Prof. Eric Aboagye 
 
 
Imperial College London 
Department of Surgery and Cancer 
 
 
A thesis submitted for the degree of Doctor of 
Philosophy at Imperial College London 
 
2 
 
Declaration 
 
I declare that the following report is my own work, and that the work of others is 
not included except where appropriately referenced. Other contributors to the 
work presented include Dr. Ola Åberg, Guillaume George, Dr. Federica 
Pisaneschi and Dr. Diana Brickute. Their precise contributions are specified 
within chapter two of this thesis.  
 
The copyright of this thesis rests with the author and is made available under a 
Creative Commons Attribution Non-Commercial No Derivatives licence. 
Researchers are free to copy, distribute or transmit the thesis on the condition 
that they attribute it, that they do not use it for commercial purposes and that 
they do not alter, transform or build upon it. For any reuse or redistribution, 
researchers must make clear to others the licence terms of this work. 
 
 
 
 
 
 
3 
 
Abstract 
 
The chemoattractive interactions of the chemokine stromal derived factor-1 (SDF1) 
and its receptor CXCR4 play a key role in tumour metastasis, with CXCR4 expression 
found to be significantly higher in cancers with aggressive phenotypes. There is 
therefore an impetus for non-invasive means to sensitively identify tumours prone to 
progression. As such, the aim of this work was to develop a number of novel CXCR4 
antagonists to assess their suitability as imaging radiotracers for positron emission 
tomography (PET).  
 
In this study, novel 14-mer peptide, pentapeptide and small molecular antagonists 
were designed, assessed for in vitro potency using radioligand binding and migration 
assays, and validated in vivo through imaging and biodistribution experiments.  
 
Several novel pentapeptide antagonists (CCIC7, CCIC15 and CCIC30) were found to 
inhibit CXCR4 function with moderate potency, although the radiolabelled tracers 
unfortunately showed poor localisation in vivo, due to rapid clearance or metabolism. 
Additionally, fluorophenylated derivatives of the small molecular antagonists It1t and 
AMD3465 were found to antagonise SDF1 binding and function at low concentrations, 
suggesting potential as CXCR4-targeting molecules. Finally, it was shown that a cation-
chelated NO2A-conjugate derivative of the 14mer peptide TN14003 could antagonise 
CXCR4 at low concentrations, and furthermore that CXCR4-expressing tumours could 
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be identified from non-expressing tumours by PET imaging with the use of a 68Ga-
labelled derivative in CXCR4-dependent manner. The tracer accumulated in CXCR4-
expressing tumours with a favourable signal-to-muscle ratio of 2.9, and was also found 
to show metabolic stability in plasma appropriate for PET imaging at 60 minutes.  
 
In conclusion, this study documents the successful validation of [68Ga]-CCIC16 for the 
identification of CXCR4-expressing tumours in vivo, and highlights several potential 
small molecular antagonist derivatives suitable for further investigation as PET tracers. 
While functionalisation of pentapeptide antagonists was generally unsuccessful, the 
report proposes further analysis and modifications that may potentially be used in 
future developments. 
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1.1 - Preamble 
 
Despite decades of intensive research, cancer is still one the most common 
causes of death in developed nations, responsible for an estimated 25% of 
mortality in Britain (Office for National Statistics, 2008). With decades of fervent 
research from countless institutions, significant advances have been made in our 
understanding of the complex and diverse molecular biology of myriad cancer 
types (Cianfrocca and Gradishar, 2009, Curtis et al., 2012, Leary and Olson, 2012, 
Sjodahl et al., 2012), and the many successive steps that must take place before 
the cancer phenotype arises (Hanahan and Weinberg, 2011). As a result of this 
huge complexity, it has become clear that the much-hoped-for ‘magic bullet’ for 
cancer will likely never be found, thus directing a shift in recent years towards 
personalised medicine, where therapies are tailored to the individual 
requirements of  patients and are therefore hoped to enable better-informed 
decisions regarding the potential fates of cancer sufferers (De Palma and 
Hanahan, 2012).  
 
This transition towards individualisation of cancer therapy involves research on 
many fronts, beginning with the identification of biomarkers that can be used to 
determine the aggressiveness of the cancer or to predict response to therapy, 
reducing the reliance on the anatomical tumour-node-metastasis (TNM) staging 
criteria. Biomarkers may take many forms, including gene expression within the 
tumour, circulating blood or urine, and abnormal phenotypes identified by 
24 
 
immunohistochemistry (Ludwig and Weinstein, 2005). A continual challenge 
faced in the personalised medicine approach is the currently limited ability of 
oncologists to interpret biomarker profiles correctly and give accurate advice or 
treatment to patients.  Despite the identification of a number of potential 
biomarkers in research, few have been translated to the clinic as a result of 
unreliability of the conclusions drawn, and high costs of biomarker tests 
(Thariani et al., 2012).  
 
A promising approach to enable the further development of novel biomarkers 
pertains to the field of molecular imaging, whereby molecular targets associated 
with cancer are utilised through contrast agents or radiotracers to visualise 
tumours in vivo (Mankoff, 2008). An advantage of molecular imaging approaches 
over commonly used biopsy tests is the non-invasive nature of imaging, which 
can allow repeated assessments over time, potentially allowing response to 
therapy to be determined. Furthermore, molecular imaging methods would 
allow oncologists the ability to determine the heterogeneity of biomarker 
expression within the tumour, which may influence therapeutic decisions. This 
introduction outlines the role of CXCR4, a chemokine receptor and emerging 
biomarker in cancer. In addition, the recent research developing potent 
antagonists to CXCR4 for their potential as therapeutic or imaging agents is also 
described, followed by the synopsis for this project in the development and 
validation of CXCR4-targeting radiotracers for positron emission tomography of 
tumours. 
25 
 
1.2 - Chemokines, chemokine receptors and CXCR4 
 
Chemokines are a family of secreted protein cytokines that are characterised by 
their ability to induce directed migration known as chemotaxis in responsive 
cells as a result of their recognition at cell surface receptors. CXCR4 is just one of 
over twenty known different chemokine receptors (Murphy, 2002), a class of G-
protein coupled receptors (GPCRs). These chemokines are categorised according 
to the positioning of conserved cysteine residues of the amino terminus, and are 
so designated C, CC, CXC, and CX3C ligands (Zlotnik and Yoshie, 2000). The CXC 
class of chemokines that contains CXCR4, the subject of this project, are split 
into two groups, ELR+ and ELR- depending on the presence or absence of a 
glutamate-leucine-arginine domain. A chemokine’s possession of the ELR 
domain is biologically relevant, as its presence denotes the angiogenic 
properties of the chemokine’s signalling pathways, whereas its absence 
indicates its role in homeostasis (Strieter et al., 1995). Stromal cell-derived factor 
1 (SDF1, also known as CXCL12), the ligand to CXCR4, is unusual among the CXC-
class chemokines in that it is angiogenic, yet it does not possess the 
characteristic ELR domain of most angiogenic CXC chemokines (Liang et al., 
2007a). 
 
The downstream physiological effects of chemokine receptor binding are 
numerous as a result of influence by many different cell signalling pathways. 
Many chemokines are considered to be ‘promiscuous’, as they usually bind with 
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more than one receptor, and, likewise, most chemokine receptors induce signal 
transduction in response to binding by a number of different ligands. This 
functional redundancy is considered a strategy to maintain normal cellular 
processes if a particular chemokine is defective, although the cellular responses 
to ligand binding can also be fine-tuned to exert minor differences in biological 
activity (Devalaraja and Richmond, 1999). In contrast, CXCR4 is notable for its 
near-monogamous relationship with its primary ligand, SDF1. Despite this, in 
recent years SDF1 has been shown to also bind with the CXCR7 receptor 
(Balabanian et al., 2005a). In addition, the ligands macrophage migration 
inhibitory factor (MIF1) and trefoil factor family 2 (TFF2), are capable of inducing 
CXCR4-dependent responses in cells (Bernhagen et al., 2007, Schwartz et al., 
2009, Dubeykovskaya et al., 2009). 
 
Signal transduction in the CXCR4-CXCL12 pathway is complex, and is largely 
dependent on homodimerisation with other CXCR4 receptors for signal 
transduction processes, including the Gαi-mediated JAK/STAT pathway (Vila-
Coro et al., 1999). Liberated Gβγ subunits may then activate other pathways 
involving phospholipase C (PLC) or phosphatidylinositide 3-kinase (PI3K), whilst 
the interaction of β-arrestin with the CXCR4 receptor (a key step in 
desensitisation by receptor internalisation) has been found to influence 
chemotaxis via p38 mitogen-activated protein kinase (MAPK) pathways (Sotsios 
et al., 1999, Sun et al., 2002). These pathways appear to be regulated by the 
process of receptor heterodimerisation, which can inhibit downstream 
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signalling. For example, dimerisation with CXCR7, the alternative CXCL12-binding 
receptor, has been found to impair CXCR4-mediated signalling mechanisms. It is 
thought that the coexpression of these receptors on cells may provide a 
mechanism for the regulation of chemotaxis (Levoye et al., 2009). A simplified 
diagram of CXCR4 dependent cell signalling pathways and biological processes is 
shown in figure 1.  
 
Figure 1. Signalling pathways of CXCR4. Adapted from (Wong and Korz, 2008) 
AC (adenylyl cyclase); AKT (protein kinase B);BAD (B-cell lymphoma-2 associated death 
promoter); cAMP (cyclic adenosine monophosphate); GDP (guanosine diphosphate); IP3 (inositol 
triphosphate); MAPK (mitogen-activated protein kinase); NFκB (nuclear factor kappa-light-chain-
enhancer of activated B cells); pERK (phospho-extracellular signal-regulated kinase); PI3K 
(phosphatidylinositide-3 kinase); PIP2 (phosphatidylinositol 4,5-bisphosphate); PKC (protein 
kinase C); PLC (phospholipase C); Src (proto-oncogene tyrosine protein kinase Src) 
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1.3 - CXCR4 in health and disease 
 
The importance of CXCR4 signalling is apparent at the earliest possible stage of 
life - conception. Recent research has demonstrated that the activation of CXCR4 
receptors present in the head of spermatozoa by SDF1 results in intracellular 
calcium increases and increased motility, which are suggested to enable sperm 
chemotaxis towards SDF1-expressing oocytes (Zuccarello et al., 2011). 
Furthermore, conceptus expression of both SDF1 and CXCR4 has been shown to 
be increased in the early pregnancies of ewes, with higher endometrial 
expression of CXCR4 at day 15 of pregnancy as compared to day 15 of the 
oestrus cycle. It is suggested that the upregulation of CXCR4 and SDF1 in early 
pregnancy may be related to an adhesive role in implantation (Ashley et al., 
2011).  
 
The role of CXCR4 signalling is also of critical importance during embryogenesis 
in mice, as knockout of either the receptor or its ligand results in a lethal 
phenotype by E18.5, with vascular, gastrointestinal or cerebellar irregularities 
(Tachibana et al., 1998, Zou et al., 1998). Furthermore, CXCR4 signalling appears 
to direct the migration of primordial germ cells (PGCs) in embryogenesis, as they 
follow a trail of SDF1 production from the production site towards the gonads, 
with a marked reduction in PGCs present in the gonads of CXCR4 null zebrafish 
and mice (Doitsidou et al., 2002, Ara et al., 2003). The severe effects of knockout 
upon embryonic development are likely due to the relatively monogamous 
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nature of SDF1-CXCR4 signalling - the lack of alternative ligands that may signal 
through CXCR4 prevent other chemokines from fulfilling the role during 
embryogenesis.  
 
In adults, CXCR4 expression is most noted for its role in the regulation of 
inflammation in various cells of the immune system. CXCR4 signalling plays both 
a homeostatic and an inflammatory role, as it is capable of reducing blood 
counts of immunocytes as well as directing their migration towards sites of 
injury. For example, neutrophils, natural killer lymphocytes and monocytes are 
retained within bone marrow until required by the presence of a chemokine 
gradient of SDF1, which is recognised by CXCR4 receptors expressed on the cell 
surface. This interaction promotes a strong chemotactic response towards the 
site of the SDF1 release at bone marrow stromal cells, ensuring retention (Beider 
et al., 2003, Wang et al., 2009, Eash et al., 2009).  
 
However, in order for the various haematopoietic cells to form an inflammatory 
response, the cells must be released from the bone marrow microenvironment; 
this is achieved through the antagonistic effects of the signalling of another 
chemokine receptor, CXCR2. This assertion is supported by the finding that the 
mobilisation of neutrophils by ligands to CXCR2 could be increased in a 
synergistic fashion by incubation with low concentrations of CXCR4 antagonist 
(Suratt et al., 2004). Furthermore, CXCR2 null neutrophils do not show the 
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normal mobilisation response expected upon application of CXCR4 inhibitors, 
whilst CXCR4 and CXCR2 double knockout neutrophils are constitutively 
mobilised (Eash et al., 2010). This CXCR2 expression reduces as neutrophils 
mature, providing a mechanism for the sequestration of senescent circulating 
neutrophils back in the bone marrow (Martin et al., 2003). The CXCR2-directed 
mobilisation response appears to be mediated by p38 MAPK as inhibitors to p38 
were able to prevent CXCR2-mediated mobilisation (Burdon et al., 2008).  
 
Signalling by CXCR2 is not the only mechanism by which CXCR4-induced 
neutrophil retention is overcome, as granulocyte colony-stimulating factor 
(GCSF) is also a major mediator of neutrophil mobilisation. It has been shown 
that GCSF (whose receptor, GCSFR, is expressed on neutrophils) can reduce SDF1 
expression by bone marrow stromal cells as well as CXCR4 expression on 
neutrophils, indirectly causing neutrophil mobilisation (Kim et al., 2006). 
Furthermore, the presence of GCSF has also been shown to promote the 
expression of the serine proteases capthepsin G and neutrophil elastase, as well 
as matrix metalloprotease-9 (MMP9) which together cause the degradation of 
SDF1 and other molecules with adhesive qualities, such as vascular cell adhesion 
protein-1 (VCAM1) (Levesque et al., 2004). This antagonism of CXCR4 action by 
CXCR2 and GCSFR signalling is an effective mechanism for the regulation of 
neutrophilia. 
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Once mobilised, chemotactic signalling on neutrophils and other immunocytes 
enables their migration towards the site of injury and disease to take part in the 
inflammatory response. This inflammation response to injury can become severe 
and uncontrolled, as is the case for acute lung injury (ALI), resulting in morbidity 
and death. As ALI progresses, there is an increase both in SDF1 expression at the 
lung epithelium, as well as in CXCR4 expression of neutrophils, whereas late-
stage neutrophilia in ALI can also be abrogated by SDF1 inhibition (Petty et al., 
2007). CXCR4 has also been indicated in the disease mechanism of the 
autoimmune disorder rheumatoid arthritis (RA), as SDF1 expression has been 
documented at the synovium of RA patients, and is considered responsible for 
the accumulation of CD4+ T cells that are associated with the disorder (Nanki et 
al., 2000). Accordingly, inhibition of CXCR4 signalling by antagonists was capable 
of reducing both hypersensitivity and inflammation in mouse models of RA 
(Tamamura et al., 2004). CXCR4 has also been linked to the activation of 
basophils and subsequent histamine release, suggesting a role in the allergic 
inflammatory response (Jinquan et al., 2000).  
 
Allergic response as a result of CXCR4 signalling appears to arise on several 
fronts, as CXCR4-mediated chemotaxis has been shown to direct the migration 
of antigen-presenting dendritic cells to the lymph nodes, with CXCR4 inhibition 
reducing in vivo contact hypersensitivity (Kabashima et al., 2007). CXCR4-
directed chemotaxis has likewise been determined to contribute to a number of 
autoimmune disorders, including ulcerative colitis, multiple sclerosis (MS) and 
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autoimmune encephalomyelitis (Kohler et al., 2008, McCandless et al., 2008, Xia 
et al., 2011).  
 
The overactivity of the CXCR4/SDF1 signalling axis in immune disorders may also 
have a genetic basis, as is the case of Warts, Hypogammaglobulinemia, 
Infections and Myelokathexis (WHIM) syndrome (Hernandez et al., 2003). As the 
name implies, sufferers show a range of clinical symptoms including a reduction 
in gamma globulins such as antibodies (hypogammaglobulinemia), increased 
susceptibility to a range of infections (particularly wart-causing human 
papillomavirus infections; HPV), and a reduction in circulating leukocyte and 
neutrophil numbers as a result of increased retention at the bone marrow 
(myelokathexis). The most common WHIM-associated autosomal dominant 
mutations result in truncation of the C-terminus of CXCR4, resulting in increased 
chemoattraction between SDF1 and CXCR4 and thus increased leukocyte 
retention (Gulino et al., 2004, Hernandez et al., 2003, Balabanian et al., 2005b, 
Kawai and Malech, 2009). Knowledge of the regulation mechanisms of CXCR4 
have been instrumental in the treatment of WHIM, as therapy options include 
treatment with GCSF (Hord et al., 1997), increases neutrophil counts through 
the antagonism of CXCR4 signalling mechanisms as previously described. 
Antagonists to CXCR4 have also been shown to reduce myelokathexis in clinical 
experiments (McDermott et al., 2011, Dale et al., 2011).  
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Whilst CXCR4 is notable for role in immunocyte retention and inflammation 
responses, the receptor itself was discovered in relation to its role in human 
immunodeficiency virus (HIV) infection of cluster of differentiation 4-positive 
(CD4+) immunocytes (Feng et al., 1996). Binding of the HIV virus to CD4 upon 
the cell surface is achieved via the HIV envelope proteins gp120 and gp41, 
although the virus is not able to fuse with the membrane until the envelope 
proteins are bound to a co-receptor, which allows a conformational change in 
gp41 to bring the viral and cellular membranes in closer proximity (Salzwedel 
and Berger, 2000). There are two main co-receptors which lead to this outcome: 
CCR5 and CXCR4, the identity of which determines the type of cell that is 
infected. CCR5-mediated HIV infects macrophages (M-tropic), whilst CXCR4 
results in T cell infection (T-tropic). It is theorised that a shift in later stages of 
the disease may involve a shift from M-tropic to T-tropic infection (Rosen et al., 
2006), so CXCR4 antagonism is a prime target for therapies attempting to halt 
progression of the disease. Concordantly, treatment with antagonists to CXCR4 
has been found to inhibit infection of T cells in vitro and with in vivo models of 
the disease (Pettersson et al., 2010, Murakami et al., 2009b).  
 
Despite appearances, the physiological role of CXCR4 is not limited to the 
chemotaxis of immunocytes, as other cell types can migrate towards SDF1 
expressing tissue in the process of injury repair. For example, CXCR4 expression 
on bone marrow mesenchymal stem cells (BMSCs) has been linked to 
differentiation to endothelial cell phenotypes which could migrate to the site of 
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vascular lesions to promote neovascularisation and hence wound repair (Li et al., 
2010b). Furthermore, both SDF1 and CXCR4 expression have been shown to 
become increased in hypoxic conditions, through downstream signalling effects 
of hypoxia-inducible factor 1 (HIF1) (Schioppa et al., 2003), enabling increased 
expression at sites of ischaemia and subsequent recruitment of progenitor cells 
for tissue regeneration (Ceradini et al., 2004).  
 
CXCR4 now represents an intriguing target for ischaemia research as 
transplantation of mesenchymal stem cells (MSCs) bearing increased CXCR4 
expression show superior migratory, angiogenic and neuroprotective qualities in 
animal models of stroke (Yu et al., 2012).  The multipotent natures of MSCs 
enables differentiation into multiple cell types and so are implicated in wound 
healing of multiple tissues. For example, the formation of new bone by MSCs in 
models of skeletal fracture could be inhibited by CXCR4 antagonists or in models 
expressing lower levels of SDF1 or CXCR4 (Kitaori et al., 2009). Furthermore, the 
involvement of the SDF1/CXCR4 signalling axis in stem cell populations is not 
limited to MSCs, as CXCR4 expression has been positively identified on a number 
of committed progenitor populations in the bone marrow, including those 
destined for neural, hepatic and muscle progenitor fates, and could migrate 
towards SDF1 by chemotaxis (Ratajczak et al., 2004).  
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As has been described, CXCR4 signalling plays a significant role in inflammation 
and wound healing, and is implicated in the disease mechanism of a variety of 
disorders. However, the role of CXCR4 in one disease has been conspicuously 
absent from this literature review - cancer, which will now be described in detail.  
 
1.4 - CXCR4 and cancer 
 
Whilst CXCR4 has been known for its role as a coreceptor in HIV virus entry to 
CD4+ cells since 1996 (Feng et al., 1996), its potential role in cancer was not 
discovered until 1998, when CXCR4 was found to be overexpressed in a number 
of glioblastoma cell lines and tissues (Sehgal et al., 1998). Since this discovery, 
CXCR4 overexpression has been positively identified in numerous cancer types, 
including breast, ovarian, prostate, melanoma, oesophageal, lung, bladder, 
colorectal cancers, as well as osteosarcomas, leukaemias and neuroblastomas, 
with expression often correlated with metastatic spread and the worst 
prognoses (Schmid et al., 2004, Jiang et al., 2006, Sun et al., 2003, Scala et al., 
2006, Sasaki et al., 2008, Phillips et al., 2003, Eisenhardt et al., 2005, Kim et al., 
2005, Laverdiere et al., 2005, Barretina et al., 2003, Russell et al., 2004).  
 
In addition, SDF1 is highly expressed in common sites of breast cancer and 
melanoma metastasis, suggesting a role of the chemokine in cancer progression 
(Muller et al., 2001). Malignant tumour cells can respond to this chemokine 
gradient to home in on and infiltrate distant ligand-secreting organs in much the 
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same manner as normal leukocyte migration to injured tissues. This mechanism 
is supported by numerous studies investigating the ability of cancer cell lines to 
migrate through matrigel-type barriers and adhere to epithelial cells, with the 
effect blocked by administration of CXCR4 antagonists (Libura et al., 2002, 
Scotton et al., 2002).  
 
In addition, it has been found that cells isolated from metastatic tumours 
express higher quantities of CXCR4 than cells derived from primary tumours 
(Marchesi et al., 2004, Nimmagadda et al., 2010). Furthermore, the inhibition of 
CXCR4 action by RNA interference (RNAi) knockdown, antibodies or antagonists 
were able to significantly reduce the number of lung metastases in animal 
models (Ma et al., 2009, Liang et al., 2007b, Liang et al., 2005, Smith et al., 2004, 
Liang et al., 2004, Yoon et al., 2007, Darash-Yahana et al., 2004), whereas 
overexpression of the receptor is able to increase metastasis burden (Bartolome 
et al., 2009). Thus the role of CXCR4 in metastasis and disease progression is 
well-characterised.  
 
Interestingly, SDF1-induced transendothelial migration (TEM) could also be 
almost completely abolished by the administration of an antibody to the matrix 
metalloprotease MMP9 to cultured leukaemia cells, suggesting the role of the 
enzyme in invasion processes of CXCR4. It was found that MMP9 expression was 
upregulated in these cells according to the activation of the ERK pathway by 
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SDF1/CXCR4 signalling, and that inhibition of MMP9 could significantly impair 
SDF1 mediated migration (Redondo-Munoz et al., 2006, Tang et al., 2008a). The 
expression of CXCR4 has been found to be linked to the expression of a number 
of MMP enzymes including MMP2 and MMP13 (Pan et al., 2013, Yu et al., 2011), 
with their expression playing a role in SDF1-induced migration and invasion. 
Proteolytic enzymes such as MMPs are vital to the invasive activity of cancer as 
they are required to degrade the vascular basement membrane and 
extracellular matrix of tissues. This role for MMP enzymes following SDF1-CXCR4 
signalling is supported by a study which showed that membrane-bound MMP 
was required for dissemination of tumour cells into metastatic sites, following 
initial homing by CXCR4-mediated pathways (Bartolome et al., 2009).  
 
Aside from CXCR4’s clear role in metastatic spread, a number of other key 
findings indicate that CXCR4 signalling is integral to maintaining a pro-tumour 
environment. Firstly, increased CXCR4 expression has been linked to enhanced 
vascularisation of tumours (Darash-Yahana et al., 2004). A number of 
mechanisms have been suggested for this effect, notably the CXCR4-mediated 
release of vascular endothelial growth factor (VEGF), an angiogenic growth 
factor, which itself induces CXCR4 expression in a positive feedback loop that 
serves to ensure the tumour is well-supplied with oxygen and other nutrients, as 
well as to promote invasion of the surrounding tissues (Bachelder et al., 2002). 
In addition to this, there is evidence for VEGF-independent means of 
angiogenesis promotion (Guleng et al., 2005), such as the downregulation of the 
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glycolytic enzyme phosphoglycerate kinase 1 (PGK1), which ordinarily cleaves 
extracellular plasminogen to produce the angiogenesis inhibitor protein, 
angiostatin. A reduction in PGK1 expression therefore allows angiogenesis to 
occur, supporting the growth of the metastatic tumour (Wang et al., 2007).  
 
CXCR4 has also been found to promote the cell proliferation in some cancers 
when cultured in suboptimal serum-free conditions (Scotton et al., 2002, Scala 
et al., 2006, Sun et al., 2003). The mechanism of this is largely unknown, but the 
effect is thought to promote tumour survival and metastasis to less favourable 
sites. CXCR4 expression can also be induced in conditions of hypoxia, which is 
common to tumours as a result of the inability of angiogenic tumour perfusion 
to keep up with the rate of tumour growth. CXCR4 expression is induced by 
signalling mechanisms of hypoxia-inducible factor-1α (HIF1α), which is 
upregulated in response to hypoxia; HIF1α has been found to bind at the 
hypoxia response element in the CXCR4 promoter (Schioppa et al., 2003). This 
may help to promote tumour survival in large tumours through the induction of 
angiogenic processes, or to promote the development of a cancer cell 
phenotype that is better able to escape to more favourable sites by metastasis 
(Hongo et al., 2013). 
 
One major factor in the effects of CXCR4 downstream signalling is the function 
of nuclear factor kappa-light-chain-enhancer-of-activated-B-cells (NFĸB), a 
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transcription factor that ordinarily binds at DNA to promote the expression of 
genes involved in cell survival, proliferation and differentiation, but which can 
also enable the exploitation of these processes when misregulated in cancer 
cells (Zubair and Frieri, 2013). There is evidence to suggest that the signalling 
processes between SDF1 and CXCR4 can result in the activation of NFĸB, 
resulting in the expression of genes associated with cancer and its progression 
(Singh et al., 2012, Rehman and Wang, 2009). Furthermore, there are also 
suggestions that NFĸB activation itself induces increases in CXCR4 expression 
(Maroni et al., 2007, Miyanishi et al., 2010), giving cause to believe that the 
NFĸB/CXCR4 signalling axis could potentially use positive feedback to generate a 
conducive environment to cancer cell survival.   
 
Another mechanism through which CXCR4-dependent signalling pathways 
maintain a cancer-promoting microenvironment is through the induction of 
immunoglobulin transcription factor 2 (ITF2) expression (Appaiah et al., 2010). 
ITF2 has been shown to promote the transformation of neoplasms (Kolligs et al., 
2002), and its expression is thereby correlated with poor diagnoses (Appaiah et 
al., 2010). Furthermore, ITF2 acted in tandem with CXCR4 to reduce the 
expression levels of ID2, a member of the inhibitor-of-differentiation (ID) family 
of transcription factors which is not favourably associated with positive patient 
outcomes. It was found that ITF2 expression in CXCR4-expressing tumours 
significantly increased the tumour growth rate, and that inhibition of ITF2-
mediated signalling could reduce the invasiveness of CXCR4-expressing cancer 
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cells. This evidence points to the role of ITF2 as an important downstream target 
of CXCR4 that promotes tumour survival and progression.   
 
An alternative mechanism for the upregulation of CXCR4 in metastatic disease 
involves the presence of additional cell types within the tumour, which promote 
transition of the cancer cells to a more metastatic phenotype through the 
upregulation of CXCR4. There is evidence to suggest that these cells may arise 
either from the infiltration of bone marrow-derived mesenchymal stem cells 
(MSCs) or from fibroblasts residing nearby to secrete factors including SDF1, 
tumour-growth factor β (TGFβ) and SDF1 to promote progression of the 
fibroblasts into the tumour-promoting cancer-associated fibroblast (CAF) 
phenotype. The tumour-promoting ability of CAFs is brought about by their 
expression of high levels of SDF1, which both promotes survival of the tumour 
cells and induces CXCR4 expression in tumour cells to give rise to the more 
metastatic mesenchymal phenotype (Kojima et al., 2010, Jung et al., 2013).  
 
There is evidence to suggest that the induction of CXCR4 expression in tumour 
cells can occur as a result of a process known as cell fusion - where over-ploid 
hybrid cells are created that stably bear the characteristics of co-cultured stem 
cells (Terada et al., 2002). Compelling evidence comes from the observation that 
tumour cells could undergo cell fusion with infiltrating haematopoietic cells to 
give rise to hybrid lines that expressed haematopoietic markers including CXCR4. 
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Furthermore, this fused population was more responsive to the presence of an 
SDF1 concentration gradient in migration assays (Ramakrishnan et al., 2013), 
The induction of CXCR4 signalling processes in the progression of the disease can 
therefore occur through variety of different mechanisms (summarised in figure 
2), highlighting the complexity of the challenge faced by researchers. 
 
One particularly interesting and clinically relevant effect of CXCR4 signalling is its 
proposed role in resistance to therapy; a number of published studies have 
noted that SDF1 and/or CXCR4 expression can be increased following treatment 
with radiotherapy, chemotherapy or anti-angiogenic therapy (Shaked et al., 
2008, Ebos et al., 2007, Arora et al., 2013), with evidence that this increase in 
expression is linked to poor prognosis in clinical settings (Xu et al., 2009, Zhu et 
al., 2009, Li et al., 2013). Furthermore, blockade of the SDF1-CXCR4 signalling 
axis can overcome resistance, often in a synergistic manner with conventional 
treatment (Singh et al., 2010, Murakami et al., 2009a, Kioi et al., 2010). The 
mechanisms involved in CXCR4-mediated resistance appear to be a combination 
of increased expression of survival proteins (such as nuclear factor kappa-light-
chain-enhancer of activated B cells (NFκB) and β-catenin), and the induction of 
metastatic and angiogenic processes. As a result, it has been suggested that anti-
CXCR4 therapy could be used in combination as a sensitizer to treatment, 
increasing the effectiveness of the chemotherapy (Duda et al., 2011). As a result 
of these collective findings regarding both the function of CXCR4 signalling in 
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cancer and its role in therapy resistance, CXCR4 is now an attractive emerging 
therapeutic target. 
 
 
Figure 2. Roles of CXCR4 expression in disease progression. 
 Hypoxia in tumour promotes expression of HIF1α, which in turn upregulates CXCR4.  
 The tumour is infiltrated by haematopoietic cells, which undergo cell fusion with the resident 
tumour cells to give rise to hybrid cells bearing characteristics of both cell types - including 
CXCR4 expression. 
 Fibroblasts near tumours overexpress SDF1 which acts in a paracrine manner upon tumour 
cells to promote increased CXCR4 expression. 
 Tumour cells bearing increased CXCR4 expression show greater metastatic potential, due to 
their ability to migrate towards SDF1-secreting organs. 
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1.5 - Approaches to CXCR4 antagonism 
 
In recent years there has been considerable interest in the use of antagonist 
molecules against CXCR4 activity as therapeutic strategies. The antagonists so far 
described chiefly fall into one of two broad groups: the peptide antagonists and 
small molecular antagonists. Peptide antagonists are derived from the horseshoe 
crab self-defence proteins tachyplesin and polyphemusin, first identified by 
screening for peptides active against HIV (Nakashima et al., 1992). Of the 
synthesised peptides originating from this screening, peptide T140 (figure 3A) 
was the most active against CXCR4, and is commonly used as a template to 
design more active and stable derivatives (Tamamura et al., 1998). For example, 
amidation at the C-terminus of T140 has yielded analogues such as TN14003, 
which bears markedly increased stability in serum in vivo. However, this 
increased stability came at the price of cytotoxicity as a result of increased net 
charge of the compound, which is less desirable for certain applications (e.g. as 
an inhibitor of HIV entry). It was found that substitution of charged amino 
residues such as arginine or lysine for neutral L-citrulline could temper this 
cytotoxicity to yield antagonists of high potency and stability, with reduced 
cytotoxiciy, such as the derivative TC14012 (Tamamura et al., 2001).  
 
In a study exploring the substitution of the individual amino acid residues that 
comprise T140, it was found that the L-3-(2-Naphthyl)alanine at position 3  is 
indispensible to receptor function, whilst the residues Arginine-2, Tyrosine-5 and 
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Arginine-14 are vital to conserve the structure-activity relationship (SAR) of the 
antagonist (Tamamura et al., 2002).  The identification of this 4-residue 
pharmacophore has led to the development of T140-derived tetra- and penta-
peptide antagonists, which show potencies to CXCR4 comparable to that of T140, 
at a much reduced size, and a reduction in undesirable peptide-specific effects, 
such as reduced bioavailability due to systemic metabolism (Tamamura et al., 
2005a).  
 
The same group also conducted an extensive investigation of the structure-
activity relationships of pentapeptide antagonists through sequential 
modification of the amino side chains and chirality (Fujii et al., 2003, Tanaka et 
al., 2009, Tamamura et al., 2005b, Ueda et al., 2007). Optimisation of the 
pentapeptide FC131 (cyclo[D-Tyr1-Arg2-Arg3-Nal4-Gly5], figure 3B) in this way 
enabled the identification of the residues that are most necessary to retain 
CXCR4 antagonism. For example, Arginine-3 must not be substituted for any 
residue that is not basic, whereas modification of Arginine-2 to include aromatic 
or methyl groups was well-tolerated. This process led to the development of the 
more potent pentapeptide compound FC122. Other modifications to the FC131 
structure included substitution of the carbonyl (C=O) group of the peptide bond 
with an imino (C=NH) group, resulting in a much improved bioactivity of the 
pentapeptide analogues (Inokuchi et al., 2011).  
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Figure 3. T140, the identification of the pharmacophore, and the pentapeptide FC131. 
A Simplified structure of T140 14-mer peptide, grey circles denote pharmacophore amino acids. 
B Structure of cyclic pentapeptide FC131.  Arg (Arginine); Nal (2-Naphthyl)alanine; Cys 
(Cysteine); Tyr (Tyrosine); Lys (Lysine); Pro (Proline); Cit (Citrulline). 
 
Whilst the peptide antagonists described above show a great potency for CXCR4 
(in terms of affinity and/or antagonism of downstream signalling), peptides are 
disadvantageously marked by the fact that they tend to show a poor 
bioavailability as a result of their vulnerability to enzymatic digestion, and 
therefore need special drug delivery systems in place (Craik et al., 2013). The 
structure-activity relationship studies described above yielded some useful 
information - that the potency of the pentapeptide for CXCR4 was derived 
primarily from three of its residues: An aromatic ring at position 4, an arginine-
like group at position 3 and either a phenol or an arginine-like group at position 1 
B 
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(Ueda et al., 2007, Tamamura et al., 2005b). The Tamamura group theorised that 
an alternative non-peptidic backbone that preserved the positions of the side-
chains might result in a small-molecular antagonist that retained the potency of 
FC131 for CXCR4 whilst not suffering from the drawbacks associated with 
peptidic drugs. They identified 5-aminoindole-2-carboxylic acid as a core 
structure that met the spatial requirements of the proposed design, as well as 
the potential for bioavailability (figure 4). As such they developed a library of 
indole-derived CXCR4 antagonists, however, none came close to the potency of 
FC131 for CXCR4 antagonism (Ueda et al., 2008).  
Figure 4. Evolution of the indole class of CXCR4 antagonist from cyclic pentapeptides 
A FC131 with a triangle superimposed above the carbon atoms joining the amino side-chains to 
the cyclopentapeptide backbone. B An example of a similar indole-derived antagonist with the 
same triangle superimposed upon the equivalent atoms. Note the relatively close fit of the 
triangle over the indole backbone. C Core structure of indole CXCR4 antagonists. Rn designates 
the presence of an amino acid R-group. Adapted from (Ueda et al., 2008). 
A 
C 
B 
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Aside from the T140-derived peptide antagonists, the other major class of CXCR4 
antagonists are the small-molecule antagonist class, which includes the bicyclam 
compound AMD3100 (figure 5A). AMD3100 is the the only CXCR4 antagonist to 
have been approved for use in humans albeit for stem cell mobilisation in non-
Hodgkin’s lymphoma and multiple myeloma, (US Food and Drug Administration 
(FDA), 2008, Genzyme, 2008). The compound’s mechanism of action appears to 
be related to its bi-protonated nature at physiological pH, enabling hydrogen 
bonding with carboxylic groups of the CXCR4 receptor, at Asp171 and Asp262 
(Hatse et al., 2002). It has been reported that AMD3100 exerts its antagonistic 
effect by acting as a partial agonist (Zhang et al., 2002), however other 
experimental data contradicts this finding (Hatse et al., 2002, Fricker et al., 
2006). AMD3100 was initially developed for its potential anti-HIV activity; 
further research in this area has largely been abandoned as a result of cardiac 
irregularities, a lack of oral availability and limited therapeutic efficacy (Hendrix 
et al., 2004). Aside from its well-documented use as a stem cell mobiliser in 
haematological malignancies (Tekgunduz et al., 2012), AMD3100 is currently 
under investigation in a phase I clinical to determine its ability to treat recurrent 
glioblastomas (www.clinicaltrials.gov, 2013). 
 
The structure of AMD3100 clearly requires optimisation to overcome its 
limitations; the molecule was therefore sequentially deconstructed in order to 
ascertain the minimum necessary composition whilst still retaining CXCR4 
antagonism. It was found that one of the cyclam rings of AM3100 could be 
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substituted for a pyridinylmethylene group that allowed for higher efficacy 
CXCR4 antagonism as a result of more potent interactions at a greater number 
of sites on CXCR4 (Rosenkilde et al., 2007). This diamine compound, designated 
AMD3465 (figure 5B), was also found to show excellent bioavailability in dogs 
(Bodart et al., 2009) and an ability to inhibit tumour invasion and metastasis in 
vivo (Ling et al., 2013), suggesting considerable potential for further 
development.  As such the substitution of the remaining cyclam group for similar 
14-member azamacrocyclic moieties resulted in the identification of two 
AMD3465 analogues bearing increased inhibition of CXCR4 (Bridger et al., 2010). 
 
The success of substituting the AMD3100 cyclam groups led researchers to 
consider whether any cyclam or macrocyclic moiety at all was necessary for 
CXCR4 inhibition. A structure-activity relationship study deconstructing 
AMD3100 led to the discovery that the central aromatic ring was vital to its 
potency as an antagonist, and that phenol groups on either end must be 
separated by a single carbon spacer and amine group in order to retain CXCR4 
antagonism (Zhan et al., 2007). Further optimisation of this lead compound 
structure led to the development of the CXCR4 antagonist class known as 
dipyrimidines, which showed more potent CXCR4 antagonism than the previous 
lead compound (Zhu et al., 2010). A potent member of this group, MSX-122 
(figure 5C), was found to be able to inhibit CXCR4-mediated invasion in vitro 
through matrigel, as well as to diminish the severity of several models of 
inflammation, and of tumour metastasis to the lung in vivo (Liang et al., 2012).  
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Figure 5. Common structural features of AMD3100 and diamine CXCR4 antagonists 
A Bicyclam AMD3100 B Monocyclam AMD3465 C Dipyrmidine MSX-122. Adapted from (Zhan et 
al., 2007). 
 
Intriguingly, it was found that this class of compounds could inhibit the Gαi-
associated cAMP modulation of CXCR4 whilst harbouring no effect upon Gαq-
mediated calcium flux, and showing an inability to inhibit SDF1α binding to 
CXCR4. This was rationalised to result from the smaller size of cyclic groups, 
which might therefore interact with less sites on CXCR4 and result in a less 
complete antagonism. 
 
An additional class of small molecular CXCR4 antagonists are the tetraquinolines, 
comprised of a core structure of benzimidazol and tetrahydroquinoline 
connected by a methylamine alkyl linking group. One notable example is 
A 
C 
B 
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AMD070 (also known as AMD11070; figure 6A), found to be a potent inhibitor of 
ligand binding to CXCR4, orally available, relatively non-cytotoxic and with 
promising pharmacokinetics (Skerlj et al., 2010). In the face of these positive 
indications, AMD070 has been tested for its ability to inhibit SDF1-mediated 
invasion in melanoma cells in vitro, and found to be more effective for CXCR4 
inhibition than AMD3100 (O'Boyle et al., 2013). Furthermore, AMD070 was 
found to be successful in increasing the lifespan of mouse models of acute 
lymphoblastic leukaemic when administered in combination therapy 
(Parameswaran et al., 2011). As a result of these findings AMD070 was assessed 
in phase I clinical trials to determine the safety and pharmacokinetics of the drug 
in healthy human subjects, and found to be slowly eliminated and well-
tolerated, with mostly grade 1 and grade 2 side-effects, with the exception of a 
single grade 3 result of lipase increase (Stone et al., 2007). AMD070 therefore 
shows considerable potential as a cancer therapeutic and CXCR4 antagonist.  
 
A final class of small molecular CXCR4 antagonists to be discussed is 
isothioureas, an isolated group of compounds developed by Novartis that does 
not share much structural similarity to either the peptide or small molecular 
antagonists so far described. The lead compound of this group is known as It1t 
(figure 6B), which was found to show extremely potent antagonism for CXCR4, 
oral availability in rats, as well as low non-specific binding to plasma samples 
(Thoma et al., 2008). This class is less developed than others published in that 
very few compounds have been synthesised, and very little research has been  
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Figure 6. Examples of CXCR4 antagonist classes 
A Tetraquinoline AMD070 B Isothiourea It1t 
 
done by way of determining their efficacy as CXCR4 antagonists in disease 
models in vivo. Despite this, the compound class holds considerable potential as 
budding CXCR4 antagonists given that the compound bears several qualities that 
suggest suitability for further development: very high potency, acceptable 
bioavailability even through the oral route, and high aqueous solubility.  
 
In summary, there are a variety of approaches to designing CXCR4 antagonists, 
each with their own advantages and drawbacks. The peptide classes of 
antagonists are potent, yet vulnerable to enzymatic digestion and cannot be 
administered orally, however advances have been made in reducing the size of 
the peptide through identification of a pharmacophore for use in cyclic 
pentapeptides. Attempts to capitalise on the potency of pentapeptide structure 
whilst replacing its cyclic pentapeptide ring with an indole backbone 
unfortunately resulted in considerably less potent CXCR4 antagonists. The 
cyclam molecules AMD3100 and AMD3465 resulted in high potency CXCR4 
B A 
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inhibition yet show poor oral bioavailability and so are restricted to parenteral 
routes of administration. AMD070 exhibited high potency and oral bioavailability 
and also displays promising signs from phase I clinical trials. Isothioureas likewise 
show high potency and oral bioavailability yet are currently underdeveloped and 
in need of further assessment.  
 
1.6 - Molecular imaging and Positron Emission 
Tomography 
 
A large variety of imaging techniques are available for the detection of cancer, 
with many of them suitable for specific molecular targets, each with their own 
advantages and drawbacks. Information on the imaging modalities used in 
molecular imaging will be briefly mentioned here, and is summarised in table 1. 
Of the major imaging modalities, Computerised Tomography (CT) scanning is the 
least developed towards utilisation in molecular imaging; even though progress 
has recently been made in the use of targeted heavy metal nanoparticle contrast 
agents (Li et al., 2010a), CT scanning is almost exclusively anatomical in nature. 
Contrast in CT images is generated by the variable densities of tissues, with high-
density heavy metal compounds exacerbating the absorption of X-rays emitted 
from the X-ray tube. Contrast in Ultrasound (US) imaging is similarly induced by 
changes in the density of tissues, although in this case it is at the interface 
between tissues of different densities, creating altered echogenicity of the 
ultrasound waves. This quality can be induced by the introduction of 
53 
 
microbubbles which can be targeted to a particular cancer biomarker (Bzyl et al., 
2013). The last of the major anatomical imaging techniques is Magnetic 
Resonance Imaging (MRI), which detects tissues structures in a very different 
manner, through the electromagnetically induced disruption of nuclear spin 
properties. Contrast agents bearing paramagnetic and superparamagnetic 
properties can be targeted towards tumour tissues through conjugation to 
biomarker-specific molecules, allowing alteration of the recovery rate of nuclei 
from disruption, generating contrast in tumour tissues (Geraldes and Laurent, 
2009). 
 
Whilst CT, US and MRI can be considered anatomical imaging techniques that 
are able to be applied towards the molecular imaging of biomarker targets, 
other imaging modalities do not provide anatomical data at all, with images 
solely consisting of the location of the injected tracer molecule. Such imaging 
methods are uniquely suitable for molecular imaging purposes as the use of 
tracer molecules that are targeted to cancer biomarkers can therefore 
theoretically generate contrast almost exclusively within the tissue of interest 
(aside from the organs of excretion), if a sufficiently specific tracer is used. One 
such imaging modality is optical imaging, whereby a biomarker-targeting 
molecule is conjugated to a fluorescent or bioluminescent dye that emits light 
within the optical light frequencies (including those of near-infrared frequencies; 
NIR) (Adams et al., 2007). Alternative molecular imaging approaches include 
nuclear imaging techniques such as Single-Photon Emission Computed 
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Tomography (SPECT) and Positron Emission Tomography (PET). These require 
the administration of tracers incorporating atoms emitting ionising radiation - 
gamma ray-emitting radionuclides in the case of SPECT, and positron-emitting 
radionuclides in the case of PET. These radionuclides are integrated into the 
design of the molecule targeting the cancer biomarker and therefore primarily 
localise within the tissues that express that biomarker (Oh et al., 2011).  
 
The purpose of this project is to develop novel radiotracers for use with PET to 
target the expression of the CXCR4 cancer biomarker. While all the imaging 
modalities described have applications in molecular imaging, PET scans bear a 
number of advantages over the others. The use of CT scanning as a method of 
molecular imaging is within its infancy and not well-characterised in clinical 
studies, whereas numerous PET radiotracers are approved for use or testing in 
humans.  Both ultrasound and optical imaging have issues with low tissue 
penetration, which makes the modalities unsuitable for the imaging of deep 
tissues, whereas PET is not affected in this way (Higgins and Pomper, 2011). MRI 
gives images of extremely high resolution, however the method is inherently 
insensitive and therefore requires the administration of large quantities of 
contrast agents (Skotland, 2012). In contrast to SPECT, PET bears a much higher 
sensitivity which in turn allows an improvement of image quality as a result of 
the increased signal-to-noise ratio. The use of short-lived isotopes in PET 
imaging also enables greater quantities of radioactivity to be administered to 
patients without additional risk, as scans can be considerably shorter and more 
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convenient to the patient and hospital department. This feature also enables 
greater temporal resolution which is of particular importance for dynamic 
scanning (Rahmim and Zaidi, 2008).  
 
PET imaging therefore possesses a number of qualities that make it a sound 
choice for molecular imaging purposes, and the mechanism of its operation will 
now be discussed in detail.  Positron emission tomography (PET) is a nuclear 
imaging technique that detects radioisotopes emitting ionising radiation in the 
form of B+ decay (positron emission).  Decay of the radiotracer is detected 
indirectly, as collision of the antimatter positrons with their matter 
counterparts, the electrons, results in annihilation of both subatomic particles 
within the surrounding tissue, producing 2 bursts of γ radiation travelling in 
approximately opposite directions, which are detected by a detector ring within 
the scanner (figure 7). The distance that the positron travels from the site of 
emission before the annihilation event occurs depends upon the energy of the 
emitted positron. This is in turn dependent upon the radioisotope source of the 
positron - for example, positron emission from gallium-68 occurs with a 
maximum energy of 3.8 MeV, whereas positron emission from copper-64 
possesses 0.58 MeV of energy. As annihilation between the positron and 
electron may only occur once the kinetic energy of the positron has dropped to 
0.551 MeV (as will occur spontaneously as a result of collisions), the spatial 
resolution of the PET image generated is both dependent upon the energy 
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Table 1. Comparative table of pre-clinical imaging modality qualities. 
Modality Spatial resolution Molecular probe types Advantages  Limitations 
Ultrasound 50-500 µm Microbubbles. 
Portable. Cheap. Widely available. No major safety 
concerns. Sensitivity can be high, depending on 
the structure of microbubble used. 
Low tissue penetration. 
Optical  2-5 mm 
Fluorescent or 
bioluminescent 
compounds. 
Ability to detect multiple probes in single imaging 
session.  
No major safety concerns. Limited 
tissue penetrance. 
CT 50-200 µm 
Heavy metal 
nanoparticles. 
Relatively cheap. High resolution. Widely 
available.  
Requires exposure to ionising 
radiation. Anatomical imaging method, 
generally not used for molecular 
imaging. Large quantities of contrast 
agent required. Low temporal 
resolution. 
MRI 25-100 µm 
Paramagnetic or 
superparamagnetic 
compounds. 
High resolution. 
Expensive. Low sensitivity. Requires 
exposure to powerful magnetic fields. 
Large quantities of contrast agent 
required. Low temporal resolution. 
SPECT 1-2 mm 
Gamma ray-emitting 
radionuclides e.g. 99mTc, 
125I and 111In. 
High sensitivity. 
Requires exposure to ionising 
radiation. Poor spatial and temporal 
resolution. 
PET 1-2 mm 
Positron-emitting 
radionuclides e.g. 11C, 
18F, 68Ga and 64Cu. 
High sensitivity. Use of 11C, 15O and 13N enables 
radiolabelling of biologically relevant molecules 
with no further modification. 
Low resolution. Requires exposure to 
ionising radiation. Must be located 
near a cyclotron or radioisotope 
generator. Expensive. 
Summarised from (Alberti, 2012, Skotland, 2012, Higgins and Pomper, 2011)
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Figure 7. Diagram of positron emission and subsequent gamma ray detection by PET scanner 
 A radiotracer accumulates in the tissue of interest (e.g. tumour). B+ decay of the radioisotope 
(in this case 18F) results in the emission of a positron (e+) which is annihilated upon collision with 
a nearby electron (e-), causing the projection of 2  ray bursts in opposite directions. These are 
detected at the detector ring of the PET scanner. 
 
possessed by the positron upon emission and the density of the tissue 
surrounding it (Sanchez-Crespo et al., 2004, Zanzonico, 2004). The localisation of 
the radiotracer within the test subject is determined by the measurement of so-
called ‘coincidence events’ - the detection of a pair of  ray bursts at 
approximately opposite sides of the detector ring (at ~180 ° apart) that are 
detected within 6-12 ns of each other. These events are designated ‘true’ 
events, and any detected paired or single events that fall outside these criteria 
18F  18O + e+  
e- 
DETECTOR RING 
58 
 
are discarded by the reconstruction as noise. The region of space that falls 
between the two detectors is known as the line of response (LOR), and 
designates the possible source of the positron emitter. The detectors 
themselves are comprised of a scintillator, which luminesces upon contact with 
ionising radiation, allowing detection by a photomultiplier tube (Zanzonico, 
2004, Tomasi and Aboagye, 2013). Considerable computational reconstruction is 
required to convert this raw coincidence event data into a quantitative PET 
image, and may include algorithms for attenuation correction and 
reconstruction, including filtered back projection and iterative reconstructions 
(Tarantola et al., 2003). Despite the advanced image processing required, PET 
imaging is ideally suited to the molecular imaging of cancer biomarkers as the 
positron-emitting radioactive isotopes such as 18F and 11C that it detects can be 
incorporated into biological molecules that are taken up or bound by cancerous 
cells. 
 
1.7 - CXCR4 as a molecular imaging target 
 
The molecular imaging of cancer by targeting CXCR4 expression is an emerging 
field, and has great potential for the identification of patients that may respond 
well to CXCR4 antagonists as therapeutic agents. Given that biopsy data are 
available for most primary tumours (with the exception of inoperable tumours), 
the most clinically relevant application of CXCR4-targeted molecular imaging 
would be in further assessment of patients who had already begun therapeutic 
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treatment, rather than for the initial analysis of primary tumours. For example, a 
patient bearing an excised primary tumour that had been tested positive for 
CXCR4 might benefit from non-invasive assessment, either to ensure that all 
lesions had been removed, or as a re-staging procedure to detect progression of 
the malignancy, given that CXCR4 expression in primary tumours is a risk factor 
for metastasis (Cabioglu et al., 2005). This utilisation of CXCR4-targeted imaging 
shows great potential, as a personalised approach to patient care may increase 
the sensitivity of the modality to tumour detection.  
 
Furthermore, CXCR4-targeted imaging methods could potentially detect 
whether a tumour that is currently unresponsive to alternative therapies might 
be sensitised by targeted CXCR4 antagonism. Given that AMD3100 has been 
shown to be well-tolerated in patients with only grade 1 toxicity reported 
(Devine et al., 2004), allowing oncologists to make a more informed choice on 
the best therapeutic regimen for a given patient would hopefully reduce 
unnecessary adverse effects or delays in effective treatment for the patients. It 
is also possible that the higher expression of CXCR4 in invasive and recurrent 
tumours might enable the use of CXCR4-targeted imaging methods as a tool for 
the prediction of disease outcome. The molecular imaging of CXCR4 therefore 
has considerable potential in clinical medicine, and the current status of the 
development of radioisotope probes for the nuclear molecular imaging of CXCR4 
will now be described in detail.  
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There has been substantial progress in the development of radiotracers 
targeting CXCR4 in recent years, beginning with a publication in 2006 regarding 
an 111In-labelled Ac-TZ14011 CXCR4 antagonist for use as a SPECT tracer 
(Hanaoka et al., 2006). A significant difference in tracer accumulation was found 
in the tumour-to-muscle and tumour-to-blood ratios of nude mice bearing 
pancreatic tumours, as compared with mice that had received blocking doses of 
10 mg/kg unlabelled Tz14011. However, accumulation within the tumours was 
still very low, with a maximum measurement of 0.51 %ID/g at 1 hour post-
injection. Nevertheless, the paper proved that the concept of a CXCR4-targeted 
radiotracer was possible, and subsequent publications have developed tracers 
with improved biodistribution data.  
 
In 2008, a 99mTc radiolabelled SDF1α was developed for use as a SPECT tracer for 
the identification of increases in CXCR4 as a result of myocardial infarction 
(Misra et al., 2008). Whilst accumulation in the infarcted tissue was low, at 
0.57 %ID/g at 2 hours post-injection, this reflected a 5-fold increase compared to 
non-infarcted tissue, as well as the biodistribution in other organs (excluding the 
kidneys). 99mTc was also utilised as radioisotope in disclosed findings in a 
communication to Chinese Chemical Letters regarding the uptake of a 99mTc-
labelled AMD3100 CXCR4 antagonist into liver tumour animal models, although 
precise values (such as %ID/g and tumour to muscle ratios) were not divulged 
(Zhang et al., 2010). However, an identical 99mTc-labelled AMD3100 was found to 
be taken up in PC-3 prostate cancer tumours to a maximum of ~1.7 %ID/g which 
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was significantly higher than in the tumours of mice that had been injected with 
a blocking dose of 20 mg/kg AMD3100. However it is important to note that this 
peak uptake occurred within the first 5 minutes following injection, and very 
rapidly washed out over the duration of the 60 minute scan. This extremely fast 
pharmacokinetics is not ideal for a radiotracer as it is not practical for either 
clinical or preclinical use. In addition, there was high uptake at 60 minutes in a 
number of non-target tissues, including the liver, lungs, thymus, intestine, spleen 
and bone, however the authors rationalised that this may be due to the 
presence of CXCR4-expressing cells, as many of the sites are known to express 
SDF1, and the uptake could be partially blocked by the AM3100 blocking dose, 
implying specific uptake (Hartimath et al., 2013). This uptake profile in additional 
tissues besides the tumour may further limit the usefulness of the tracer in 
identifying tumours in these localities. 
 
The first reported study to investigate the uptake of a radiolabelled probe in 
tumour models of both high and low CXCR4 expression was in the form of an 
125I-labelled monoclonal antibody, which showed a significant difference in 
tracer accumulation in comparison to the radiolabelled control antibody 
(~6 %ID/g and ~3 %ID/g, respectively) (Nimmagadda et al., 2009). However, 
considerable uptake of the control antibody was also seen, suggesting some 
probe uptake in the tumour did not arise as a result of receptor-mediated 
binding, but instead by the enhanced nonspecific permeability and retention of 
large macromolecules such as antibodies (Maeda et al., 2000). Furthermore, no 
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significant difference in control and CXCR4 antibody binding was seen in smaller 
tumours (<200 mm3), and further analysis led the group to conclude that the 
greater visibility of CXCR4 antibody in larger tumours was due to an increase in 
CXCR4 expression as a result of the hypoxic tumour microenvironment, rather 
that the endogenous difference in CXCR4 expression. 
 
In recent years SPECT tracers being developed that target CXCR4 have explored 
bimodality with optical imaging fluorophores as a way to increase the practical 
applications of the tracers. The first of these was an 111In- and Cy5.5-like 
fluorophore-labelled derivative of the T140 CXCR4 antagonist, which was found 
to accumulate specifically in CXCR4-expressing tumours at a 3.8-fold higher level 
than in CXCR4-negative tumours, although there was also high uptake of the 
tracer in the liver, kidneys, spleen and intestines (Kuil et al., 2011b). However, as 
the affinity of the tracer for CXCR4 was adversely affected by 20-fold following 
the conjugation of the bimodal label, the same group attempted multimodal 
labelling of a dendrimeric version of the Ac-TZ14011 antagonist, which was 
found to bear an increased affinity for CXCR4. While the tracer had low uptake in 
the CXCR4-expressing tumour (0.42 %ID/g for the tetrameric tracer), the use of 
this dendrimeric tracer reduced the background uptake in muscle by 3.6-fold, 
therefore increasing the tumour-muscle ratio. Unfortunately the background 
uptake in almost all other tissues measured was higher than in the tumour, 
suggesting that the signal-noise ratio is poor (Kuil et al., 2011a).  While the use 
of an optical imaging label within the bimodal tracer also allows some additional 
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functions including in vitro labelling of CXCR4 expression for confocal microscopy 
and flow cytometry (Buckle et al., 2013) it also comes with some disadvantages. 
For example, it is important to consider that the conjugation of both a metal ion-
chelating group and a fluorophore to the already-macromolecular T140 CXCR4 
antagonist results in an extremely bulky radiotracer, particularly in the case of 
the dendrimerised antagonist tracer. It is therefore perhaps unsurprising that 
the imaging of tumours with these tracers took place a full 24 hours post-
injection, which is not practical for clinical use.  
 
Despite the announcement of several of the SPECT tracers described above, 
there was no published PET radiotracer targeting CXCR4 before 2009. In the 
years since, there has been an upsurge in interest in such developments 
(summarised in table 3), which began with the chelation of 64Cu within a cyclam 
ring of the small molecular antagonist AMD3100 (Jacobson et al., 2009). This 
same tracer was utilised by the Nimmagadda group in various tumour models to 
show that the tracer accumulated significantly more in tumours of high CXCR4 
expression versus tumours of lower expression using both transfected 
glioblastoma cellular models (35 %ID/g and 9 %ID/g, respectively) and cancer 
cell lines exhibiting endogenous high or low CXCR4 expression. Furthermore, 
they showed that it was possible to use this tracer to image lung metastases, 
which showed an increased CXCR4 expression profile in comparison to lungs 
without metastases (Nimmagadda et al., 2010). However, high uptake was 
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observed in many tissues, including the lungs, liver, spleen and kidneys, and 
there was evidence of considerable binding of AMD3100 to blood proteins, 
suggesting non-specific binding, with similar findings also reported by the group 
who first developed the 64Cu-AMD3100 tracer (Weiss et al., 2011).  
 
A significant advance was the development of a 64Cu-labelled monocyclam 
antagonist AMD3465 (De Silva et al., 2011), which has shown 102 %ID/g of 
tracer uptake in CXCR4-overexpressing tumour tissue versus 3 %ID/g in the 
control tumour. Furthermore, the maximum tracer uptake showed a tumour-to-
muscle ratio of 361 (versus 18 for the non-CXCR4-transfected tumour), with the 
differences in uptake vividly apparent upon PET images. The uptake of tracer in 
CXCR4-expressing tissues could also be blocked by the administration of 
unlabelled Cu-AMD3465, providing compelling evidence of CXCR4-specificity in 
vivo. This level of specific uptake is far superior to previously reported data for 
CXCR4-targeting compounds; however, for all its strengths, there was 
considerable uptake of non-targeted [64Cu]CuCl2 at the tumour. Furthermore, 
the tracer is limited by the undesirability of 64Cu as a PET radionuclide, which will 
now be described.  
 
As table 2 shows, the half-life of 64Cu is long, relative to the other commonly 
used PET radioisotopes. This is exacerbated by the fact that only 19% of the total 
radioactivity emitted occurs by positron emission - the rest occurs primarily by 
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beta decay and electron capture. This means that a higher dose of ionising 
radiation would be required to be administered to the patient in order to 
receive the same quality of data. PET imaging can be conducted with even 
longer-lived radioisotopes such as 89Zr and 124I (with half lives of 3.3d and 4.2d, 
respectively), although this is most suited to immunoPET applications, where the 
labelled antibody takes considerably longer to penetrate the tumour than the 
far smaller antagonists (Verel et al., 2003). For these reasons, it would be better 
to choose a radionuclide with both a short half-life, and a high proportion of 
positron emission for the development of antagonist-based radiotracers. While 
the radionuclides 15O, 13N and 11C would appear to fulfil these requirements, the 
half-lives are so short as to be very impractical for many applications unless the 
clinical department or preclinical laboratory is located extremely close to a 
cyclotron. Thus 18F is considered to be an excellent compromise - its decay is 
97% positron emission and the half-life is a very manageable 109.8 minutes, 
which enables delivery of radiotracers to users within a limited distance 
(Zanzonico, 2004). Furthermore, the positrons emitted are very low-energy, and  
Table 2. Properties of commonly used radionuclides for positron emission tomography 
Radionuclide Half-life % e+ emission 
Maximum e+ energy 
(MeV) Produced by 
Oxygen-15 2.1 min 100 1.7 Cyclotron 
Nitrogen-13 10.0 min 100 1.2 Cyclotron 
Carbon-11 20.4 min 99 1 Cyclotron 
Gallium-68 1.1 h 88 1.9 Generator 
Fluorine-18 1.83 h 97 0.6 Cyclotron 
Copper-64 12.7 h 19 0.6 Cyclotron 
Yttrium-86 14.7 h 32 1.4 Cyclotron 
Summarised from Zanzonico (2004). 
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so there is a short linear range within tissues and thus high resolution 
comparative to many other radionuclides. 
 
The first implementation of an 18F label into a CXCR4-targeting radiotracer was 
in 2010 [when this project had already commenced], and involved an 18F-
fluorobenzoate derivative of the T140-derived antagonist TN14003 (Jacobson et 
al., 2010). This tracer accumulated in CXCR4-expressing, but not in CXCR4-
negative tumours at a tumour-to-muscle ratio of 21.6. However, the ability of 
the tracer to discern tumours of varying CXCR4 expression was only possible 
following coinjection of a blocking dose of the cold antagonist; it was proposed 
that the tracer would otherwise bind in a non-specific manner on red blood cells 
(RBCs) to such a degree that there was insufficient radiotracer left for specific 
binding at the tumour. The requirement to coinject subjects with additional 
compound would be extremely inconvenient in a clinical setting, and would 
drive up the costs of the procedure. In an attempt to address these concerns, 
the group modified the T140-derived peptide tracer by instead introducing the 
radionuclide through chelation at a conjugate NOTA or DOTA group (Jacobson et 
al., 2012), resulting in a tumour-to-muscle ratio of ~5. Whilst radiolabelling the 
tracer in this way considerably improved the specificity of the tracer for CXCR4, 
as it was no longer subject to unintended binding to red blood cells, it came 
notionally with the caveat of 64Cu as the radionuclide, rather than the more 
preferable 18F. Nonetheless, this approach was considerably more effective than 
conjugation of the peptide with 64Cu-DOTA at lysine residues 7 and 8, which 
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again resulted in the requirement for a cold peptide coinjection to prevent 
unspecific tracer uptake within the blood before CXCR4 expression within 
tumours could be elucidated (Jacobson et al., 2011).  
 
The situation regarding 18F imaging of CXCR4 was not improved until 2013, when 
the T140 derivative Ac-TC14012 was conjugated to 18F via either a 
fluorobenzoate or fluoroproprionate group at Lys-7, which were found to 
accumulate in CXCR4-expressing tumours at levels of around 4 or 5-fold higher 
than in CXCR4-negative tumours (Zhang et al., 2013). Unlike previous efforts, 
there was minimal binding to red blood cells, leading the authors to conclude 
that the C-terminal placement of fluorobenzoate must have been responsible 
for this effect in the 18F- and 64Cu- labelled versions of this T140-derived peptide 
antagonist (Jacobson et al., 2010, Jacobson et al., 2011). However, the authors 
also purported evidence for some specific binding of the tracer at the liver, as 
the coinjection of a small quantity of cold compound resulted in reduced liver 
uptake, and increased uptake of the tracer in CXCR4-expressing tumours, 
presumably as a result of the increased circulation of the tracer. However, it 
seems plausible that this may instead have been due to reduced clearance of the 
tracer by the liver when excess unlabelled is present in competition. This 
suggestion is supported by the observation that the blocking dose did not have 
the effect of increasing contrast at the tumour, as binding within the CXCR4-
negative tumour increased at the same proportion as in the CXCR4-expressing 
tumour. Despite the improvement, tracer uptake within CXCR4-expressing 
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tumours was still low, at a maximum of 4.81 %ID/g with cold peptide 
coinjection, or 2.4 %ID/g without. Thus there is still some way to go in the 
development of 18F-labelled PET tracers targeting CXCR4 expression, and further 
optimisation of tracer design may well be possible.  
 
Despite all the advantages of 18F as a PET radionuclide described previously, 
there are situations where its use is not practical. As mentioned in table 2, 18F, 
along with most other commonly used PET radionuclides, is generated within a 
cyclotron. The expense of running such machinery, along with the short half-life 
of fluorine puts limits upon the feasibility of using such tracers at locations more 
distant from cyclotrons, or where higher costs are prohibitive. In contrast, 68Ga is 
produced by the decay of 68Ge with the aid of a generator, which extracts the 
clinically useful 68Ga product from the parent isotope. 68Ge also has a long half-
life of 271 days, enabling cost-effective production of 68Ga from a generator for 
a year or more, even where cyclotron facilities are unavailable (Breeman and 
Verbruggen, 2007). The half-life of 68Ga is also a relatively convenient 68 
minutes, with 88% of radioactive decay occurring by positron emission. These 
desirable qualities counteract the potentially negative aspect of a high positron 
energy level (which may reduce maximum image resolution); thus 68Ga may be 
considered a very desirable radionuclide to use in PET imaging.  
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As such, progress has recently been made in the development of a 68Ga-labelled 
cyclic pentapeptide ligand to CXCR4 known as CPCR4-2. It was found that this 
tracer accumulated in the tumour at a concentration higher than in any other 
organ, to a maximum of 6.2 %ID/g (Gourni et al., 2011). Furthermore, the same 
group developed a dimeric pentapeptide moiety that could be labelled with 
68Ga-DOTA (Demmer et al., 2011)  although the maximum tumour uptake with 
this tracer was considerably lower, at 2.1 %ID/g, and there was high uptake 
measured in non-target tissues. In neither of these investigations was there 
were a CXCR4-negative tumour model used; given non-specific binding 
characteristics with previous radiotracers have affected the ability to discern 
CXCR4-positive and CXCR4-negative tumours without the coinjection of 
competing cold compound, the omission of this control condition is starkly 
apparent. Some progress has been made in the 68Ga-DOTA labelling of a 
TN14003 derivative at lys-7, which showed a significant difference in uptake in 
cell lines of differing CXCR4 expression in vitro, although no in vivo data have yet 
been reported for this compound (Hennrich et al., 2012). Given that the 
radiotracer contains the same fluorobenzoyl group blamed for the nonspecific 
binding of other tracers, it is likely that similar difficulties would be seen. There 
is therefore considerable scope for further investigation of the use and 
development of 68Ga-labelled PET probes targeting CXCR4 in cancer, as there has 
been only very limited research into this area thus far.  
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Table 3. Comparative table of recent attempts to develop CXCR4-targeting PET tracers for cancer detection in vivo 
Radioisotope Probe 
CXCR4+ tumour 
uptake ( %ID/g) 
CXCR4+/CXCR4- 
tumour uptake 
Tumour/
muscle Notes Reference 
18
F T140 4* 4* 21.6* 
High uptake of tracer in blood and spleen. High blood retention 
of tracer prevented identification of CXCR4+ tumour without 
additional pre-administration of cold peptide. 
(Jacobson et 
al., 2010) 
64
Cu AMD3100 33 6 47 
Tracer could also be used to identify lung metastases and 
tumours endogenously expressing CXCR4. Highest tracer 
uptake in liver, spleen and kidneys. 
(Nimmagadda 
et al., 2010) 
64
Cu T140-2D 4.1* 2* 3.8* 
High tracer uptake in blood, liver, spleen, kidneys and bone 
marrow. High blood retention of tracer prevented visualisation 
of CXCR4+ tumour without pre-administration of cold peptide. 
(Jacobson et 
al., 2011) 
64Cu AMD3100 12.3 8 59 
Highest tracer uptake seen at 6 hours. High tracer uptake in 
liver and kidneys. High uptake also seen in CXCR4+ lung and 
liver tumours.  
(Weiss et al., 
2011) 
64Cu 
4F-benzoyl-
TN14003 
4.4 9 39.3 
Highest tracer uptake in liver and kidneys. Minimal blood 
retention. 
(Jacobson et 
al., 2012) 
64Cu AMD3465 102.7 17 362.5 
Higher tracer uptake in tumour than in liver or kidneys. Some 
specific uptake evident in bone marrow. 
(De Silva et al., 
2011) 
68Ga CPCR4-2 6.1 - 18.5 Higher tracer uptake in tumour than in any other tissue, 
however no CXCR4- tumour was used in the study.  
(Gourni et al., 
2011) 
68Ga Dimer-7 2.1 -  6.0 High tracer uptake in liver, spleen and kidneys. No CXCR4- 
tumour used in this study. 
(Demmer et 
al., 2011) 
18F Ac-TC14012 4.8* 3 
Not 
stated 
Minimal blood retention. Low dose cold peptide increased 
uptake in CXCR4 tumour, but also in CXCR4 negative tumour. 
High tracer uptake in liver, kidneys and spleen. Low maximum 
uptake within CXCR4-expressing tumours. 
(Zhang et al., 
2013) 
* denotes that the maximum uptake was achieved following injection of a blocking dose of unlabelled compound. 
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1.8 – Considerations for the synthesis of novel CXCR4-
targeting radiotracers  
 
The literature described indicates the high potential of radiolabelled antagonists 
to CXCR4 as radiotracers for PET imaging, particularly where 18F and 68Ga-
radionuclides are incorporated. However, when designing novel radiotracers, 
the common characteristics of successful radiotracers should be taken into 
account.  
 
Chief amongst all concerns, it is vital that any novel CXCR4-targeting radiotracer 
should bind selectively to the target, enabling high target-to-background ratios. 
There are three facets to this issue: Firstly, the tracer should bind selectively to 
CXCR4, with minimal interactions to other related structures (such as other 
chemokine receptors). Secondly, the tracer should bind with high affinity, so 
binding can be achieved at low physiological concentrations. For consideration, 
other successful radiotracers targeting cell surface proteins typically bind their 
target protein with affinities between 10 pM-1 nM (Laruelle et al., 2003), 
although lower affinity tracers have been shown to be acceptable for targets 
that are highly expressed (Dean et al., 1997). Lastly, non-specific binding should 
be avoided, where uptake of the tracer occurs independently of site-specific 
interactions. Non-specific binding is most commonly observed in tracers and 
compounds bearing high lipophilicity, which encourages binding at plasma 
proteins (Ermondi et al., 2004). As a result, highly lipophilic compounds are 
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generally avoided in pharmaceuticals (Leeson, 2012), and novel radiotracers 
assessed for specificity in the presence of an excess of a competitor, which 
saturates site-specific binding. These characteristics all contribute to the ability 
of a tracer to accumulate in tissues expressing the target protein, with low 
uptake elsewhere (known as a high target-to-background ratio).  
 
However, the binding characteristics of the tracer is only part of the story, as in 
vivo processes also frequently have a significant effect upon the distribution of 
the tracer, such as the metabolic and excretory pathways. Metabolism refers to 
enzyme-catalysed reactions of the tracer that are employed physiologically 
(primarily by the liver) as a means to reduce toxicity of a given compound, or to 
increase the ability to excrete it (Meyer, 1996). Potential radiopharmaceuticals 
should remain relatively metabolically stable for the duration of imaging to 
maximise specific tracer uptake at the tissue of interest, as metabolites may gain 
undesirable non-specific binding characteristics that will reduce the target-to-
background ratio (Pike, 2009).  The excretion of a tracer is primarily performed 
by the kidneys and liver, through a variety of transporter mechanisms that drugs 
and drug metabolites are frequently substrates for (Mizuno et al., 2003). It is 
preferable for radiotracer metabolites to be cleared quickly and for the 
radiotracer itself to be more slowly cleared, in order maximising radiotracer 
circulation to allow specific tissue uptake.  
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There are also considerations for the physical properties of a radiotracer, as 
radiopharmaceutical preparations for PET must also conform to high levels of 
“specific activity”. This is defined as the radioactivity present per unit of mass 
(such as µmol or mg) of a labelled compound. This is especially important for 
tracers targeting cell-surface receptors such as CXCR4, as even very small 
concentrations of ligand can saturate receptors. The lower the specific activity, 
the lower the signal received from the target, which may contribute to a low 
target-to-background signal ratio. Thus the most successful PET radiotracers 
targeting cell receptors so far have therefore been those produced with the 
highest specific activities (Mankoff et al., 2008), highlighting the importance of 
this characteristic in any future PET tracer development.  
 
Central to all of the above concerns is the structure of a given radiotracer; 
ideally, a radiotracer would differ very little in structure to the antagonist it is 
derived from, so as to fulfil the conditions outlined above and therefore 
maximise specific tracer uptake. However, fluoride and gallium atoms do not 
typically reside within the CXCR4 antagonists described in chapter 1.5, and so 
derivatives must be designed to include functional groups that contain them. 
These designs may be dictated by the available radiolabelling techniques, which 
will influence where and how a radionuclide is to be incorporated. Furthermore, 
the radiolabelling protocol used to synthesise them must be rapid enough that 
the decay of the short-lived positron-emitting radioisotopes used in PET is kept 
to a minimum. There are three general methods of incorporating radionuclides 
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into molecules to be used as targeted radiotracers: direct labelling, indirect 
labelling via a linker group, or indirect labelling via chelation (Sugiura et al., 
2014). A number of mechanisms commonly used to covalently label compounds 
with the radionuclides 18F and 68Ga will now be described. 
 
Direct labelling with the 18F radionuclide is possible due to its highly nucleophilic 
nature, and so is capable of replacing leaving groups such as halide, nitro or 
tetramethylammonium groups upon aromatic and aliphatic groups by 
nucleophilic substitution reactions (Ding et al., 1990, Machulla et al., 2000, 
Becaud et al., 2009). Direct labelling methods such as these frequently require 
harsh conditions to react which are unsuitable for precursor molecules that may 
react in that environment, and are also generally limited in variety. As a result, 
18F is more frequently introduced via prosthetic groups incorporated into the 
target molecule alongside the radionuclide. Methods of achieving this include 
fluoroamidation such as with [18F]fluoroethylamine (Jelinski et al., 2002), 
fluoroacylation such as with N-succinimidyl [18F]fluorobenzoate ([18F]SFB)(Tang 
et al., 2008b), and fluoroalkylation such as with fluoromethyl bromide or 
fluoroethyl tosylate (Tsukada et al., 2006). Despite the many benefits of 18F-
labelling with prosthetic linkers, the methods are sometimes associated with 
nonselectivity for the intended molecular site, time-consuming preparation of 
the prosthetic precursor, and instability of the prosthetic group in biological 
systems. [18F]fluorobenzaldehyde, however, can be formed in a single step, and 
reacts by reductive amination with aminooxy groups to create a radiotracer 
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containing an [18F]fluorophenyl group attached to an oxime linkage, and has 
been found to be highly chemoselective, and stable in vivo (Poethko et al., 
2004a, Poethko et al., 2004b), and is therefore widely used in 18F radiolabelling. 
Similarly popular is the “click” reaction between alkyne-containing precursors 
and an 18F-labelled azide, which forms a radiotracer containing a [18F]1,2,3-
triazole group (Glaser and Arstad, 2007); This reaction is capable of achieving 
high yields under mild conditions, with the labelled azide prosthetic produced 
efficiently in a one-step reaction.  
  
While the methods described above are frequently used in 18F radiosynthetic 
chemistry, the formation of radiotracers via prosthetic groups is, by definition, a 
multi-step reaction, which therefore takes time to produce, reducing the specific 
activity of the finished tracer. The use of radiometal chelation chemistry is a 
simple, fast single-step alternative, used for the incorporation of cationic 
radionuclides such as 68Ga (Anderson and Welch, 1999, Burke et al., 2014), 
although chelation of the 18F radionuclide has recently been achieved in the 
form of [Al18F]2+ (McBride et al., 2012). The most commonly used chelating 
agent for radiopharmaceuticals was until recently 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), which complexes 68Ga 
through hexadentate interactions with amine and carboxylate groups. However, 
incorporation of the 68Ga radionuclide into DOTA is generally slow unless heated 
to temperatures that are impractical for many pharmaceutical compounds  
76 
 
 
 
 
 
 
 
 
 
 
 
(Blom et al., 2009). In contrast, 1,4,7-triazacyclononanetriacetic acid (NOTA) 
chelates incorporates 68Ga at high radiochemical yields very rapidly at room 
temperature (Velikyan et al., 2008), and has been shown to form especially 
A 
B 
C 
E D 
Figure 8. Summary of commonly used 
18
F and 
68
Ga radiolabelling methods. 
A Direct labelling by nucleophilic substitution with 
18
F- for the synthesis of 
[18F]fluorodeoxythymidine (Machulla et al., 2000). Indirect l belling via a prosthetic group by      
B benzaldehyde nucleophilic substitution or C “click” chemistry reactions. Indirect radiometal 
labelling via chelation to D DOTA and E NOTA macrocycles. 
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stable interactions with Ga(III) ions as a result of the small size of the 
triazanonane ring and the favourable steric orientation of the donor groups 
(Clarke and Martell, 1991). NOTA is therefore an especially favourable chelating 
agent for the rapid 68Ga radiolabelling of PET radiopharmaceuticals sensitive to 
harsh conditions. Another frequently used chelating moiety is the cyclam group, 
which is present in some CXCR4 antagonists (including the well-characterised 
AMD3100) and strongly complex copper(II) ions, as well as a number of other 
transition metals. While most frequently complexed with the SPECT 
radioisotopes 64Cu, 67Cu and 99mTc (Engelhardt et al., 2002), beta-emitting 
radioisotopes such as 94mTc and 60Cu may also be possible (Laforest and Liu, 
2008), although these are non-standard PET radionuclides, and beyond the 
scope of this report.  
 
The mechanisms described above outline several radiolabelling methods that 
may be suitable for 18F or 68Ga labelling of CXCR4 antagonists, and are outlined 
in figure 8. This enables the comprehensive investigation of a variety of 
functionalised antagonists to determine which antagonist structures are most 
capable of retaining features appropriate for the use of PET radiotracers, such as 
high affinity for the CXCR4 target and in vivo stability.  
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1.9 – Potential of CXCR4-targeting tracers to 
noninvasively determine response to HSP90 inhibiting 
cancer therapeutics 
 
An advantage of PET as an imaging modality is the ability to noninvasively 
determine the expression of clinically relevant biomarkers. As has been 
discussed in section 1.3, CXCR4 is clinically relevant to cancer in its own right, 
with its expression correlated with various diagnostic measures, and is therefore 
a target for PET imaging probes. However, PET imaging tracers targeting CXCR4 
expression could also be used to detect changes in CXCR4 expression that are 
indirectly elicited by other triggers, such as treatments targeting a particular 
oncogenic pathway. One such pathway that affects CXCR4 expression is the 
regulation of chaperone protein heat shock protein 90 (HSP90), which plays a 
role in signalling protein function, protein folding and stabilisation, and protein 
trafficking throughout the cell. HSP90 is responsible for the stabilisation of a 
number of oncogenic proteins, including CXCR4 (Mandawat et al., 2010), but 
also the cell cycle-associated protein CDK4 (Fu et al., 2013), the epidermal 
growth factor receptor (EGFR) family of proteins (Ahsan et al., 2012), as well as 
mutant versions of the tumour suppressor protein p53 (Li et al., 2011) that are 
associated with cancer phenotypes.  
 
The mechanism of HSP90 substrate stabilisation is most well-characterised in 
steroid hormone receptors and must be considered in tandem with HSP70, a 
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chaperone that interacts with HSP90 in the substrate-chaperone complex. 
Unchaperoned proteins may partially unfold to a conformation that exposes a 
binding domain that HSP70 binds to, in conjunction with HSP40 which 
modulates the ATPase function of HSP70 and hence its substrate binding ability 
(Kanelakis et al., 2002). The HSP70-HSP90 organising protein (Hop) possesses 
binding domains for both HSP70 and HSP90 and helps to assemble the 
chaperone complex around the substrate (Johnson et al., 1998). Upon 
recruitment of the cochaperone p23, the Hop-HSP70 dissociates from the 
complex, leaving HSP90 and the remaining cochaperones to stabilise the 
substrate until the complex dissociates (Morishima et al., 2003). A model has 
been proposed whereby the stabilisation of proteins is subject to a triage 
decision; HSP70 is associated with the ubiquitination of the substrate while 
subsequent HSP90 binding prevents its ubiquitination (Chen et al., 2012, 
Stankiewicz et al., 2010). As long as HSP90 is present and can interact with the 
binding domain, the protein is protected from HSP70-mediated proteasomal 
degradation (Pratt et al., 2010). A simplified mechanism of HSP90 stabilisation of 
proteins is summarised in figure 9. 
 
Given HSP90’s role as the ‘cancer chaperone’, it is unsurprising that its inhibition 
has been investigated as a therapeutic target. As such, a number of inhibitors 
have been developed (Neckers and Workman, 2012), which have chiefly been 
based upon the natural products radicicol and geldanamycin (see figure 9). 
These inhibitors exert their action via blockade of the nucleotide-binding pocket 
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of HSP90, preventing binding and subsequent hydrolysis of adenosine 
triphosphate (ATP) and so inactivating the chaperone (Roe et al., 1999). 
Substrate-binding by HSP90 is dependent upon its ATPase activity although the 
mechanism is so far not completely understood; when HSP90 is not bound to 
ATP, the dimeric chaperone possesses high affinity for the substrate and 
promotes binding. The binding and subsequent hydrolysis of ATP promotes the 
dissociation of the chaperone-substrate complex, enhanced by the presence of 
the cochaperone p23, releasing newly reduced adenosine diphosphate (ADP) 
and inorganic phosphate (Pi) (Young and Hartl, 2000). This ATP-dependent 
substrate release mechanism may allow rapid cycling, enabling HSP90 to 
stabilise a greater number of proteins, as even transient HSP90-binding is 
sufficient to prevent proteasomal degradation (Peng et al., 2009). As such, the 
inhibition of HSP90 results in the proteasomal degradation of numerous proteins 
normally stabilised by HSP90 through HSP70-dependent ubiquitination. 
 
While radicicol showed promise as a cancer therapeutic in vitro (Schulte et al., 
1998), the compound was found to be inactive in vivo (Yang et al., 2004), and 
the toxicity profile of geldamycin was found to be unacceptable (Supko et al., 
1995). Development of HSP90 inhibitors has therefore primarily focused upon 
the development of more suitable derivatives such as the geldanamycin family 
of inhibitors, which include the drug candidates 17AAG and 17DMAG (see figure 
10) that show reduced toxicity compared to geldanamycin. The relative 
hepatotoxicities of geladanamycin and its derivatives has been linked to their 
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Figure 9. Diagram of mechanism of protein stabilisation by HSP90  
Partial unfolding of client proteins results in binding by HSP70 complex. Subsequent binding of 
CHIP promotes ubiquitination, whereas binding by Hop allows recruitment of HSP90, and thus 
stabilisation of the protein. Heat shock protein 70 (HSP70); Heat shock protein 40 (HSP40); C-
terminus of HSP70-interacting protein (CHIP); Ubiquitin (Ub); HSP90-HSP70 organising protein 
(Hop); Heat shock protein 90 (HSP90); Proteolytically resistant 23 kDa (p23). Adapted from (Pratt 
et al., 2010). 
 
redox properties and reactivity with thiols; both 17AAG and 17DMAG showed 
more favourable properties in this regard (Samuni and Goldstein, 2012, Guo et 
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al., 2008). 17AAG has been particularly effective in combination with 
Trastuzumab in clinical trials in breast cancer patients expressing human 
epidermal growth factor receptor 2 (HER2), a sensitive HSP90 client protein 
(Modi et al., 2007, Modi et al., 2011), highlighting the promise of HSP90 
inhibitors as therapy options.  
 Figure 10. Structures of HSP90 inhibitors 
A Radicicol B Geldanamycin-derived structures.  
 
The degradation of many HSP90 substrate proteins following HSP90 inhibition 
offers an opportunity for therapy monitoring and as such many client proteins 
and downstream targets have been researched as biomarkers of response to 
treatment, such as HSP70 (Dakappagari et al., 2010), AKT (Yamazaki et al., 2011) 
and HER2 (Smith-Jones et al., 2006). Molecular imaging techniques are ideally 
suited to development as noninvasive means of assessing biomarker expression 
and patient response to therapy. As CXCR4 has been shown to be degraded in 
Radicicol 
Geldanamycin 
R = OCH3 
17AAG 
R = NHCH2CH=CH2 
17DMAG 
R = NHCH2CH2N(CH3)2 
A 
B 
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response to HSP90 inhibition (Mandawat et al., 2010), it may also be possible to 
use novel radiotracers targeting CXCR4 as tools of response to therapy. The 
possibilities of similar methods have been explored in a number of studies, 
summarised in table 4. However, of the PET imaging studies described, many 
target their biomarker using large macromolecular antibodies (Niu et al., 2009, 
Nagengast et al., 2010, Oude Munnink et al., 2012), which are prone to suffer 
from issues with poor penetrance in tumours as a result of their large size, 
resulting in lengthy intervals between tracer injection and imaging. Alternatively, 
the tracers may be non-specific (Li et al., 2012) or else use undesirable PET 
radionuclides. Thus the PET tracers currently in development to detect 
biomarkers of HSP90 inhibition leave a lot to be desired, creating an opportunity 
for smaller 18F and 68Ga-labelled PET tracers targeted to an alternative 
biomarker of HSP90 inhibition, CXCR4.  
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Table 4. Comparative table documenting recent attempts to image changes in HSP90 activation with positron emission tomography.
HSP90 
target Inhibitor Probe Notes Reference 
HER2 17AAG 
[68Ga]-DOTA-F(ab')2-
trastuzumab 
Response detected after 24 hours. More 
sensitive than [18F]fluorodeoxyglucose (FDG). 
(Smith-Jones 
et al., 2006) 
EGFR 17AAG [64Cu]-DOTA-cetuximab 
Response detected after 24 hours. High 
accumulation of tracer in blood and liver. 
(Niu et al., 
2008) 
HER2 17DMAG 
[64Cu]-DOTA-
trastuzumab 
Response detected after 24 hours. More 
sensitive than [18F]FDG. High accumulation 
of tracer in blood. 
(Niu et al., 
2009) 
VEGF 
NVP-
AUY922 
[89Zr]-Bevacizumab 
Response detected after 2 weeks. High 
accumulation of tracer in blood and liver. 
Images obtained 144 hours after tracer 
injection. 
(Nagengast et 
al., 2010) 
HER2 17AAG 
[89Zr]-Trastuzumab-
F(ab')2 
Response detected after 24 hours. High 
accumulation of tracer in kidneys. Images 
obtained 6 hours after tracer injection. 
(Oude 
Munnink et 
al., 2012) 
ALK 
NVP-
AUY922 
[18F]-3’-fluoro-3’-deoxy-
L-thymidine(FLT) 
Reponse detected after 5 days. More 
sensitive than [18F]FDG. Not truly targeted to 
ALK expression. 
(Li et al., 2012) 
85 
 
1.10 – Rationale for Project 
 
The aim for this project was to develop cellular models appropriate for the study 
of CXCR4 to subsequently enable validation of the test compounds. It was 
planned to assess the potential of a range of novel compounds from within 4 
classes of currently described CXCR4 antagonists - the T140-related 
oligopeptides, FC131-derived pentapeptides, It1t-related isothioureas and 
AM3100-related cyclam compounds. The analogues were designed to allow 
incorporation of chemical groups amenable to radiolabelling and with the 
following desirable characteristics: 
 Potent antagonism of CXCR4 receptor binding and CXCR4-dependent 
cellular processes 
 Preferential use of 68Ga and 18F radionuclides 
 Rapid radiolabelling procedures to maximise the potential of short-lived 
radioisotopes 
 
In order to establish the potential of the newly synthesised compounds as PET 
imaging agents, the compounds needed to be assessed for the potency of their 
antagonism for CXCR4 (in terms of affinity and efficacy), to ensure that the 
tracer would bear specificity for the receptor. This was achieved with the 
following methods: 
86 
 
 Competitive CXCR4 radioligand binding, to determine the relative 
affinities of the compounds for CXCR4 
 Inhibition of CXCR4-directed migration, to ascertain the effect of 
antagonist binding upon CXCR4-dependent biological processes 
 
Following this initial characterisation, promising candidate compounds were 
selected for radiolabelling and assessed for their suitability as CXCR4-targeting 
PET imaging agents in the following ways: 
 Uptake into CXCR4 cell lines in vitro, to determine the tracer’s specificity 
for CXCR4 
 In vivo imaging experiments, to confirm accumulation of radiotracer in 
CXCR4-expressing tumours, and a sufficiently high target-to-background 
ratio (contrast) to clearly visualise lesions against background uptake 
 In vivo biodistribution experiments to confirm precise organ-by-organ 
uptake of the tracer, and to suggest likely routes of excretion.  
 In vivo metabolite studies to determine the metabolic stability of 
circulating and excreted radioactivity  
 
In order to aid the above experiments, appropriate cellular models were to be 
characterised, beginning with the identification of cell lines that express CXCR4 
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endogenously, followed by modification by transfection with CXCR4 expression 
vectors to create parallel sublines that differ only in their expression of CXCR4, 
which was verified by qRT-PCR, western blot and flow cytometry. Ideally the 
developed radiotracers would display the ability to accumulate in tissues 
according to CXCR4 expression, minimal ‘noise’ in background tissues such as 
blood or muscle, and a pharmacokinetic profile that favours the circulation of 
unmetabolised radiotracer for the duration of the experiment before clearance 
through excretory routes.  
 
A further evaluation of CXCR4-targeting was to examine CXCR4 expression as a 
biomarker for response to therapy, such as the inhibition of HSP90.  
 To evaluate the potential of radiolabelled probes to detect degradation 
of CXCR4 as a result of HSP90 inhibition by 17AAG through differential 
radiotracer uptake in cell lines and tumours. 
 
1.10 - Hypotheses 
 
 The antagonists developed will exert an inhibitory effect upon CXCR4-
dependent in vitro biological processes, including radioligand binding and 
ligand-directed migration, enabling the determination of the IC50 values 
for the compounds.  
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 The radiolabelled antagonist tracer will accumulate in CXCR4-
overexpressing cell lines at a significantly higher level than in non-
expressing lines in vitro. Any uptake seen will be significantly reduced by 
preincubation with unlabelled tracer.  
 The radiolabelled antagonist will accumulate in CXCR4-expressing 
tumours at a significantly higher level than in non-CXCR4 expressing 
tumours in vivo, which can be significantly reduced by coinjection with 
unlabelled tracer.  
 The radiolabelled antagonist will accumulate in the tumours of 17AAG-
treated mice at a significantly lower level than in the tumours of 
untreated mice.  
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Chapter Two - Materials and Methods 
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2.1 - Reagents 
 
AMD3100 was purchased from Sigma-Aldrich (Missouri, USA), whereas the 
compounds AMD3465, TC14012 and It1t were purchased from Tocris Bioscience 
(R&D Systems, Minneapolis, USA).  
 
2.2 - Cell lines and culture 
 
The human cell lines Jurkat clone E6-1 (T cell lymphocyte), MDA-MB-231 (breast 
cancer), MDA-MB-435S (disputed origin – potentially breast cancer or 
melanoma) and HCT116 (colon carcinoma) were purchased from the American 
Type Culture Collection (ATCC, Virginia, USA) and maintained in Roswell Park 
Memorial Institute 1640 (RPMI) medium (Invitrogen, California, USA). The 
human non-small cell lung cancer A549 cell line was purchased from ATCC, and 
maintained in low glucose Dulbecco’s Minimum Essential Medium (DMEM) 
(Invitrogen, California, USA). The stably transfected human glioblastoma cell 
lines U87.MG, U87.CD4 and U87.CD4.CXCR4 were gifts from Dr. Erman Mandaci 
at the NIH-AIDS Research and Reference Reagent Programme (Maryland, USA), 
and were maintained in low glucose DMEM medium. The medium for U87.CD4 
was supplemented with 300 µg/ml G418 (Sigma, Missouri, USA), whilst 
U87.CD4.CXCR4 was cultured in medium containing 300 µg/ml G418 and 
1 µg/ml puromycin (Sigma, Missouri, USA). All cell lines were cultured in the 
presence of 10% Foetal Bovine Serum (FBS) (Sigma-Aldrich, Missouri, USA), 2mM 
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L-glutamine (Invitrogen, California, USA) and 100 U/ml penicillin-streptomycin 
(Invitrogen, California, USA) in a humidified atmosphere of 5% CO2 at 37 °C.  
2.3 - qRT-PCR 
i) RNA extraction 
Cells were seeded at 60-80% confluency in 60 mm dishes (MDA-MB-231: 1×106 
cells, MDA-MB-435S: 1×106 cells, HCT116: 1.4×106 cells, A549: 4×105 cells, 
U87.MG: 1×106 cells, U87.CD4: 1×106 cells, U87.CD4.CXCR4: 1×106 cells Jurkat: 
3×106 cells) in 5 ml complete medium (as specified in section 2.2) 48 hours 
before RNA extraction using the QIAGEN RNeasy RNA purification kit (QIAGEN, 
Germany) as follows: Medium from the 60 mm dishes was aspirated and 
replaced with 600 µl buffer RLT, scraped, and collected in RNA-free 
microcentrifuge tubes. Lysates were homogenised by vortexing for 1 minute, 
before dilution in an equal volume of 70% ethanol. 700 µl of the solution was 
then loaded into an RNeasy spin column placed inside a 2 ml collection tube, and 
centrifuged at >10,000 g for 15 seconds. The flow-through was discarded, and 
the process repeated with any remaining lysate from the sample. The spin 
column was then washed with 700 µl buffer RW1 by centrifugation at >10,000 g 
for 15 seconds, and flow-through discarded. The spin column was then 
additionally washed by 2 centrifugation steps with 500 µl buffer RPE at 
>10,000 g, first for 15 seconds, then for 2 minutes. The spin column filter was 
then dried by centrifugation into a fresh collection tube at >16,000 g for 1 
minute. The spin column was then placed into an RNAse free microcentrifuge 
tube and the RNA eluted with 2 × 50 µl RNAse-free water. The RNA 
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concentration of 2 µl of the resulting samples were analysed for concentration 
and quality by a Nanodrop 1000 (Thermo Scientific Fisher, Massachusetts, USA). 
ii) Reverse transcription 
 
RNA samples were transcribed to complementary deoxyribonucleic acid (cDNA) 
using the QuantiTect Reverse Transcription kit (QIAGEN, Germany) as follows: 
Genomic DNA contaminants in 1000 ng of the RNA samples were eliminated by 
incubation for 2 minutes at 42 °C in the presence of 1X gDNA Wipeout Buffer in 
a total sample volume of 20 µl. 14 µl of this RNA sample mixture was then mixed 
with 1 µl Quantiscript Reverse Transcriptase, 4 µl Quantiscript RT buffer and 1 µl 
of the supplied RT primer mix. This reaction mixture was incubated at 42 °C for 
15 minutes to form the cDNA, and then incubated at 95 °C for 3 minutes to 
inactivate the reverse transcriptase.  
iii) Polymerase chain reaction 
 
Polymerase chain reaction (PCR) was performed with a Taqman system 
(Invitrogen, California, USA) as follows: 45 ng cDNA was mixed with 1X Taqman 
universal mastermix II, 1X Taqman assay mixture for CXCR4 or glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) and water to give a total volume of 20 µl. 
The samples were then loaded into duplicate wells of a 96-well reaction plate 
and loaded into a 7900HT Fast Real-Time PCR System (Applied Biosystems, 
California, USA), which conducted the amplification reaction (1 cycle of 95 °C for 
20 seconds, followed by 40 cycles of 95 °C for 1 second followed by 60 °C for 20 
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seconds) and derived the cycle number threshold (CT) value for each sample. 
This CT value was averaged over the duplicate samples, and converted to a ΔΔCT 
value of expression by two successive antilog steps, which were expressed   
relative to the values of a control sample (Jurkat cells), according to the 
following equations: 
ΔCT = 2 
-(average Ct) 
Relative expression = ΔCT CXCR4/ΔCT GAPDH 
ΔΔCT = 2 
–(relative ΔCTsample – relative ΔCTcontrol) 
The graphical images shown were representative of 3 independent experiments. 
2.4 - Immunoblotting 
i) Preparation of lysates from cell culture 
Cells were cultured in 6 well plates at 60-80% confluency [MDA-MB-231: 5×105 
cells, MDA-MB-435S: 7×105 cells, HCT116: 7×105 cells, A549: 2×105 cells, Jurkat: 
1.5×106 cells, U87-derived lines: 5×105 cells] in 2 ml complete medium at 48 
hours before lysis with 200 µl radioimmunoprecipitation assay (RIPA) buffer 
(Sigma-Aldrich, Missouri, USA) supplemented with 1/100 Halt™ protease and 
phosphatase inhibitor cocktail (Thermo Fisher Scientific, Massachusetts, USA) on 
ice using cell scrapers. All lysates were sonicated to homogenise, and 
centrifuged at 17,800 rpm for 5 minutes to remove precipitates, and protein 
concentration of the supernatants determined by mixing of 25 µl of lysates with 
200 µl bicinchoninic acid (BCA) assay kit reagents (Thermo Fisher Scientific, 
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Massachusetts, USA) prepared to a 1:50 ratio mixture of reagent A to reagent B. 
The samples were incubated for 30 minutes at 37 °C in the dark, and then 
analysed using a spectrophotomer for absorbance at 560 nm. Protein 
concentration of the samples was calculated by comparison to a standard curve 
of known protein concentrations.  
ii) Preparation of lysates from snap-frozen tumour samples 
 Tumour lysates were prepared by addition of 500 µl RIPA buffer containing 
1/100 Halt™ protease and phosphatase inhibitor cocktail (Thermo Fisher 
Scientific, Massachusetts, USA) the frozen tumours within Precellys® CK14 lysing 
kit tubes (Berlin Technologies, France). These tubes were homogenised at 
6500 rpm for 2×25 seconds using Precellys®24 lysis equipment (Berlin 
Technologies, France), and the tubes centrifuged at 17,800 rpm for 5 minutes to 
settle the liquid supernatant. The protein concentrations of these supernatants 
were determined with a BCA kit (Thermo Fisher Scientific, Massachussetts, USA) 
and spectrophotometer analysis as described in chapter 2.4i. 
iii) Immunoblotting 
120 µl of the lysate samples were mixed with 50 µl NuPage® lithium dodecyl 
sulphate (LDS) loading buffer and 20 µl NuPage® reducing agent (Invitrogen, 
California, USA) within microcentrifuge tubes and heated at 70 °C for 10 minutes 
to denature.  Sample volumes corresponding to a fixed quantity (15-30 ug) of 
cell lysate mixtures were loaded into Mini-PROTEAN® TGX™ 4-15 % pre-cast gels 
(Bio-Rad, California, USA), and separated by gel electrophoresis at 250 V for 20 
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minutes in a Tris-Glycine running buffer [25 mM Tris, 192 mM glycine, 0.1% 
SDS]. The size-separated samples were then removed from the gel cassette and 
placed within a Trans-Blot® Turbo™ System loaded with a Trans-Blot® Turbo™ 
PVDF transfer pack (Bio-Rad, California, USA) for the transfer of the protein 
samples to the supplied membrane by application of a 2.5 A current for 7 
minutes. Following transfer, the membranes were blocked for 30 minutes by 
agitation in the presence of 5% milk in tris-buffered saline with TWEEN 20 
(TBST), and then incubated with primary antibodies in 5% milk-TBST overnight at 
4 °C. Following three 5 minute washes in TBST, secondary antibodies were 
incubated for 45 minutes in 5% milk-TBST at room temperature. The membranes 
were washed 3 more times in TBST, and incubated with 3 ml of reagent mixture 
(1:1) from the Amersham enhanced chemiluminescence (ECL) Plus Western 
Blotting Detection Kit (GE Healthcare Life Sciences, UK). The following primary 
antibodies were used: rabbit anti-human CXCR4 (clone UMB2, Epitomics, 
California, USA) at a concentration of 1/2000, rabbit anti-human CD4 (Epitomics, 
California, USA) at a concentration of 1/1000, mouse anti-human CDK4 (New 
England Biolabs, Massachusetts, USA) at a concentration of 1/1000, mouse anti-
human α-tubulin (Santa Cruz Biotechnology, California, USA) at a concentration 
of 1/500, rabbit anti-human β-actin (Sigma-Aldrich, Missouri, USA) at a 
concentration of 1/5000, and rabbit anti-human GAPDH (New England Biolabs, 
Massachussetts, USA) at a concentration of 1/1000. Secondary antibodies used 
were goat anti-mouse Immunoglobin G-horseradish peroxidise (IgG-HRP) and 
goat anti-rabbit IgG-HRP (Santa Cruz Biotechnology, California, USA), all at a 
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concentration of 1/2000. Protein expression was quantified by densitometric 
analysis using a GS-800 Imaging Densitometer (Bio-Rad, California, USA), with 
bands selected using Quantity One® software (Bio-Rad, California, USA), and the 
CXCR4 expression of each sample lane expressed relative to the loading control 
within the same lane. 
2.5 - Flow cytometry 
Cells were cultured in T75 flasks and detached while at 60-80% confluence with 
4 ml 0.5mM ethylenediaminetetraacetic acid in Dulbecco’s phosphate-buffered 
saline (EDTA-DPBS) buffer (Sigma-Aldrich, Missouri, USA). 1.4×106 cells were 
washed three times in 3 ml 0.1% bovine serum albumin in phosphate-buffered 
saline (BSA-PBS) by centrifugation at 600 g for 3 minutes, and then resuspended 
at a density of 4×10-6 cells/ml in 1% BSA-PBS for 30 minutes to block non-specific 
binding. 100 l aliquots of the cellular suspensions were incubated with 20 l 
either phycoerythrin (PE)-conjugated anti-human CXCR4 monoclonal antibody 
(clone IgG5) or PE-conjugated mouse Ig2B isotype control antibody (R&D 
Systems, Minnesota, USA) for 45 minutes on ice. Unbound antibody was 
separated from the cells by two washes with 0.1% BSA-PBS using centrifugation 
at 600 g for 3 minutes. Cells were strained and placed in 5 ml flow cytometry 
tubes (BD Bioscience, New Jersey, USA) on ice prior to analysis by flow 
cytometry using the FACS Canto (BD Biosciences, New Jersey, USA). The 
photomultiplier voltage gains were set so that the cells stained with the isotype 
control antibody appeared in the first quantile of the output scatterplot [Jurkat 
FSC:5 SSC:400 ; MDA-MB-231 FSC:5, SSC:320 ; MDA-MB-435S FSC:5, SSC:320; 
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HCT116 FSC:5, SSC:330 ; A549 FSC:5, SSC:330; U87 FSC: 5, SSC:330]. 
Fluorescence emissions were detected by 488 nm argon laser excitation with 
emissions filtered to 585/42 nm. The cell populations were gated for viability 
using FlowJo7.6.4 software (Treestar, Oregon, USA), and CXCR4 expression 
described in terms of median fluorescence intensity (PE-A). Histogram 
representations of anti-CXCR4 PE staining for each cell line were compared 
against the isotype control PE staining for the positive control cell line (Jurkat 
cells or stable 3). 
2.6 - Vector cloning 
i) Cloning 
Vectors used were as follows: pcDNA™3.1 empty vector control (Invitrogen, 
California, USA), pcDNA™3.1-CXCR4 and pcDNA3.1™-3xHA-CXCR4 (Missouri 
cDNA S&T Resource Center, Missouri, USA). E. coli transformation was achieved 
by incubation of 50 l Subcloning Efficiency™ DH5α™ Competent E. coli with 
10 ng of the appropriate vector on ice for 30 minutes, followed by heat shock for 
20 seconds at 42 °C, and then incubation on ice for a further 2 minutes. The  
transformed cell were cultured in 950 l super optimal broth with catabolite 
repression (SOC) medium (Invitrogen, California, USA) at 37 °C for 1 hour before 
being spread onto agar plates containing 100 µg/ml ampicillin (Sigma-Aldrich, 
Missouri, USA) and cultured at 37 °C overnight. Individual colonies were selected 
and amplified in 3 ml lysogeny broth (LB) medium (Sigma-Aldrich, Missouri, USA) 
containing 100 µg/ml ampicillin for 8 hours, before inoculation of a larger 100 ml 
culture medium for further expansion overnight. The cloned vectors were 
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purified using a QIAGEN plasmid midi kit (QIAGEN, Germany) as follows: The 
cells were collected by centrifugation at 15 minutes at 6000 g at 4 °C and 
resuspended in 4 ml buffer P1. Lysis was achieved by addition of 4 ml buffer P2 
followed by vigorous shaking and incubation at room temperature for 5 minutes. 
The addition of 4 ml buffer P3 precipitated genomic DNA, proteins and debris, 
enabling their separation from the vector-containing supernatant by two 
centrifugations at 20,000 g for 30 minutes at 4 °C. This supernatant was added 
to a QIAGEN-tip 100 (primed with 4 ml buffer QBT) and allowed to empty by 
gravity. The tip was washed twice with 20 ml buffer QC, and the vector eluted 
with 5 ml buffer QF. Finally, the vector was precipitated by the addition of 3 ml 
isopropanol and collected by centrifugation at 15,000 g for 30 minutes at 4 °C. 
The pellet was washed in 70% ethanol, dried, and re-dissolved in 250-500 µl Tris-
EDTA buffer [10 mM Tris, 1 mM EDTA, pH 8.0] and stored at -20 °C until 
required.  
ii) Analysis 
DNA concentration and quality of the vector samples were determined by 
analysis of 2 l samples with the Nanodrop 1000 (Thermo Scientific Fisher, 
Massachusetts, USA) at 260, 280 and 230 nm wavelengths, with samples bearing 
260/280 nm below 1.8, and 260/230 nm values below 2.0 discarded. Presence of 
the transgene-coding insert region within the plasmid samples was confirmed by 
analysis of sample aliquots following restriction digest. In the digestion reaction 
2ng of DNA samples were incubated with 2 g acetylated BSA (Promega, 
Wisconsin, USA), 2 l 10X restriction enzyme buffer D (Promega, Wisconsin, 
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USA), and 0.5 l of the appropriate restriction enzyme [12 u/l EcoRI and 
10 u/l XhoI for the pcDNA3.1™-CXCR4 vector, 10 u/l HindIII and 10 u/l XhoI 
for the pcDNA3.1™-3xHA-CXCR4 vector (all enzymes obtained from Promega, 
Wisconsin, USA)] were incubated at 37 °C for 4 hours. 15 l of the digested 
samples were then loaded directly into an 0.8% eGel (Invitrogen, California, USA) 
system, separated by gel electrophoresis for 10 minutes with the eGel iBase 
power system (Invitrogen, California, USA), and then visualised using a UV 
transilluminator.  
2.7 - Transfections and maintenance of cloned cell 
lines 
 
4×105 HCT116 cells were seeded per well of a 6 well plates in 2 ml antibiotic-free 
RPMI medium 24 hour prior to transfection. The following day, 2.5 g of sample 
vector was mixed with 150 l opti-MEM medium (GIBCO, California, USA) and 
2.5 l Lipofectamine Plus reagent (Invitrogen, California, USA) added. This 
mixture is added to 9 l of Lipofectamine LTX reagent (Invitrogen, California, 
USA) diluted in 150 l opti-MEM medium, and incubated at room temperature 
for 5 minutes, before being added dropwise to cells cultured in 1.5 ml opti-MEM 
medium. At 48 hours post-transfection the cells were detached with 1 ml 0.05% 
trypsin-EDTA (Invitrogen, California, USA) and passaged at 1:10 dilution in 
100 mm dishes in complete medium supplemented with 1000 µg/ml G418 
(Sigma-Aldrich, Missouri, USA). Once colonies had formed (7-10 days later), 
geographically isolated colonies were selected by local detachment with 50 l 
0.05% trypsin-EDTA (Invitrogen, California, USA) in cloning cylinders (Millipore, 
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Massachusetts, USA), and remaining clones pooled together by detachment with 
3 ml 0.05% trypsin-EDTA.  All clonal populations were maintained in medium 
supplemented with 1000 µg/ml G418 for 3-4 weeks before a reduction in G418 
concentration to 500 µg/ml thereafter.  
2.8 - Doubling time assay 
 
U87.MG, U87.CD4 and U87.CD4.CXCR4 cells were detached and counted by Cell 
Scepter 2.0 Automated Cell Counter with 60 µm Scepter Sensors (Millipore, 
Massachusetts, USA), then seeded into triplicate wells of five 6-well plates at a 
density of 1×104 cells per well in 2 ml complete DMEM medium. After each 48 
hour time-point, one triplicate wells of each cell line was aspirated with 1 ml 
0.05% trypsin-EDTA (Invitrogen, California, USA), diluted in 4 ml complete 
DMEM medium and the cells in sample counted by haemacytometer. Medium 
within the wells was replenished with complete medium every 48 hours. The cell 
counts for each cell line over the 10-day period was used to calculate doubling 
time according to the following exponential growth calculation: 
Cell number at time t = cell number at time 0 × e (doubling time × time)  
2.9 - Scratch wound assay 
U87.CD4 and U87.CD4.CXCR4 cells were detached and seeded at a density of 
2×105/well in 12 well plates 24 hours before commencement of the experiment 
in 1 ml complete DMEM medium. At the beginning of the experiment the 
medium was removed from the wells to allow thin tracks of cells to be scraped 
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away with a p10 pipette tip (forming a scratch wound) and then washed with 
500 l PBS to remove debris. The well plates were then incubated with 1 ml 
serum-free DMEM media containing either no additives, 400 ng/ml SDF1, or 
both 400 ng/ml SDF1 and 20 µM AMD3100. An Axiovert 100 (Zeiss, New York, 
USA) time-lapse microscope was used to photograph scratch wounds at fields of 
view for three separate scratches at two time points, 12 hours apart. The cells 
were incubated at 37 °C in the presence of 5% CO2 for the duration of the time-
lapse experiment. The sizes of the scratches photographed at t=0 and t=12 for 
each sample were quantified using ImageJ software (NIH, Maryland, USA) by 
outlining the scratch wound by hand, and expressing the scratch area in terms of 
pixel quantity. Closure of the scratch wound was calculated according to the 
following equation below. 
 
2.10 – Synthetic chemistry and radiosynthesis  
i) CCIC7/[18F]CCIC7 
CCIC7 was synthesised at Imperial College London by Dr. Ola Åberg (illustrated in 
figure 12) using a purchased aminoxyfunctionalised precursor, Cyclo-[D-Tyr-
Arg(PEG2-O-NH2)-Arg-2-Nal-Gly] (Cambridge Research Biochemicals, UK). This 
precursor was reacted with 4-fluorobenzaldehyde dissolved in methanol and 
10 mM ammonium formate (pH 2.5) to give CCIC7 at a 74% yield, and a 
distribution coefficient at pH 7.4 (logDpH 7.4) of 1.09. The compound was 
formulated at a concentration of 10 mM in 100% DMSO and frozen at -20°C in 
% change = ((areascratch t0 - areascratch t12)/areafield of view ) × 100 
102 
 
aliquots. [18F]CCIC7 was radiosynthesised at Imperial College London by Dr. Ola 
Åberg by the reaction of [18F]fluorobenzaldehyde in methanol with a freshly 
prepared suspension of the aminooxy functionalised peptide precursor, cyclo-[D-
Tyr-Arg(PEG2-O-NH2)-Arg-2-Nal-Gly], in 100 mM ammonium formate buffer (pH 
2.0), before venting and dilution in ammonium formate buffer (pH 3.5). The high 
performance liquid chromatography (HPLC) purified fraction was immobilised 
upon a Waters SepPak tC18 cartridge (Waters, Massachusetts, USA) before 
elution with 5 mM hydrochloric acid in ethanol. The resultant [18F]-CCIC7 
possessed a mean specific activity of 31 GBq/µmol, a radiochemical yield of 22%, 
and a radiochemical purity of >99%. 
ii) CCIC16 
CCIC16 (illustrated in figure 26) was custom-synthesised by Peptide Protein 
Research Ltd (Fareham, UK), whereas Ga3+, [AlF]2+, In3+ and Cu3+ cation chelates 
were synthesised at Imperial College London by Guillaume George. The chelates 
Ga-CCIC16, AlF-CCIC16, In-CCIC16 and Cu-CCIC16 were synthesised according to 
a general protocol as follows: A solution comprising CCIC16 in buffer [0.1M 
sodium acetate pH 4.0 for Ga3+ and [AlF]2+ chelates, 65 mM ammonium acetate 
pH 6.0 for In3+ and Cu3+ chelates] was reacted with a solution of the metal salt 
[GaCl3, AlCl3, InCl3 and CuCl2.H2O] before purification by semi-preparative HPLC 
using a Luna C18(2) column (Phenomenex, California, USA) and elution in 
ethanol-PBS (7:3). The compound was then freeze-dried to derive the solid 
compound with a measured logDpH 7.4 of -3.58. [
68Ga]-CCIC16 was 
radiosynthesised at Imperial College London by Guillaume George using the 
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custom-synthesised CCIC16 (Peptide Protein Research Ltd, UK) as the peptide 
precursor. [68Ga]GaCl3 was directly eluted from an Eckert & Ziegler Isotope 
Products IGG100-10M Gallium-68 Generator (Eckert & Ziegler Strahlen-
Medizintechnik, Germany) into a solution of CCIC16 in 0.5 M acetate buffer (pH 
5.8) and allowed to react for 5 minutes at 90 °C. The reaction mixture was 
purified by HPLC with a Light C18 cartridge (Waters, UK) and the tracer eluted in 
ethanol-PBS (7:3). [68Ga]-CCIC16 showed a radiochemical yield of 90%, a 
radiochemical purity of 98%, and a specific activity of 2.76 GBq/µmol.  
iii) Cyclopentapeptide synthesis/[18F]CCIC15/[18F]CCIC30 
CCIC15, CCIC29, CCIC30 and CCIC36 were synthesised at Imperial College London 
by Guillaume George (illustrated in table 10). The general procedure for the 
synthesis of these compounds involved reaction between protected amino 
acids, N,N-diisopropylethylamine, hydroxybenzotriazole, HBTU peptide-coupling 
reagent, and H-Glycine-chlorotrityl resin in a solution of dimethylformamide to 
form a resin-bound pentapeptide. The resin was later cleaved by treatment with 
1:1:3 mixture of acetic acid, trifluoroethylene and dichloromethane to form a 
linear pentapeptide. Cyclisation was achieved by treatment with sodium 
carbonate in dimethylformamide and 2,2-diphenylphosphoroazide, followed by 
filtration  of the suspended products in methanol-chloroform. The peptide 
product was precipitated with ethanol and then dissolved in a 190:5:5 mixture of 
trifluoroacetic acid (TFA), triisopropylsilene and water to give a TFA salt of the 
cyclised pentapeptide precursor. Finally, the alkyne groups of the 
cyclopentapeptide precursors underwent click chemistry reactions in copper 
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sulphate, sodium ascorbate, 2-fluroethylazide and sodium acetate buffer. The 
triazole-containing cyclopentapeptide final products were produced in 
quantitative yields of 89-99%. The measured logDpH 7.4 for CCIC15 and CCIC30 was 
-0.11 and -2.30, respectively. Radiosynthesis of [18F]CCIC15 and [18F]CCIC30 
perfomed by Dr. Federica Pisaneschi at Imperial College London by successive 
addition of 238 mM CuSO4 in water, 262 mM sodium ascorbate in 250 mM 
acetate buffer (pH 5), 298 mM bathophenanthrolinedisulfonic acid disodium salt 
in water, 2-[18F]fluoroethylazide in acetonitrile, and 15 mM  of the alkyne-
containing cyclopeptide precursor [cyclo(D-Tyr-Prg-Arg-2-Nal-Gly) for 
[18F]CCIC15 and cyclo(D-Prg-Gly-Arg-2-Nal-Gly) for [18F]CCIC30] in 
dimethylformamide. The reaction was continued in the presence of benzylazide 
in methanol, and the reaction product purified by reverse phase semi-
preparative HPLC using a Luna C182 column (Phenomenex, California, USA). 
[18F]CCIC15 was eluted in 25 mM HCl in ethanol, and showed a decay-corrected 
radiochemical yield of 63%, a radiochemical purity of >98%, and a mean specific 
activity of 19.4 GBq/µmol. [18F]CCIC30 was eluted in 25 mM HCl in ethanol, and 
showed a decay-corrected radiochemical yield of 55%, a radiochemical purity of 
>98%, and a mean specific activity of 6.7 GBq/µmol. 
iv) GG343, CCIC8, GG345, CCIC27, GG337 and GG338 
GG343, CCIC8, GG345, GG337 and GG338 were synthesised at Imperial College 
London by Guillaume George (illustrated in table 14) according to a common 
procedure, by the reaction of 0.5 mmol 3-(chloromethyl)-6,6-dimethyl-5H,6H-
imidazo[2,1-b][1,3]thiazol with 0.5 mmol thiourea precursor [3-cyclohexyl-1-(2-
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fluorophenyl)thiourea for GG343, 3-cyclohexyl-1-(1-fluorophenyl)thiourea for 
CCIC8, 3-cyclohexyl-1-(4-fluorophenyl)thiourea for GG345, 1-cyclohexyl-3-{1-[4-
fluorophenyl)methyl]piperidin-4-yl}thiourea for CCIC27, 3-cyclohexyl-1-{1-
[2[fluoroethyl)-1H-1,2,3-triazol-4-yl]cyclohexyl}thiourea for GG337, 1-cyclohexyl-
2-{2-[1-(2-fluoroethyl)-1H-1,2,3-triazol-4-yl]propan-2-yl}thiourea for GG338] in 
anhydrous acetonitrile and ethanol. The reaction mixture for the synthesis of 
CCIC27 was further treated by purification by flash column chromatography, and 
the acidification of the product with 2 N hyrdrochloric acid in diethyl ether, and 
centrifugation to give the finished CCIC27 product. All compounds were also 
purified by preparative HPLC. 
v) GG366 
GG366 was synthesised at Imperial College London by Guillaume George 
(illustrated in table 14) by reaction of 0.05 mmol of the isothioureapiperidine 
precursor [N’-cyclohexyl-N-(piperidine-4-yl)[({6,6-dimethyl-5H,6H-imidazo[2,1-
b][1,3]thiozol-3-yl}methyl]methanimidamide] in anhydrous acetonitrile with 
0.255 mmol potassium carbonate. 0.05 mmol fluoroethyltosylate was added to 
the reaction mixture to produce GG366 in an alkylation reaction before 
quenching with 2 N aqueous hydrochloric acid and purification by preparative 
HPLC.  
vi) GG248 
GG366 was synthesised at Imperial College London by Guillaume George 
(illustrated in table 14) by reaction of a 1:5 solution of the alkyne precursor N-
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[(cyclohexylimino)[({6,6-dimethyl-5H,6H-imidazo[2,1-b][1,3]thiazol-3-
yl}methylsulfanyl]methyl]-2-[2[(prop-2-yn-1-yloxy)ethoxy]ethan-1mine in 
dimethylfluoride, with 250 mM sodium acetate buffer (pH 5), 0.038 mmol 
copper sulphate and 0.95 mM sodium ascorbate. The reaction product was 
purified using flash column chromatography and preparative HPLC.   
vii) DB011  
DB011 was synthesised by Dr. Diana Brickute (DB011, illustrated in figure 43) in 
a multi-step process. The cyclam was coupled with ethyl trifluoroacetate to yield 
a protected cyclam [4,8,11-tris(trifluoroacetyl)-1,4,8,11-tetra-
azacyclotetradecane], which was alkylated by α,α’-dibromo-p-xylene in the 
presence of potassium carbonate and acetonitrile to form a protected 
bromoxylene cyclam, enabling a further reaction in acetonitrile to substitute the 
halide group for ethylenediamine. A reductive amination reaction of the 
reaction products with fluorobenzaldehyde in the presence of sodium 
triacetoxyborohydride provided 4, followed by deprotection of the cyclam group 
with 5 M sodium hydroxide in methanol. The reaction product was then 
converted into a hydrochloride salt with hydrochloric acid in the presence of 
ether, giving rise to DB011, which was then purified using preparative HPLC.  
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2.11 - 125I-SDF1α radioligand binding assays 
i) Method A 
 
The experiment was conducted using siliconised 1.5 ml microcentrifuge tubes 
(Sigma, Missouri, USA) to prevent non-specific binding of radioactivity.  A 100 l 
suspension of 2×105 Jurkat cells assay buffer [PBS containing 50 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 1 mM CaCl2, 5 mM 
MgCl2, 0.3 mM NaN3, 0.5% BSA; pH 7.4] was placed in the tube, followed by 
50 l of the indicated antagonist to give a variable final concentration [may 
include 0 nM, 1 mM, 200 M, 100 M, 10 M, 1 M, 100 nM, 10 nM, 1 nM, 
100 pM, and 10 pM], along with 50 l of 125I-SDF1α radioligand (PerkinElmer, 
Massachusetts, USA) to give a final concentration of 0.1 nM. The tubes were 
then incubated at room temperature for 90 minutes. Following incubation, the 
bound and unbound radioactivity within the sample was separated by filtration 
using a 96-well MultiScreen HTS GV filter plate system (Millipore, 
Massachusetts, USA) with a vacuum manifold, followed by 3 washes of 200 l 
assay buffer. The filters were then punched out and counted in an NE1600 
gamma counter (Thorn-EMI/Nuclear Enterprises, UK) for 240 s. The bound 
radioactivity was expressed as a percentage of the ICmax using GraphPad Prism 5 
(GraphPad Software, CA, USA).   
ii) Method B 
 
2.5×106 U87.CD4.CXCR4 cells were detached with 0.05% Trypsin-EDTA 
(Invitrogen, California, USA) and incubated at 37 °C in 5 ml complete DMEM 
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medium for 2 hours to recover from trypsinisation, then resuspended in binding 
buffer [PBS containing 2 mg/ml BSA] at a concentration of 1.5×106/ml. To each 
1.5 ml siliconised microcentrifuge tube (Sigma-Aldrich, Missouri, USA), 1.5×105 
cells were added in 50 l binding buffer, followed by 25 l of the indicated 
antagonist  in binding buffer [variable concentration; may include final 
concentrations of 0 nM, 1 mM, 500 M, 200 M, 100 M, 50 M, 10 M, 1 M, 
100 nM, 10 nM, 1 nM, 100 pM, and 10 pM], and 25 l 125I-SDF1α radioligand 
(PerkinElmer, Massachusetts, USA) in binding buffer to give a final concentration 
of 0.1 nM. The tubes were then incubated on ice for 90 minutes under agitation. 
Following incubation the bound and unbound radioactivity within the samples 
were separated by filtration using a 96-well MultiScreen HTS GV filter plate 
system (Millipore, Massachusetts, USA) with a vacuum manifold, followed by 3 
200 l washes in assay buffer. The filters were then punched out and counted in 
an NE1600 gamma counter (Thorn-EMI/Nuclear Enterprises, UK) for 240 s. The 
bound radioactivity was expressed as a percentage of the ICmax using GraphPad 
Prism 5 (GraphPad Software, CA, USA). 
2.12 - Migration assays 
4×106 Jurkat cells were serum-starved in 1% FBS-RPMI media for 24 hours prior 
to the commencement of the experiment. The transwell plates contained 2 
chambers separated by a polycarbonate membrane of 8 µm pore diameter (BD 
Biosciences, New Jersey, USA). The lower chamber was filled with 1 ml medium 
(1% FBS) containing either no additives or 100 ng/ml SDF1 (R&D Systems, 
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Minneapolis, USA). The upper chambers were filled with a 300 l suspension of 
1×105 Jurkat cells, which had either been untreated or pre-treated with the 
indicated concentration of antagonist for 30 minutes (suspended in 1% FBS 
medium). The plates were then incubated for 3 hours in a humidified 
atmosphere at 37 °C and 5% CO2. Following incubation the upper wells and their 
contents were discarded, and the medium from the lower wells collected, the 
numbers of cells in each well counted, and expressed as a percentage of the 
number of cells seeded into each well. All conditions were repeated in triplicate.  
2.13 - In vitro uptake assay 
Cells were seeded in triplicate wells of 6 well plates to be 60-80% confluent at 24 
hours [HCT116: 7×105 cells per well, A549: 2×105 cells per well, U87.CD4: 5×105 
cells per well, U87.CD4.CXCR4: 5×105 cells per well]. On the day of the 
experiment, the wells were treated with 1 ml of either the indicated 
concentration of competitive inhibitor-containing complete media [variable; 
included 10 M AMD3100, 10 M Ga-CCIC16, or 20 M FC131] or inhibitor-
naive media, and incubated for 15 minutes at 37 °C 5% CO2. The wells were then 
incubated with the indicated radiotracer [variable; included 0.37 MBq 
[18F]CCIC7, 0.74 MBq 68Ga-CCIC16, 0.37 MBq [18F]CCIC15, or 0.37 MBq 
[18F]CCIC30] in 1 ml complete medium for a further 60 minutes. Following 
incubation the medium was aspirated on ice and washed two times with 1 ml 
ice-cold PBS. The cells were scraped in 1 ml PBS and collected in microcentrifuge 
tubes and centrifuged at 5000 rpm for 5 minutes. The supernatant was removed 
and replaced with 350 l RIPA buffer (Thermo Fisher Scientific, Massachusetts, 
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USA) and the lysates transferred to counting tubes. Bound radioactivity was 
immediately counted using an LKB Wallac 1282 Compugamma laboratory 
gamma counter (PerkinElmer, Massachusetts, USA). The protein concentration 
of the lysates was determined by BCA assay (Thermo Fisher Scientific, 
Massachusetts, USA) as previously described. The radioactivity counts per 
minute (CPM) of each sample was divided by the total quantity of protein in the 
sample (in g) in order to calculate the CPM normalised to the protein 
concentration of the sample (CPM/µg protein).  
2.14 - Xenotransplantation 
 
All animal work was carried out in accordance with the United Kingdom’s 
Guidance on the Operation of Animals (Scientific Procedures) Act 1986 and 
within guidelines set out by the United Kingdom National Cancer Research 
Institute Committee on Welfare of Animals in Cancer Research (Workman et al., 
2010). Female BALB/c nu/nu athymic nude mice aged between 6-8 weeks were 
obtained from Charles River (Massachusetts, USA). Anaesthesia was induced in 
the animals at 3-4% isoflurane in a 1:4 mixture of nitrogen and oxygen at a flow 
rate of 1 L/minute, and then reduced to 2% isoflurane for anaesthesia 
maintenance. Xenotransplants were performed by injection of a 100 µl 
suspension of 4.5 x 106 cells [HCT116, A549, U87.CD4 or U87.CD4.CXCR4 cells] in 
PBS subcutaneously to the nape of the neck using a 25 mm 25 gauge needle. 
Animals were allowed to recover from anaesthesia for 5-10 minutes at 37 °C 
before being returned to their cages. Tumour size was measured every 2-3 days 
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using callipers, and tumour volume calculated according to the equation 
π*length*width*depth/6 (to give volume in mm3) in order to determine when 
further in vivo experiments would commence. 
2.15 - In vivo imaging and biodistribution 
 
Imaging and biodistribution experiments began once the tumours had reached 
at least 80 mm3 (2-4 weeks post-transplant, depending on the cellular model).  
i) In vivo imaging experiments with Inveon CT/PET scanner 
 
Anaesthesia was induced in the animals at 3-4% isoflurane in a 1:4 mixture of 
nitrogen and oxygen at a flow rate of 1 L/minute, and then reduced to 2% 
isoflurane for anaesthesia maintenance during imaging. A cannula was inserted 
into the lateral tail vein of the animal and fixed in position with tape. The 
animals were then placed in a thermostatically controlled rig at 37 °C in a 
dedicated small animal CT/PET scanner (Siemens Multimodality Inveon, Siemens 
Molecular Imaging Inc., Knoxville, USA). A low-dose CT orientation scan was 
performed (80 kVp, 0.5 mA, 220° rotation, 600 ms per degree exposure time, 80 
µm reconstruction pixel size) to use as an anatomical reference and as a 
reference for attenuation correction of PET data. 3.7 MBq of the indicated 
radiotracer [[18F]CCIC7, or 68Ga-CCIC16] in 100 l 100 units/ml heparin-PBS was 
injected via the lateral tail vein at commencement of a dynamic PET scan, which 
was acquired over 60 minutes in a list-mode format to give decay-corrected 
values of radioactivity accumulation in tissues. The collected data were then 
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ordered into 0.5 mm sonogram bins and 19 time frames (4 × 15, 4 × 60, 11 × 300 
seconds) and reconstructed by filtered back-projection (FBP), ordered subset in 
2 dimensions (OSEM2D), and ordered subset in 3 dimensions with maximum a 
posteriori (OSEM3D-MAP ; 2 OSEM 3D iterations and 18 MAP iterations) 
algorithms. The OSEM3D-MAP reconstruction was used for the visual 
representation of PET images only, whereas the OSEM2D-FBP was used to 
derive dynamic data from the regions of interest (ROIs). These ROIs (tumour, 
thigh muscle) were selected using Siemens Inveon Research Workplace software 
(Siemens Molecular Imaging Inc., Knoxville, USA) by hand, and the count 
densities (counts/ml) of these ROIs were averaged for each of the 19 time points 
to obtain time against radiactivity concentration curves (TACs) for each ROI. The 
radioactive counts for each tissue at any given time-point was divided by the 
total injected dose to the animal in order to obtain the standardised uptake 
value (SUV), expressed as %ID/ml. At the end of the experiment the animals 
were sacrificed and tissues collected under terminal anaesthesia as described in 
section 2.15iii. Certain subsets of mice were treated with competing 
nonradioactive compound to block CXCR4 receptors as follows: For in vivo 
[18F]CCIC7 studies, CXCR4 receptors in mice were blockaded by administration of 
a single 5 mg/kg AMD3100 dose in 50 l 100 units/ml heparin-PBS via the lateral 
tail vein at 30 minutes prior to [18F]CCIC7 injection via the same route. For in vivo 
[68Ga]-CCIC16 studies, CXCR4 blockade was induced by coinjection of 50 g Ga-
CCIC16 together with the competing [68Ga]-CCIC16 in 100 l 100 units/ml 
heparin-PBS via the lateral tail vein at commencement of the scan.  
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ii) In vivo imaging experiments with Genisys4 PET scanner 
 
Anaesthesia was induced in the animals at 3-4% isoflurane in a 1:4 mixture of 
nitrogen and oxygen at a flow rate of 1 L/minute, and then reduced to 2% 
isoflurane for anaesthesia maintenance during imaging. A cannula was inserted 
into the lateral tail vein of the animal and fixed in position with tape. Animals 
were then placed in a thermostatically controlled rig at 37 °C in a dedicated 
small animal Genisys4 PET scanner (SOFIEBIOSCIENCES, CA, USA). 1.1 MBq of the 
[18F]CCIC30 in 100 l 100 units/ml heparin-PBS was injected via the lateral tail 
vein at commencement of the dynamic PET scan, acquired over 60 minutes in a 
list-mode format to give decay-corrected values of radioactivity accumulation in 
tissues. The collected data were then ordered into 0.5 mm sonogram bins and 
19 time frames (4 × 15, 4 × 60, 11 × 300 seconds) and reconstructed according to 
ordered subset in 3 dimensions with maximum a posteriori (OSEM3D-MAP ; 2 
OSEM 3D iterations and 8 MAP iterations) algorithms. The ROIs (tumour, thigh 
muscle) were selecteded using Siemens Inveon Research Workplace software 
(Siemens Molecular Imaging Inc., Knoxville, USA) by hand, and the count 
densities (counts/ml) of these ROIs averaged for each of the 19 time points to 
obtain time against time-activity curves (TACs) for each ROI. The radioactive 
counts for each tissue at any given time-point was divided by the total injected 
dose to the animal in order to obtain the standardised uptake value (SUV), 
expressed as %ID/ml. At the end of the experiment the animals were sacrificed 
and tissues collected under terminal anaesthesia as described in section 2.15iii.  
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iii) Biodistribution experiments 
Biodistribution experiments were either conducted immediately after imaging 
experiments had finished, or by themselves as standalone experiments 
(anaesthesia non-recovery to mimic imaging studies) at the indicated time 
(various; includes 2, 5, 15, 30 or 60 minutes) post-radiotracer injection (3.7 MBq 
in 100 µl 100 units/ml heparin-PBS). Whilst under anaesthesia (2.5% isoflurane) 
the animals were exsanguinated by cardiac puncture using a 25 gauge 25 mm 
needle and syringe pre-coated in 10,000 units/ml heparin, and the collected 
blood separated into plasma and cellular blood fractions by centrifugation at 
14,000 rpm. The remaining tissues of interest (heart, lung, liver, gall bladder, 
spleen, kidney, stomach, duodednum, jejunum, caecum, colon, muscle, brain) 
were harvested and collected in pre-weighed counting tubes. Urine samples 
were collected by immersion on pre-weighed filter paper. Radioactivity within all 
tissue samples was counted for in the LKB Wallac 1282 Compugamma laboratory 
gamma counter (PerkinElmer, Massachusetts, USA), and then weighed to 
determine the mass of the tissue. The counts per minute for each sample was 
normalised to the total injected dose of radioactivity to the animal to give the % 
injected dose (%ID), and then normalised to the weight of the counted tissue to 
give the radioactivity uptake of the tissue as %ID/g.  
2.16 - Metabolism experiments 
i) Preparation of animals and tissues 
Female BALB/c mice aged between 6-8 weeks were obtained from Charles River 
(Massachusetts, USA). Anaesthesia was induced in the animals at 3-4% 
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isoflurane in a 1:4 mixture of nitrogen and oxygen at a flow rate of 1 L/minute, 
and then reduced to 2% isoflurane for anaesthesia maintenance during imaging. 
A cannula was inserted into the lateral tail vein of the animal and fixed in 
position with tape. The radiotracer [3.7 MBq [18F]CCIC7, 7.4-11.1 MBq [68Ga]-
CCIC16, or 7.4-11.1 MBq [18F]CCIC30] in 100 l 100 units/ml heparin-PBS was 
injected via the cannula at commencement of the experiment. At the indicated 
time post-injection [various; includes 2 minutes, 5 minutes, 15 minutes or 60 
minutes], the animal was sacrificed by cardiac puncture using a 25 gauge 25 mm 
needle and syringe pre-coated in 10,000 units/ml heparin, and the collected 
blood separated into plasma and cellular blood fractions by centrifugation at 
14,000 rpm. The remaining tissues of interest (liver and urine) were also 
collected. Samples of plasma, urine and liver were stored in microcentrifuge 
tubes on ice prior to processing as described in the following steps.  
ii) Liquid samples 
This protocol was used for processing of the collected samples of urine and 
plasma, and was performed jointly with Dr. Ola Åberg (for 18F-CCIC7), Guillaume 
George (for 68Ga-CCIC16) and Dr. Federica Pisaneschi (for 18F-CCIC30). To each 
sample was added 100 µL of an aqueous solution saturated with urea at 37 oC 
and this mixture was added dropwise to an equivalent volume of ice-cold 
methanol. The mixture was vortexed for 30 seconds and centrifuged (15 rpm, 5 
minutes, 4 oC). The supernatant was added to an equivalent volume of ice-cold 
methanol, and the mixture was vortexed and centrifuged as earlier. The 
radioactivity recovery of plasma samples treated in this was 81%, defined as the 
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radioactivity remaining in the liquid supernatant following methanol-induced 
protein precipitation, expressed as a percentage of the total sample radioactivity 
(supernatant + pellet). The supernatant was added to 3 mL of ice-cold H2O–
trifluoroacetic acid (TFA; 999:1). This mixture was filtered through a 0.20 µm 
Millipore Millex-LG 0.20 µm × 13 mm polytetrafluoroethylene (PTFE) syringe-
driven filter unit (Millipore, Massachusetts, USA) and injected into the high 
performance liquid chromatography (HPLC) machine.  
iii) Liver samples 
This protocol was performed jointly with Dr. Ola Åberg (for 18F-CCIC7), Guillaume 
George (for 68Ga-CCIC16) and Dr. Federica Pisaneschi (for 18F-CCIC30). To each 
liver sample was added 100 µL of an aqueous solution saturated with urea at 
37 oC and 1 mL of ice-cold methanol and was homogenised with an IKA Ultra-
Turrax T25 basic homogeniser (IKA, Germany) at 25,000 rpm/min. The resulting 
suspension was centrifuged (15 rpm, 5 minutes, 4 oC). The supernatant was 
added to 3 mL of ice-cold H2O – TFA (999:1). This mixture was filtered through a 
0.20 µm Millipore Millex-LG 0.20 µm × 13 mm PTFE syringe-driven filter unit 
(Millipore, Massachusetts, USA) and injected into the HPLC. 
iv) High performance liquid chromatography (HPLC) 
The HPLC procedures were carried out using a Agilent 1100 Series G1312A pump 
and Lablogic Laura 3 software equipped with a linear Agilent 1100 Series 
G1314A UV detector (λ = 254 nm), a IN/US Systems γ-RAM model 3 detector and 
a Waters µBondapak C18 125 Å 10 µ 7.8 × 300 mm HPLC column, and a 5 ml 
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injection loop. Following injection of the prepared sample, a 5-65% solvent 
gradient was set up over 15 minutes was at a flow rate of 5 ml/min between 
mobile phase solution A (water, 0.1% trifluoroacetic acid; TFA) and solution B 
(acetonitrile ; MECN, 0.1% TFA). The data was analysed by reference to the area 
under curve (AUC) measurements of the peaks on the HPLC trace. The 
percentage of unmetabolised (parent) compound within each sample was 
calculated according to the following equation: 
% parent  =  AUCparent × 100 
   AUCtotal 
 
2.17 – 17AAG treatment in vitro and in vivo 
i) In vitro treatment of cells with 17AAG 
U87.CD4 and U87.CD4.CXCR4 cells were seeded into the wells of a 6-well plate 
48 hours before commencement of the experiment (5×105). The cells were 
cultured in 2 ml complete DMEM medium in the presence of either 100 nM 
17AAG, 500 nM 17AAG or no additives (control condition). Following either 24 
or 48 hours’ treatment in the above conditions, the cells were either lysed and 
analysed for protein expression as described in sections 2.4i and 2.4iii, or else 
used to assess in vitro uptake of [68Ga]-CCIC16 as described in section 2.13.  
ii) In vivo treatment of tumour-bearing mice with 17AAG 
U87.CD4 and U87.CD4.CXCR4 cells were introduced into BALB/c nu/nu mice by 
xenotransplantation, and tumour growth progress tracked as described in 
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section 2.14. Once the tumours reached 80 mm3 in size, the mice were treated 
intraperitoneally (i.p) with either 80 mg/kg 17AAG or the vehicle solution 
(DMSO) daily for 48 hours. 24 hours after the final treatment had been given, 
the accumulation of [68Ga]-CCIC16 within the tumours and other tissues was 
assessed in biodistribution experiments as described in 2.15iii. Tumour samples 
were excised and snap-frozen in liquid nitrogen for use as samples for western 
blots as described in section 2.4ii and 2.4iii. 
2.18 - Statistical Analysis 
Where specified, data were statistically analysed using either two-tailed 
independent t-tests where only 2 sets of data were compared, or analysis of 
variance (ANOVA) tests with Bonferroni post-tests in comparisons of three or 
more datasets. These tests were conducted using GraphPad Prism v5.01 
(GraphPad Software, CA, USA). Results were considered statistically significant 
when P values < 0.05 had been obtained.  
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3.1- Development of [18F]CCIC7 and tumour 
model characterisation 
3.11 - Use of A549, HCT116 and Jurkat cells as cellular models of CXCR4 
expression 
In order to assess the affinity of novel antagonists for CXCR4, it was first 
necessary to determine the most appropriate cellular models to use to 
investigate CXCR4. The relative CXCR4 expression of a number of cell lines was 
compared, including a small panel of cancer cell lines that was available in the 
department and were known to express CXCR4 at varying levels. These cell lines 
were the human breast cancer cell line MDA-MB-231 (Siciliano et al., 1979), the 
MDA-MB-435S line of disputed source (there is evidence to suggest either 
human breast or melanocytic origin (Ellison et al., 2002, Chambers, 2009), the 
human colon colorectal cancer HCT116 line (Brattain et al., 1981), and human 
lung epithelial adenocarcinoma line A549 (Lieber et al., 1976). The CXCR4 
expression in these cell lines were compared (according to the protocol 
described in section 2.4) against Jurkat cells, an immortalised human T-
lymphocyte line of known high CXCR4 expression (Hesselgesser et al., 1998), 
which served as a positive control. As shown in figure 11, the quantity of CXCR4 
protein expressed varied between cell lines, with the positive control Jurkat cell 
line expressing the most CXCR4, followed by A549 cells, which expressed 77% of 
the CXCR4 expressed by Jurkat cells. This was closely followed by the MDA-MB-
231 line (57% of Jurkat cell expression), and trailed by the HCT116 and MDA-MB-
435S lines (32% and 28% of Jurkat cell expression, respectively).  
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Figure 11. Analysis of endogenous CXCR4 protein expression in a small panel of cell lines.  
A Western blot of CXCR4 protein expression, an example of 3 independent experiments               
B Mean densitometric analysis of CXCR4 expression, normalised to GAPDH expression and 
expressed as relative values to CXCR4 expression in Jurkat cells (n=3).  
 
Any novel radiotracer that aims to target CXCR4 should be capable of 
distinguishing between cell lines of differing CXCR4 expression. Thus a pair of 
cell lines of high and low CXCR4 expression would be the most appropriate 
cellular models to determine whether a novel radiotracer bound to cells in a 
CXCR4-dependent manner. Whilst the Jurkat cell line clearly expressed CXCR4 
protein the most, it was not deemed to be suitable for many of the intended 
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applications due to its lack of tumorigenicity in vivo (Deguchi and Kehrl, 1993), as 
well as its status as a suspension, rather than adherent, line which made it 
considerably less practical for much of the planned in vitro work. The A549 and 
HCT116 cell lines were chosen as models of high and low CXCR4 expression for 
use in investigations as a result of their 2.4-fold difference in expression and 
tumourigenicity in vivo. While impractical for uptake assay (refer to section 2.13) 
or in vivo tumour growth (section 2.14), the Jurkat cell line was considered ideal 
as a model of CXCR4-directed migration, as their expression of high levels of 
CXCR4 and their status as a suspension cell line enables SDF1-induced migration 
assays to be conducted rapidly at comparatively low ligand concentrations, with 
minimal processing before quantification, unlike adherent cell lines. The Jurkat 
cell line was therefore utilised for the testing of novel antagonist compounds in 
migration assay.  
 
3.12 - Development of CCIC7 and in vitro characterisation of [18F]CCIC7 
CCIC7, a novel CXCR4 antagonist that was synthesised by Dr. Ola Åberg, is based 
on the structure of the potent cyclopentapeptide antagonist FC131. As 
described in the introduction, it has previously been noted that modifications to 
the arginine-2 of FC131 can be well-tolerated (Ueda et al., 2007), and so it was 
theorised that this would be the pentapeptide residue with the greatest 
potential for incorporation of a radionuclide-containing chemical group. Thus, a 
fluorobenzyl (FB) chemical group that is amenable to radiolabelling with 18F was 
attached to the pentapeptide structure via a hydroxy-imino linker (see figure 
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12).  When migration of Jurkat cells towards 100 ng/ml SDF1 was assessed 
(according to the protocol in section 2.12) significantly fewer Jurkat cells 
migrated when incubated with 10 µM CCIC7, in comparison to untreated cells, 
with a mean 42.4% reduction in the number of migrated cells after 3 hours.  This 
appeared to confirm the antagonistic activity of CCIC7 towards CXCR4, albeit not 
as potently as the commercially available bicyclam antagonist 
 
Figure 12. Structure of lead pentapeptide FC131 and novel peptide CCIC7 
A Candidate pentapeptide FC131 B Novel pentapeptide CCIC7. CCIC7 bears a PEGylated FBA 
group on arg-2, for the purposes of radiolabelling with 18F. Tyr (Tyrosine); Arg (Arginine); PEG2 
(poly[ethylene glycol]); FB (fluorobenzyl); Nal (2-Naphthylalanine); Gly (Glycine) 
Cyclo[Tyr-Arg-Arg-2-
Nal-Gly] 
Cyclo[Tyr-Arg-(PEG2-
FB)-Arg-2-Nal-Gly] 
 
FC131 
CCIC7 
Tyr-1 
Arg-2 
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AMD3100, which at the same concentration inhibited Jurkat cell migration by a 
mean of 80.3%. While disappointing in comparison to AMD3100, the moderate 
potency of CCIC7 was considered encouraging enough to attempt to further 
characterise the potential of CCIC7 as a PET tracer by assessing the radiolabelled 
compound’s ability to accumulate in CXCR4-expressing cancer cells in vitro. 
Uptake assays confirmed that following a 60 minute incubation with 0.37 MBq 
radioactivity (refer to section 2.13), significantly more [18F]CCIC7 remained 
bound to A549 cells compared HCT116 cells, with a difference of approximately 
1.6-fold, a difference that is comparable to the fold-difference in protein 
expression of CXCR4 shown in figure 13. Furthermore, blockade of the CXCR4  
Figure 13. In vitro characterisation of CCIC7 
 A Mean inhibition of SDF1-mediated Jurkat cell migration in the presence of 10 µM CCIC7 or 
AMD3100, relative to the control (n=3; refer to section 2.12). B In vitro uptake of 0.37MBq 
[
18
F]CCIC7 in A549 and HCT116 cells at 60 minutes (refer to section 2.13). Values are normalised 
to protein concentration of the wells. Figure shown is an example of 3 independent experiments 
with triplicate samples. Error bars represent SEM (***, p=0.001).    
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receptor by pre-incubation with 10 M AMD3100 (chosen over the more 
analogous FC131 due to the commercial availability of AMD3100 at the time the 
experiment took place) prevented the high radioactivity uptake within A549 
cells, suggesting specificity of [18F]CCIC7 for the CXCR4 receptor. These findings 
suggest that despite the low potency of CXCR4 antagonism that CCIC7 exerts, 
there was still ample promise in its utilisation as a radiotracer that can 
differentiate between varying levels of CXCR4 expression.   
 
3.13 - In vivo assessment of [18F]CCIC7 
As a result of this potential, [18F]CCIC7 was further assessed by in vivo imaging of 
HCT116 and A549 tumour xenografts following an injection of 3.7 MBq 
[18F]CCIC7 (n=4 and 7 respectively; protocol as described in section 2.15i). As the 
PET images in figure 14 show, there was little discernible difference in tracer 
accumulation between HCT116- and A549-derived tumours. While the dynamic 
uptake of radioactivity in the tumour regions of interest yielded time-against-
concentration (TAC) curves suggesting potential modest increases in levels of 
tracer uptake in the higher-expressing A549 tumours than in the lower-
expressing HCT116 tumours, there was no significant difference in the 
standardised uptake values of the two tumours at 60 minutes (SUV60), or indeed 
at any time-point measured (figure 15A). Furthermore, uptake of [18F]CCIC7 in 
A549 tumours was not found to be significantly different following pre-injection 
of 5 mg/kg AMD3100 (a quantity >1000-fold higher than the mean  
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 Figure 14. PET/CT images of HCT116 or A549 tumour-bearing BALB/c nu/nu mice following 
injection of 3.7 MBq [18F]CCIC7  
Representative transverse (left), coronal (middle) and sagittal (right) merged PET/CT images 
from A HCT116 and B A549 tumour-bearing mice, 60 minutes after lateral tail-vein injection of 
[
18
F]CCIC7 (refer to section 2.15i). Arrow identifies location of tumour.  
 
 
 
  
A 
 
 
  
  
B 
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Figure 15. PET imaging of HCT116 or A549 tumour-bearing BALB/c nu/nu mice following 
injection of 3.7 Mq [18F]CCIC7.  
Cohorts of mice bearing HCT116 or A549 tumours (n= 4 and 7, respectively) were imaged using 
dynamic PET/CT immediately post-injection (refer to section 2.15i). A separate cohort of A549 
tumour-bearing mice (n=3) were pre-treated with an i.v. blocking dose of 5 mg/kg AMD3100 30 
minutes prior to imaging with [
18
F]CCIC7. A Dynamic time-activity curves for the tumour ROIs 
over the 60 minute scan with [18F]CCIC7. Mean standardised uptake value (SUV) of tumour ROIs 
at B 18 and C 60 minutes. D Mean area-under-curve values for tumour ROI between 0-60 
minutes. 
injected quantity of [18F]CCIC7) 30 minutes prior to  radiotracer injection (n=3; 
figure 15). In addition, the overall shape of the time-activity curves show initial 
delivery of [18F]CCIC7 into the tumour immediately followed by a relatively rapid 
and sustained reduction of tracer localisation in the tumour ROIs in all cases. 
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The biodistribution profile of [18F]CCIC7 at 60 minutes (figure 16; refer to section 
2.15iii) was in keeping with the imaging data, as in addition to the lack of 
increased uptake within A549 tumours in comparison to HCT116 tumours (n=4, 
3, respectively) there was also no notable tracer uptake in many tissues of 
reported high CXCR4 expression, such as the lung, bone, and spleen (Rimland et 
al., 1991, Federsppiel et al., 1993, Shao et al., 2011). Indeed, the most 
prominent sites of [18F]CCIC7 uptake were the gallbladder, liver, stomach, 
duodenum, jejunum, kidneys and urine of the mice, which indicate that 
radiotracer accumulation was primarily associated within organs of excretion. 
Whilst CXCR4 expression has been reported in the liver (Rimland et al., 1991), 
the lack of blockade in liver tissues following pre-injection with 5 mg/kg 
AMD3100 (n=3) appears to preclude CXCR4-specific uptake of [18F]CCIC7 in this 
situation.   
 
To elucidate the reasons for the poor uptake a time-course metabolite and 
biodistribution study was conducted (as described in section 2.16), in order to 
determine the role that metabolism of [18F]CCIC7 might have played in the 
eventual biodistribution of the radiotracer. It was found that within even 5 
minutes (n=3) the majority of circulating [18F]CCIC7 in the plasma had been 
metabolised to a smaller fragment (with 44 ± 12% tracer remaining), and that by 
15 minutes (n=3) the unmetabolised [18F]CCIC7 was almost entirely absent from 
the plasma (6 ± 2% remaining) (figure 16 and table 5). This provides a possible 
explanation for the disappointing findings of the in vivo imaging experiments, as  
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Figure 16. Biodistribution of 3.7 MBq [18F]CCIC7 at 60 minutes post-injection in tissues of HCT116 or A549 tumour-bearing BALB/c nu/nu mice, or A549 tumour bearing 
mice treated with 5 mg/kg AMD3100 30 minutes prior to radioactivity injection (n=3, 4, and 3, respectively).  
Mice were sacrificed immediately following the 60-minute scan by exsanguinations and tissues harvested as described in section 2.15iii. The radioactivity present in the 
tissue was then counted and normalised to the weight of the tissue, and to the injected dose.  
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it suggests that a high degree of metabolism within a short period of time may 
be responsible for the lack of CXCR4-dependent [18F]CCIC7 accumulation within 
A549 tumours.  
 
In contrast, [18F]CCIC7 appeared to be less rapidly metabolised at the liver, 
where a considerable majority (88 ± 10%) of [18F]CCIC7 remained unmetabolised 
at 5 minutes post-injection (n=3), although this proportion decreased steadily 
over the remaining hour to 44 ± 3% (see table 5 and figure 16; n=3). At least two 
radioactive fragments were present in liver homogenates, with the proportion of 
the largest of these gradually diminishing over time, possibly reflecting 
successive stages of metabolism of [18F]CCIC7. The role of the liver in the course 
of [18F]CCIC7 in vivo processing and elimination was supported by time-course 
biodistribution study data (n=3) as shown in figure 18; the rapid accumulation of 
radioactivity within the liver precedes the passage of radioactivity from the liver 
to the duodenum and jejunum of the gastrointestinal (GI) tract, confirming the 
rapid clearance of [18F]CCIC7 through the hepatic excretory pathway. Rapid 
clearance of [18F]CCIC7 was also observed through the urinary route of 
excretion, as peak radioactivity levels at the kidneys occurred at 5 minutes 
following injection, and within the urine at 15 minutes post-injection. The fast 
action of both the hepatic and urinary routes of excretion for [18F]CCIC7 are 
likely to be a key reason for the poor performance of the radiotracer in 
differentiating CXCR4 expression in tumours.  
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Figure 17. HPLC traces showing parent compound and metabolite peaks in liver and plasma 
extracts of BALB/c mice following 5, 15, 30 and 60 minute inoculation of 3.7 MBq [18F]CCIC7. 
Representative example radiochromatograms (n=3) from acetonitrile extracts from mouse 
plasma and homogenised liver samples at the indicated time points. The parent tracer [18F]CCIC7 
has a retention time of 10m50s, whereas metabolite peaks 1 and 2 arise at 4m30s and 5m50s, 
respectively. Refer to protocol described in section 2.16.  
  
 
Plasma Liver 
5 minutes 
15 minutes 
30 minutes 
60 minutes 
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 Table 5. In vivo metabolism of compound [
18
F]CCIC7 at selected time points, showing the 
percentage of [18F]CCIC7 present in plasma, liver and urine extracts (n=3) 
Time (min) Plasma  Liver  Urine  
5 44 ± 12  88 ± 10 33 
15 6 ± 2 64 ± 10 71 
30 4 ± 7 38 ± 34 0 
60 0 ± 0 47 ± 3 0 
 
The values shown for plasma and liver samples are the mean of three test subjects (± the SEM), 
the urine samples are n=1. Refer to section 2.16. 
 
3.14 - Changes to CXCR4 expression analysis methology and transfection of 
HCT116 colon carcinoma cells 
 
Following the failure of [18F]CCIC7 to identify A549 from HCT116, alternative 
methods to were considered. While the outcome of in vivo validation of 
[18F]CCIC7 was perhaps doomed to fail from the outset as a result of the poor 
pharmacokinetics of the tracer, doubts had also begun to arise regarding the 
specificity of the antibody used to detect CXCR4 by immunoblotting 
(ab2074)(Smith et al., 2004, Dubrovska et al., 2012a), as the presence of 
numerous bands upon the anti-CXCR4 immunoblot was a considerable cause for 
concern. However, the band sized at ~43kDa was the predicted size of the 
CXCR4 protein, and appeared to show data in line with observations from 
literature (Wendt et al., 2008, Tang et al., 2008a), and so had previously been 
the only data taken into consideration when quantifying relative protein 
expression. As figure 19 shows, the blots yielded with this antibody (using the 
protocol described in section 2.4) were cluttered with additional bands, which 
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were presumed at the time to be non-specific and not relevant to the 
investigation.   
 
This conclusion was re-evaluated once subsequent qRT-PCR findings (refer to 
section 2.3) showed mRNA expression of CXCR4 within the cell lines to be 
considerably different to the protein expression levels reported using antibody 
ab2074 shown in figure 19; in this case Jurkat cells expressed by far the most 
CXCR4 mRNA, followed by MDA-MB-231, HCT116, A549 and finally MDA-MB-
435S (with mean relative expression levels of 972.0, 58.6, 1.6, 1 and 0, 
respectively; see figure 20A and 20B). A departure from the mRNA expression 
levels of cell lines might be explained by differences in the processing of mRNA 
before protein synthesis in each cell line, such as in the regulation of post-
transcriptional, translational and degradation processes (Vogel and Marcotte, 
2012). However, the apparent presence of CXCR4 protein within cell lines that 
did not express CXCR4 mRNA cannot be explained, except to conclude that the 
antibody used was inappropriate for the detection of CXCR4 or reduced 
coverage of the PCR primers. The result of the qRT-PCR data, which suggested 
approximately equal low-level CXCR4 expression within the HCT116 and A549 
lines, further explains why [18F]CCIC7 could not differentiate between the cell 
lines MDA-MB-435S and A549, as there was indeed almost no difference in 
CXCR4 expression between them. It was therefore decided that an alternative, 
more specific antibody should be found, and that it should be used to identify 
CXCR4 expression stably induced within a given cell line through transfection,  
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Figure 18. Biodistribution of [18F]CCIC7 at 5, 15, 30 and 60 minutes following injection of 3.7 MBq [18F]CCIC7 in healthy BALB/c mice (n=3). 
Mice were exsanguinated by cardiac puncture and tissues harvested. The radioactivity present in the tissue was then counted and normalised to the weight of the tissue, 
and to the injected dose. Refer to section 2.15iii.
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Figure 19. Evidence of poor specificity of ab2074 anti-CXCR4 antibody for CXCR4 protein. 
A CXCR4 mRNA expression in vitro, normalised to GAPDH mRNA expression, and expressed as a 
factor of CXCR4/GAPDH mRNA expression (n=3; error bars denote SEM). Refer to section 2.4.     
B Example whole-view image of immunoblot using ab2074 anti-CXCR4 antibody. Note the 
numerous bands, and non-conformity with mRNA expression reported in A. Band previously 
presumed to represent CXCR4 shown adjacent to arrow.  
 
allowing the utility of pairs of isogenic cell lines differing only in their CXCR4 
expression. 
 
To this end, the UMB2 clone CXCR4 antibody was used (according to the 
protocol described in section 2.4) as a result of reports of its high specificity for 
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CXCR4 in comparison to other commercially available antibodies (Fischer et al., 
2008). This antibody identified Jurkat cell lysates (used in this regard as a 
positive control, due to their high reported CXCR4 expression) with a strongly 
stained broad smear, chiefly above 50 kDa in size. In contrast, the cell lines 
MDA-MB-231, MDA-MB-435S, HCT116 and A549 showed very little staining 
(figure 20A and 20B), corroborating the qRT-PCR findings. The cell lines were 
further assayed by flow cytometry (described in section 2.5) using a different 
CXCR4 antibody (clone G5) to validate the findings of the UMB2 clone CXCR4 
antibody used in immunoblotting, and in particular to give an indication of the 
surface expression of CXCR4 receptors, which would naturally be of utmost 
importance to the development of novel radiotracers for CXCR4 expression. The 
flow cytometry data were in agreement with the results of the new 
immunoblotting experiments - both HCT116 and A549 expressed similarly low 
quantities of CXCR4 protein which was not detectable above background levels. 
The Jurkat cells, in contrast, exhibited strong CXCR4 expression as expected 
(Hesselgesser et al., 1998). 
 
With two antibodies for detecting CXCR4 now validated, it became clear that the 
A549 and HCT116 cell lines were unsuitable as models of differential CXCR4 
expression. However, it remained to be ascertained why the in vitro uptake 
assays had previously appeared to confirm a difference in CXCR4 expression 
between the two cell lines (figure 13). It was suspected that the difference in 
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Figure 20. Reanalysis of endogenous CXCR4 expression in a panel of cell lines using alternative 
antibodies and techniques. 
A Representative western blot (see section 2.4) with UMB-2 clone rabbit anti-CXCR4 antibody. 
Primary band is visible at ~50 kDa, faint band observed ~25 kDa. B Mean densitometric analysis 
of immunoblots with clone UMB2 anti-CXCR4 antibody. CXCR4 expression is normalised to α-
tubulin expression, and represented relative to expression in Jurkat cells (n=3). C Flow cytometry 
of same cell lines using PE-conjugated anti-CXCR4 clone 47717, with mean PE-A values included 
(n=3). ‘Control’ refers to Jurkat cells stained with isotype control antibody. See section 2.5. 
 
uptake may have related to differences in size of the cells assayed, as A549 cells 
covered a considerably larger surface area than HCT116 cells. No difference in 
[18F]CCIC7 uptake in vitro was seen between HCT116 and A549 cells before 
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normalisation to the protein content of the lysate sample, yet significance was 
obtained following normalisation (figure 21). The normalisation of radiotracer 
uptake to the protein content of the cells would ordinarily be an appropriate 
control to take into account slight differences in confluency of the cell lines. 
However, in this circumstance it appears that false significance may have been 
achieved through equivalent binding at the cell surface, with the large 
differences in the size of A549 and HCT116 cell lines (and hence overall cellular 
protein expression data) skewing the normalised result towards significance. It 
was unfortunate in this circumstance that the false positive result appeared to 
confirm the expected difference predicted from the findings of immunoblots 
that are now known to be inaccurate.  
 
Figure 21. Effect of protein normalisation upon perceived in vitro [18F]CCIC7 uptake at 60 mins. 
A Representative example of in vitro [18F]CCIC7 uptake in HCT116 and A549 cells prior to protein 
normalisation. Perceived uptake in HCT116 and A549 cells approximately the same.  B Same 
assay data as A, but instead normalised to protein content of wells. Perceived uptake in HCT116 
cells significantly lower than in A549 cells. A549 an HCT116 cells were seeded to give equivalent 
confluency of 70% surface area coverage. Counts per minute (CPM).  
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The results of the investigation into the effectiveness of [18F]CCIC7 as a CXCR4-
targeting tracer therefore highlighted a number of issues with the methodology 
used up to this point. Firstly, the anti-CXCR4 antibody used in the 
characterisation of the protein expression of CXCR4 in the various cell lines was 
determined to be insufficiently specific for CXCR4; the UMB-2 and 12G5 
antibodies for western were postulated as suitable replacements. Secondly, the 
results of radiotracer uptake assays may be prone to give false suggestions of 
differential uptake in cells of markedly different sizes. The use of isogenic pairs 
of cell lines in future investigations would restore faith in the method, as the 
similarity between the cell lines would ensure that any difference in uptake 
would occur as a result of differences in CXCR4 expression, rather than other 
physiological characteristics. These two errors combined led to the utilisation of 
cellular models of CXCR4 expression that were unsuitable for the purpose of the 
investigation.  
 
To correct this issue it was decided to introduce CXCR4 expression into the 
HCT116 colon carcinoma cell line by transfection, thereby obtaining a syngeneic 
pair of cell lines appropriate for the development of new CXCR4-targeting 
radiotracers. However, despite many attempts to derive clones of stable CXCR4 
transgene expression with a pcDNA3.1 vector (described in section 2.7), very few 
of the clones derived showed any substantial level of CXCR4 expression as 
judged by western blot or flow cytometry (figure 22; refer to sections 2.4 and 
2.5). For example, the most encouraging clone, Stable 3, was found to stably 
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express only twice as much CXCR4 as the untransfected HCT116 cells, and 
approximately half as much CXCR4 as Jurkat cells. In contrast, other clones 
survived under G418 selection with no additional expression of CXCR4 protein at 
all.  
 
3.15 - Characterisation of CXCR4 transfected cancer cell lines 
Given the previous concerns regarding the use of appropriate cellular models it 
was decided that more reliable data could be obtained by acquiring a pair of 
CXCR4-transfected lines from the National Institute of Health (NIH) AIDS 
Research and Reference Reagent Program derived from the U87.MG human 
glioblastoma cell line, called U87.CD4 and U87.CD4.CXCR4. The U87.CD4.CXCR4 
cell line had been shown to express far higher CXCR4 than its parent cell line 
U87.CD4 (Endres et al., 1996, Bjorndal et al., 1997), much more so than the 
HC116 transfectants described in figure 22. As such, the acquired 
U87.CD4.CXCR4 cell line showed markedly higher CXCR4 expression than the 
parent U87.CD4 line in our own investigations, which did not express CXCR4 at 
all, as judged by qRT-PCR, western blotting and flow cytometry (figure 23). The 
cell line even proved to express more CXCR4 protein than the Jurkat cell line, 
used as a positive control for CXCR4. The high degree of agreement between the 
three methods of assessing CXCR4 expression strongly indicated the veracity of 
these findings, putting any remaining concerns regarding the specificity of the 
antibodies currently in use firmly in the past. 
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Figure 22. Transfection of HCT116 colorectal line with pcDNA.CXCR4 vector  
A Representative example of CXCR4 protein expression in stably transfected HCT116 clones by 
western blot using the UMB2 clone anti-CXCR4 antibody. B Densitometric analysis of CXCR4 
expression normalised to α-tubulin and expressed relative to HCT116 cell expression (n=1). Refer 
to section 2.4. C Flow cytometric analysis of CXCR4 expression in CXCR4-transfected stable 
HCT116 transfectants, showing median PE-A values (n=1). ‘Control’ refers to the ‘stable 3’ cell 
line stained with isotype control antibody. Refer to section 2.5. 
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With these considerations addressed, it remained to consider the effect of the 
CXCR4 overexpression upon downstream cellular processes, such as 
proliferation and SDF1-directed migration. In order to check that the difference 
in motility in wound closure was not mediated by alternative CXCR4-dependent 
process, such as increased proliferation, a doubling time assay was conducted as 
described in section 2.8, which confirmed no significant difference in the 
proliferation rate of U87.CD4 and U87.CD4.CXCR4 cells (figure 24A). A scratch 
wound motility assay was then conducted as described in section 2.9, and it was 
found that significantly greater wound closure occurred in cells overexpressing 
CXCR4, and that this difference in motility could be blocked by the presence of 
AMD3100 (figure 24B). A difference in CXCR4 expression between U87.CD4 and 
U87.CD4.CXCR4 was maintained in vivo (protocol described in section 2.4ii), 
albeit at a mean 2.6-fold difference (figure 25), considerably lower than the 10-
fold difference in CXCR4 expression in the same cell lines in vitro (figure 22B).  
 
The data observed so far points to the U87.CD4 and U87.CD4.CXCR4 cell lines as 
excellent syngeneic models of differential CXCR4 expression, and are therefore 
expected to be far superior for the characterisation of novel antagonists and 
tracers for PET imaging than the A549 and HCT116 cell lines used in chapter 3.1. 
The previous use of unreliable methods to assess CXCR4 expression in these 
HCT116 and A549 cell lines was a confounding factor to the early positive 
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Figure 23. In vitro characterisation of CXCR4-overexpressing glioblastoma line 
Comparison of CXCR4 expression in transfected U87 models against endogenous CXCR4 
expression in panel of cancer cell lines by A qRT-PCR (showing expression values as relative to 
Jurkat CXCR4 mRNA ; n=3, error bars denotes SEM; refer to section 2.3), B by western blot of cell 
lines in vitro (example immunoblot and mean densitometric analysis, relative to Jurkat 
expression ; n=3, error bars show SEM; refer to section 2.4), and C analysis of cell lines by flow 
cytometry, showing average (n=3), refer to section 2.5. ‘Control’ refers to Jurkat cells stained 
with isotype control antibody.   
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Figure 24. Effect of CXCR4 expression on CXCR4-dependent processes in glioblastoma in vitro 
A Calculated doubling time of parental U87.MG, U87.CD4 and U87.CD4.CXCR4 cell lines in vitro 
(n=3 ; error bars show SEM). Refer to section2.8.  B Effect of CXCR4 expression upon SDF1-
induced wound closure in glioblastoma cells over 12 hours (n=3 ; P ≤ 0.001 ; error bars show 
SEM). Refer to section 2.9. 
 
Figure 25. In vivo characterisation of U87.CD4 and U87.CD4.CXCR4 glioblastoma lines 
A Representative image of homogenised snap-frozen tumour samples analysed by western 
blotting with CXCR4, CD4 and α-tubulin antibodies. B Densitometric analysis of CXCR4 expression 
in U87 glioblastoma tumours in vivo (n=3 ; error bars show SEM ; P ≤ 0.01). Refer to section 2.4ii 
and 2.4iii.  
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indications for the use of [18F]CCIC7 as a CXCR4-specific tracer, with in vitro 
uptake experiments appearing to confirm the specificity of uptake into the 
supposedly higher CXCR4 expressing A549 cells (later disproved). However, 
[18F]CCIC7 uptake was later judged to be nonspecific, as differential uptake into 
tumour cells was largely associated with differences in tumour cell size, rather 
than any true specificity for CXCR4. Furthermore, [18F]CCIC7 was found to be 
extremely metabolically unstable in vivo, and therefore not suitable for further 
development using the newly characterised U87.CD4 and U87.CD4.CXCR4 
glioblastoma models of low and high CXCR4 expression, respectively. It was 
therefore necessary to consider the characterisation of alternative novel CXCR4 
antagonists, as described in the following chapters. 
 
3.2 - Design of 14mer peptide CCIC16 and 
characterisation of effects of ion chelation and 
subsequent development of [68Ga]CCIC16 
 
3.21 - Design of novel antagonist CCIC16 
 
In addition to the radiolabelling of the cyclic pentapeptide CCIC7, development 
was also sought with the well-characterised 14mer T140 derivative antagonist, 
TN14003. As reported in chapter 1.7, while some T140-derived PET tracers 
exhibited issues with non-specific binding on RBCs (Jacobson et al., 2010), it was 
possible to avoid this disadvantage with the replacement of the interfering 
fluorobenzoyl group that introduced the radiolabel with chelating groups such as 
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1, 4, 7, 10-tetraazacyclododecane 1, 4, 7, 10-tetraacetic acid (DOTA) and 1, 4, 7-
triazacyclononane 1, 4, 7-triacetic acid (NOTA) for the introduction of 64Cu into 
TN14003. However, even with these improvements the uptake of the 
radiotracer in CXCR4-expressing tumours was low, suggesting the possibility for 
further optimisation (Jacobson et al., 2012).  
 
A number of further modifications to the structure of TN14003 tracer reported 
above were considered necessary. Firstly, for the reasons described previously, 
the 64Cu radionuclide was exchanged for the more preferable 18F or 68Ga. Whilst 
DOTA or NOTA groups have been shown to be well-tolerated at the C-terminal 
of the 14-mer peptide (Jacobson et al., 2012), it is possible that a reduction in 
size of the conjugated chelating group may improve the affinity of the receptor, 
as a result of reduced steric hindrance. This suggestion is supported by the 
recently-reported crystal structure of CXCR4, which shows that both the N- and 
C-terminals of a T140-derived CXCR4 antagonist are buried within the 3D 
structure of CXCR4 (Wu et al., 2010), implying that the structures at these points 
may be important for binding affinity. It was therefore considered that direct 
conjugation of a 1, 4, 7-triazacyclononane 1, 4-diacetic acid (NODA or NO2A) 
group upon the C-terminus of the peptide antagonist might be suitable, as it is 
considerably smaller than the NOTA-Bn-thiourea chelating group used 
previously by Jacobson et al. (2005 ; figure 26B), and is also amenable to 
labelling with gallium-68 (Notni et al., 2012) and aluminium fluoride-18 (McBride 
et al., 2012). It was hoped that these changes would result in a 14mer PET tracer 
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with an improved target-to-background ratio. The resulting peptide was 
designated CCIC16 (figure 26C).   
 
Figure 26. Evolution of TN14003 to NOTA-NFB-T140 to CCIC16. 
A Structure of TN14003 B Structure of NOTA-NFB-T140 reported by (Jacobson et al., 2012)           
C Structure of CCIC16. Arginine (Arg) ; 2-Naphthylalanine (Nal) ; Cys (Cysteine) ; Tyr (Tyrosine) ; 
Citrulline (Cit) ; Lysine (Lys) ; Proline (Pro). 
 
3.22 - Assessment of CXCR4 antagonism by ion-chelated derivatives of CCIC16 
The newly synthesised CCIC16 was then labelled with a number of different 
metal cations that could potentially be used in nuclear imaging applications, 
A 
B 
C 
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including Ga3+, [AlF]2+, Cu2+, and In3+. In order to assess their potential as novel 
antagonists, their ability to antagonise CXCR4 was investigated with competitive 
radioligand binding assays and migration assays. The potencies of these 
antagonists in these applications were compared against the commercially 
available T140 derivative known as TC14012 (Arg-Arg-Nal-Cys-Tyr-Cit-Lys-D-Cit-
Pro-Tyr-Arg-Cit-Cys-Arg-NH2). With the radioligand binding assay (refer to 
section 2.11i) it was seen that the affinities of the Ga3+, [AlF]2+, Cu2+ labelled 
CCIC16 antagonists were very similar to the affinity of the unlabelled CCIC16 
antagonist, with mean IC50 values of 69-103 nM when competing for binding 
sites against 0.1 nM 125I-SDF1. In contrast, the reference compound TC14012 
and In-labelled CCIC16 showed higher affinity for the CXCR4 receptor, with IC50 
values of 18.2 nM and 17.6 nM, respectively (figure 27A and table 6).  
 
The compounds also showed an ability to inhibit CXCR4-mediated migration 
(refer to section 2.12), as Jurkat cells cultured in the presence of cation-labelled 
CCIC16 could prevent cell migration to transwell chambers containing 100 ng/ml 
SDF1 (Figure 27B). Similarly to the radioligand binding assay data, TC14012 again 
showed the greatest potency of the compounds assayed with an IC50 of 6.3 nM, 
while chelation with metal cations increased the antagonism shown by CCIC16 
from 355.7 nM to values as low as 43.9 nM and 60.7 nM (as shown by AlF-
CCIC16 and Ga-CCIC16, respectively). The high degree of antagonism shown by 
Ga-CCIC16 for CXCR4 (table 6) along with the benefits of 68Ga as a PET  
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Figure 27. In vitro assessment of CCIC16 antagonism 
A Inhibition of [125I]SDF1α binding to U87.CD4.CXCR4 cells by indicated concentrations of 
antagonists. Curves shown are representative of at least 3 independent experiments, with error 
bars showing the SEM. Refer to section 2.11i. B Inhibition of CXCR4-mediated migration at 3 h in 
Jurkat cells. Curves shown are representative of at least 3 independent experiments, with error 
bars showing the SEM. Refer to section 2.12.  
 
Table 6. Summary of the effects of ion chelation upon CCIC16 potency of CXCR4 binding and 
antagonism in vitro 
Compound Binding Assay (nM) Migration Assay (nM) 
TC14012 18.2 6.3 
CCIC16 102.3 355.7 
Ga-CCIC16 69.6 60.7 
AlF-CCIC16 84.3 43.9 
In-CCIC16 17.6 100.0 
Cu-CCIC16 90.9 221.5 
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radionuclide as described in chapter 1.7 made 68Ga-CCIC16 an obvious target for 
development as a PET tracer. 
 
3.23 - Investigation of specificity of [68Ga]-CCIC16 for CXCR4 
 
In order to determine whether 68Ga-CCIC16 could selectively label CXCR4-
expressing cell lines, 0.74 MBq of the tracer was incubated with U87.CD4 and 
U87.CD4.CXCR4 cells for 60 minutes before measurement of bound radioactivity 
as described in section 2.13; it was found that 68Ga-CCIC16 uptake was 
significantly higher in U87.CD4.CXCR4 cells than in the CXCR4-negative U87.CD4 
cells by a mean of 3.1-fold. A 15 minute preincubation with 10 µM Ga-CCIC16 
prevented this increased uptake in U87.CD4.CXCR4 cells, suggesting that uptake 
of radiotracer onto the cells was specific to CXCR4 expression (figure 28).  
 
3.24 - In vivo validation of [68Ga]-CCIC16 
 
With evidence of specificity for CXCR4, it was decided to further assess the 
potential of [68Ga]-CCIC16 as a CXCR4-targeting PET imaging tracer though in 
vivo imaging experiments as described in section 2.15i. To this end, BALB/c 
nu/nu mice bearing either CXCR4-negative U87.CD4 or CXCR4-positive 
U87.CD4.CXCR4 (n=6, 5, respectively) were injected with 3.7 MBq [68Ga]CCIC16 
at the commencement of a 60 minute dynamic PET/CT scan. As figure 29A and 
29B show, there was a clear difference in radiotracer uptake between the two 
tumour types at 60 minutes. This occurred as a result of a time-dependent  
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Figure 28. Uptake of [68Ga]-CCIC16 in vitro following a 60 min incubation.  
Uptake of 0.74 MBq 68Ga]-CCIC16 in U87.CD4 and U87.CD4.CXCR4 cells. Figure shown is 
representative example of 3 independent experiments (*** signifies P≤0.001; error bars show 
SEM). Refer to section 2.13. 
 
accumulation of radiotracer within the U87.CD4.CXCR4 tumours, whereas 
radiotracer accumulation within the CXCR4-negative U87.CD4 tumours steadily 
dropped following an initial peak at around 10 minutes post-injection (figure 
29C). This curve shape is indicative of washout of [68Ga]-CCIC16 from the 
U87.CD4 tumours, and is mirrored by tumour uptake in mice bearing 
U87.CD4.CXCR4 tumours that had been coinjected with 50 µg Ga-CCIC16 (>50-
fold of injected radioactive dose; n=5), suggesting that the accumulation of 
radiotracer within the U87.CD4.CXCR4 tumours was specific to its increased 
CXCR4 expression. This was supported by the fact that the standardised uptake  
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Figure 29. PET/CT imaging following a 3.7 MBq injection of [68Ga]-CCIC16 in BALB/c nu/nu mice 
bearing U87.CD4 (yellow arrow) and U87.CD4.CXCR4 (red arrow) tumours, and U87.CD4.CXCR4 
tumour-bearing mice that had been coinjected with 50 µg Ga-CCIC16 (n=6, 5, 5 respectively) 
Representative A transverse and B sagittal merged PET/CT images of radiotracer at 60 minutes 
post-injection. C Time-activity curve of dynamic uptake of radioactivity in tumours over 60 mins. 
D Standardised uptake value at 60 minutes (SUV60) and E tumour-to-muscle ratios of tumours. 
Error bars show SEM ; * signifies P≤0.05, ** signifies P≤P.01). Refer to section 2.15i.  
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value at 60 minutes (SUV60) was significantly higher in U87.CD4.CXCR4 tumours 
than in the U87.CD4.CXCR4 tumours. Furthermore, the tumour-to-muscle ratios 
for the mice bearing these different tumour types were also significantly 
different, with the increase in this ratio within U87.CD4.CXCR4 tumours almost 
entirely blocked by the coinjection of the cold Ga-CCIC16 peptide.  
 
The biodistribution of the radiotracer at 60 minutes (U87.CD4 tumour bearing 
n=3; U87.CD4.CXCR4 tumour bearing n=4) experiment conducted as described in 
section 2.15iii) within the mice was largely located within the liver, gallbladder, 
kidneys and urine (figure 30A and table 7), consistent with hepatic and urinary 
routes of excretion. Other sites of notable radiotracer uptake include the bone 
and spleen. The lack of significant reductions in tracer uptake within the bone 
and spleen following coinjection of 50 µg Ga-CCIC16 (n=5) suggest that the 
uptake in these areas may not have been CXCR4-specific, although CXCR4 
expression has been reported in both these tissues (Shao et al., 2011, 
Federsppiel et al., 1993); alternatively, the sensitivity of the technique may not 
be high enough to discriminate the lower levels of expression likely associated 
with these tissues. Despite this possibility, it is apparent that [68Ga]-CCIC16 
allows the differentiation of tumours of high and low CXCR4 expression. 
 
Given that peptidic compounds such as [68Ga]-CCIC16 are notorious for poor 
bioavailability as a result of metabolism and clearance (Craik et al., 2013), it was 
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Figure 30. Biodistribution of [68Ga]-CCIC16 A in BALB/c nu/nu mice bearing U87.CD4 or U87.CD4.CXCR4 tumours at 60 min post-injection, and blockade in U87.CD4.CXCR4-
bearing mice by coinjection of 50 µg Ga-CCIC16 [n = 3, 4 and 5, respectively], and B in healthy BALB/c mice at 2 minutes, 30 minutes and 60 min post-injection (n=6, 4 and 
4). Refer to section 2.15iii for protocol details. 
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Table 7. Biodistribution of 3.7 MBq [
68
Ga]-CCIC16 at 60 minutes in BALB/c mice bearing 
U87.CD4 and U87.CD4.CXCR4 tumours, and in U87.CD4.CXCR4 tumour-bearing mice that had 
been coinjected with 50 µg Ga-CCIC16 (n=3, 4 and 5, respectively; refer to section 2.15iii) 
 
Biodistribution [68Ga]-CCIC16 at 60 minutes 
(%ID/g ± SEM) 
Tissue No treatment 50 µg Ga-CCIC16 
Plasma 1.467 ± 0.290 2.174 ± 0.441 
Blood 0.617 ± 0.161 0.467 ± 0.164 
Heart 0.817 ± 0.093 1.351 ± 0.267 
Lung 3.104 ± 0.513 3.573 ± 0.755 
Liver 21.034 ± 6.154 11.799 ± 5.584 
Gallbladder 21.129 ± 6.221 11.552 ± 5.848 
Stomach 0.977 ± 0.367 1.375 ± 0.359 
Duodenum 1.037 ± 0.155 1.325 ± 0.290 
Jejunum 0.840 ± 0.136 1.362 ± 0.238 
Caecum 0.432 ± 0.075  0.689 ± 0.140 
Colon 0.844 ± 0.139 1.447 ± 0.243 
Spleen 3.462 ± 0.782 3.027 ± 0.731 
Kidney 24.004 ± 4.920 45.212 ± 16.688 
Muscle 0.619 ± 0.078 0.899 ± 0.187 
Bone 2.518 ± 0.531 2.443 ± 0.386 
Brain 0.093 ± 0.010 0.149 ± 0.063 
Urine 30.667 ± 11.590 66.298 ± 51.603 
U87.CD4 tumour 1.582 ± 0.228   
U87.CD4.CXCR4 tumour 5.329 ± 1.836 4.356 ± 0.970 
U87.CD4 Tumour/Muscle 2.373 ± 0.337   
U87.CD4.CXCR4 Tumour/Muscle 9.502 ± 1.709  4.839 ± 0.751 
U87.CD4 Tumour/Plasma 1.175 ± 0.118   
U87.CD4.CXCR4 Tumour/Plasma 4.571 ± 1.525 1.945 ± 0.259 
 
decided to conduct time-course biodistribution and metabolism experiments 
(described in section 2.15iii and 2.16, respectively) in order to observe the 
clearance of [68Ga]-CCIC16 over time, and to determine whether metabolism of 
the compound may play a significant role in the tracer’s bioavailability. Non-
tumour-bearing BALB/c subjects were injected with 7.4-11.1 MBq [68Ga]-CCIC16 
and sacrificed at 2, 30 and 60 minutes post-injection (n=6, 4, 4, respectively). It 
was seen that there were time-dependent increases in radiotracer accumulation 
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in the liver, gallbladder, kidneys and urine over the course of 60 minutes, with 
maximum accumulation in all these tissues at 60 minutes. In agreement with 
biodistribution studies at 60 minutes (figure 30A and table 7), time-dependent 
increases in tracer uptake were also observed in the bone and spleen (figure 
30B). Tracer presence in plasma did not significantly decrease at 60 minutes, a 
considerable improvement in clearance characteristics as compared to [18F]-
CCIC7, which rapidly accumulated in the kidneys and liver (reaching maximal 
uptake in these tissues within a mere 5 minutes), resulting in a dramatic decline 
in radiotracer presence within the plasma within 30 minutes (figure 16).  
 
Alongside the collection of biodistribution data for this experiment, tissues were 
also collected to assess the metabolism status of [68Ga]-CCIC16 within these 
tissues at various time-points (n=3), as described in section 2.16. It was seen that 
the radiotracer was fairly serum-stable, with a mean 33% parent compound 
remaining in circulation at 15 minutes (figure 31 and table 8). However, a high 
proportion (>92%) of tracer within the urine had metabolised to more 
hydrophilic 68Ga-containing metabolite fragments at every time-point tested 
from 2 minutes post-injection. Despite this, the relative abundance of 
unmetabolised tracer circulating in the plasma was very encouraging, as it 
suggests that the serum stability of the peptide was sufficient to allow the time-
dependent uptake of [68Ga]-CCIC16 observed in the imaging studies at 60 
minutes (figure 28). 
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Figure 31. HPLC traces showing parent compound and metabolite peaks in liver and plasma 
extracts of BALB/c mice following 2, 15, and 60 minute inoculation of 7.4-11.1 MBq [
68
Ga]-
CCIC16 (n=3). Representative radiochromatograms of acetonitrile extracts from mouse plasma 
and homogenised liver samples at the indicated time points.  
 
Table 8. In vivo metabolism of compound [68Ga]-CCIC16 at selected time points, showing the 
percentage of [68Ga]GaCCIC16 present in plasma, liver and urine extracts (n=3) 
n=3 Plasma Urine Liver 
2 mins 94 ± 7% 5 ± 4% 5 ± 2% 
15 mins 43 ± 21% 6 ± 1% 3 ± 3% 
60 mis 33 ± 12% 8 ± 1% 5 ± 4% 
 
3.25 - Use of [68Ga]-CCIC16 to identify 17AAG-induced changes in CXCR4 
expression 
Following the success of [68Ga]-CCIC16 in identifying tumours of varying CXCR4 
expression, it was considered whether the tracer could adapted for use as a non-
invasive tool to detect response to treatment, in particular, the degradation of 
CXCR4 as a marker of response to HSP90 inhibitors. The following data shown is 
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the result of an investigation to determine whether [68Ga]-CCIC16 could be used 
to noninvasively detect changes in CXCR4 expression induced by 17AAG, an 
HSP90 inhibitor. The first task was to confirm whether treatment of 
U87.CD4.CXCR4 cells with 17AAG (as described in section 2.17i) could result in 
the expected decrease in CXCR4 expression. As figure 32 shows, CXCR4 
expression does indeed decrease markedly with increasing dose and duration of 
17AAG treatment, to a maximum of 50% following 48 hours treatment with 500 
nM 17AAG. In support of the involvement of HSP90 inhibition in the decrease of 
CXCR4 expression, the expression of HSP70 was also shown to be increased by 
incubation with 17AAG. HSP70 expression has been shown to be induced by 
HSP90 inhibition through withdrawal of HSP90-mediated suppression of heat 
shock factor 1 (HSF1)(Kim et al., 1999). These findings confirm the ability of 24 
and 48 hour treatments of 100-500 nM 17AAG to reduce functionality of HSP90 
and the downregulation of CXCR4 protein expression, a client of HSP90. 
 
With the above significant reduction in CXCR4 expression observed following 48 
hours treatment, it was decided to assess the ability of [68Ga]-CCIC16 to 
differentiate between U87.CD4.CXCR4 cells that were either treated with 
100 nM 17AAG for 48 hours or treated only with the vehicle using an in vitro 
uptake assay (as described in section 2.17i). The 100 nM dose was chosen over 
the more effective 500 nM dose due to the considerably reduced viability of 
U87.CD4.CXCR4 cells following 48 hours treatment with 500 nM 17AAG. The 1.4-
fold difference in CXCR4 expression between U87.CD4.CXCR4 cells treated with 
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100 nM 17AAG for 48 hours and untreated cells is considerably less than the 10-
fold difference in expression between U87.CD4 and U87.CD4.CXCR4 cell models 
used in the previous uptake assay experiment (figure 28), so it was encouraging 
to observe that the difference in expression of the two groups could be detected 
in the form of a mean 1.6-fold reduction in [68Ga]-CCIC16 uptake, which 
compares very favourably with differences in protein expression (figure 32). 
Uptake in both 17AAG-treated and untreated cells was reduced by 
preincubation with 10 µM cold Ga-CCIC16, confirming CXCR4-dependent uptake 
of [68Ga]-CCIC16 in the cell lines.  
 
Figure 32. Effect of 17AAG treatment upon protein expression 
Protein expression in U87.CD4.CXCR4 cells treated at the indicated concentration and 
length of time was determined by western blot. A Representative immunoblot showing 
expression of CXCR4, HSP70 and GAPDH. B Densitometric analysis of CXCR4 expression, 
normalised to GAPDH expression and to the control (n=3 ; error bars show SEM ; * 
signifies P≤0.05, ** signifies P≤0.01, *** signifies P≤0.001). Refer to section 2.17i. 
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As a result of the promising findings above, it was decided to further examine 
the ability of [68Ga]-CCIC16 to detect 17AAG-induced changes in CXCR4 
expression by beginning an in vivo experiment, where mice bearing 
U87.CD4.CXCR4 tumours were either treated with 80 mg/kg 17AAG or vehicle 
control daily for 48 hours prior to injection with 3.7 MBq [68Ga]-CCIC16 (n=6, 5, 
respectively), as described in section 2.17ii. Unfortunately at this stage in the 
project there were no imaging facilities available due to the closure of the 
Biological Imaging Centre (BIC) at Imperial College London, and so the only in 
vivo investigations that could be performed were biodistribution experiments. 
Disappointingly, there was no difference in uptake of the radiotracer in the 
tumours of 17AAG-treated mice, as compared to the vehicle-treated mice 
Figure 33. [
68
Ga]-CCIC16 uptake in U87.CD4.CXCR4 cells either treated or untreated with 
100 nM 17AAG for 48 hours. 
Representative figure of three independent experiments. Error bars show SEM (* signifies 
P=0.05). Refer to section 2.17i. 
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 (figure 34). There were also no notable differences in the spleen and bone of 
treated and untreated mice (table 9), which had been associated with time-
dependent increases in [68Ga]-CCIC16 uptake (figure 30B), possibly as a result of 
their endogenous CXCR4 expression.  
Figure 34. Uptake of [68Ga]-CCIC16 at 60 minutes in U87.CD4.CXCR4 tumours of mice treated 
with either 80 mg/kg 17AAG daily for 48 hours or vehicle 
Error bars show SEM (n=6, 5, respectively). Refer to section 2.17ii.  
It was considered that the dose of 17AAG administered may not have been 
sufficient to result in CXCR4 degradation within the tumour, or alternatively that 
the reductions in CXCR4 expression associated with U87.CD4.CXCR4 tumour 
growth in vivo (figure 25) might have reduced the maximum fold-difference in 
CXCR4 expression achievable in vivo. Thus protein analysis of CXCR4 expression 
was carried out on the homogenised snap-frozen tumour samples by western 
blot (as described in section 2.17i and 2.4ii). At first glance it appeared that daily 
treatment with 80 mg/kg 17AAG for 48 hours resulted in an increase in CXCR4 
expression in U87.CD4.CXCR4 tumours (figure 35A), rather than the expected 
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Table 9. Biodistribution of [
68
Ga]-CCIC16 at 60 minutes in U87.CD4.CXCR4 tumour-bearing  
mice treated with either 80 mg/kg 17AAG daily for 48 hours or vehicle (n=6, 5, respectively) 
 
Biodistribution [68Ga]CCIC16 at 60 minutes 
(%ID/g ± SEM) 
Tissue Vehicle 80 mg/kg 17AAG 
Plasma 1.681 ± 0.366 1.568 ± 0.247 
Blood 0.552 ± 0.101 0.548 ± 0.072 
Heart 1.389 ± 0.175 1.23 ± 0.154 
Lung 4.728 ± 0.554 4.595 ± 0.492 
Liver 18.857 ± 2.758 16.656 ± 1.402 
Gallbladder 25.488 ± 2.903 22.022 ± 2.762 
Stomach 0.591 ± 0.164 0.374 ± 0.081 
Duodenum 1.253 ± 0.160 1.252 ± 0.149 
Jejunum 1.133 ± 0.202 1.144 ± 0.133 
Caecum 0.954 ± 0.173 0.743 ± 0.129 
Colon 1.456 ± 0.418 1.271 ± 0.160 
Spleen 4.630 ± 0.688 5.072 ± 0.547 
Kidney 36.884 ± 6.444 39.378 ± 6.560 
Muscle 1.152 ± 0.276 0.873 ± 0.122 
Bone 4.737 ± 0.649 4.755 ± 0.997 
Brain 0.127 ± 0.015 0.132 ± 0.018 
Urine 42.968 ± 11.611 48.217 ± 8.681 
U87.CD4.CXCR4 Tumour 7.208 ± 0.874 7.153 ± 1.037 
U87.CD4.CXCR4 Tumour/Muscle 7.194 ± 1.074 8.522 ± 1.316 
U87.CD4.CXCR4 Tumour/Plasma 4.691 ± 0.653 5.442 ±1.618 
 
decrease, although this difference was determined to be nonsignificant 
following densitometric analysis (figure 35B).  However, this unexpected mean 
2-fold increase was seen in mice that had been treated in separate cohorts, and 
so had been treated and processed on separate occasions, which would appear 
to preclude the possibility of investigator error (for example confusion of the 
subject groups). Furthermore, this finding coincided with a statistically 
significant mean 3.5-fold increase in HSP70 expression, in line with expectations 
for HSP90 inhibition. The reason for the unexpected departure in CXCR4 
expression in vivo as compared to that predicted by the in vitro data (figures 32 
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and 33) is currently unconfirmed; however potential reasons are discussed 
further in chapter 5.  
   
Figure 35. Assessment of the effect of 48 hours daily 80 mg/kg 17AAG treatment upon the 
expression of HSP90 targets CXCR4 and HSP70 in U87.CD4.CXCR4 tumours in vivo 
 A Representative western blot of homogenised snap-frozen tumour samples with CXCR4, HSP70 
and β-actin antibodies. Densitometric analysis of B CXCR4 and C HSP70 expression in tumour 
samples, normalised to β-actin and mean expression in vehicle-treated samples. Error bars show 
SEM; (vehicle n=5, treated n=6); ** signifies P≤0.01. 
 
While it is possible that with increased sample sizes that a significant difference 
in CXCR4 expression between the two groups of treated tumour samples might 
reach significance, the fact remains that [68Ga]-CCIC16 was unable to 
differentiate between the tumours of treated and untreated subjects to any 
discernible degree (figure 33), let alone with the confidence of statistical 
significance. However, it is likely that insufficient difference in CXCR4 expression 
was the root cause of the tracer’s failure in this investigation. 
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3.3- Design and structure-activity relationships 
of pentapeptide library, and characterisation of 
[18F]CCIC15 and [18F]CCIC30 
 
3.31 - Design of pentapeptide library 
As discussed in the introduction, tetra- and penta-peptide derivatives of T140 
have previously been found to antagonise CXCR4 with a similar efficacy to T140, 
with cyclisation of pharmacophore enabling downsizing and a reduction in 
peptide character (Tanaka et al., 2008). However, as chapter 3.1 shows, 
modification of the FC131 structure to include a PEG2-FB functional group which 
was designed to allow incorporation of 18F into the pentapeptide structure 
resulted in a compound with lacklustre affinity for CXCR4, and extremely poor 
bioavailability. It was theorised that the poor pharmacokinetics of [18F]CCIC7 in 
vivo may have occurred as a result of the increased size of the pentapeptide 
structure. The increased size of the compound may also account for the modest 
antagonism CCIC7 bore against CXCR4-directed migration in vitro; the affinity of 
the antagonist for the receptor was possibly reduced by the linker group, as the 
FC131 structure upon which CCIC7 was based shows extremely high potency in 
CXCR4 antagonism (Tanaka et al., 2008).   
 
Alternative methods of incorporating radionuclides suitable for PET into 
pentapeptides were therefore investigated, with a particular focus on size 
reduction. It was decided that a fluorinated triazole (FTA) group would be an  
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Table 10. Structures of novel pentapeptide CXCR4 antagonist library 
CCIC29 
CCIC36 
FC131 
CCIC30 
CCIC15 
Name Structure 
cyclo[tyr-arg-arg-
nal-gly] 
cyclo[FTA-arg-
arg-nal-gly] 
cyclo[tyr-arg-arg-
FTA-gly] 
cyclo[tyr-arg-
FTA-nal-gly] 
cyclo[tyr-FTA-
arg-nal-gly] 
Simplified structure 
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appropriate conjugate, as it appeared to meet the desired criteria, both in terms 
of size and ease of radiolabelling. Furthermore, it rationalised that the best 
position of the FTA group should be determined, in order to optimise the affinity 
of the antagonist for CXCR4. Thus a small pentapeptide library was created for 
testing, comprised of novel antagonists CCIC15, CCIC29, CCIC30 and CCIC36 (see 
table 10).  
 
3.32 - Assessment of CXCR4 antagonism, and modification of radioligand 
binding assay protocol 
The first step in evaluating the above novel antagonist compounds for their 
potential as radiotracers was to assess their affinity for CXCR4. This proved to be 
more difficult than anticipated, as initial attempts to derive the half maximal 
inhibitory concentration (IC50) of antagonists in a radioligand binding assay (as 
described in section 2.11i) resulted in values far higher than expected. For 
example, the antagonists CCIC29 and CCIC30 showed IC50 values of >50 µM and 
5.6 µM, respectively (fig 36A), much greater than the values reported in the 
literature for the FC131 pentapeptide antagonist (5-150 nM (Tanaka et al., 2008, 
Tamamura et al., 2005c), on which their designs were based. Furthermore, when 
FC131 was purchased and investigated under the same assay conditions the IC50 
value yielded by this protocol (method A, referred to in chapter 2.11i) was 18.9 ± 
5.0 µM, over 120-fold higher than the expected value. This enormous 
discrepancy between the values from published literature and observed results 
suggested that the assay conditions for method A were not optimal, and that in 
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order to determine accurate IC50 values for the novel compounds an alternative 
method would have to be used.  
 
As such, a number of different techniques were attempted with no success, until 
the implementation of a modified procedure (method B, described in chapter 
2.11ii) which used a PBS-based buffer for the assay, with no added salts.  
Following this protocol, an IC50 of 600 nM was obtained for FC131, reflecting a 
30-fold improvement on the previously used method. Subsequently, novel 
antagonists assayed using this method were found to show affinity for CXCR4, 
and were capable of competitively binding to CXCR4 in the presence of 125I-SDF1. 
Most notably, the compounds CCIC15 and CCIC30 performed comparably to 
FC131, with IC50 values of 962 and 305 nM, respectively (figure 36B and table 
11). In addition to the radioligand binding assay, the novel compounds were also 
assessed for CXCR4 antagonism using a transwell migration assay (according to 
the protocol described in 2.12), where their abilities to inhibit SDF1α-induced 
migration of Jurkat cells was determined (figure 36C). In this assay, FC131 
inhibited migration with an IC50 value of 80 nM, far surpassing that of its 
nearest competitor, CCIC15. A complete overview of the IC50 values of the novel 
compounds in both the radioligand binding and migration assay is provided in 
table 11 (CCIC30 and CCIC36 was not tested due to a shortage of available 
compound), and enables a structure-activity relationship to be tentatively 
suggested. Substitution of the naphthylalanine with FTA at the C5 position  
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   Figure 36. In vitro characterisation of novel pentapeptide antagonists 
A Radioligand binding assay with FC131, CCIC29 and CCIC30 using method A (described in 
chapter 2.11i). B Radioligand binding assay with FC131 and other novel antagonists using 
improved method B (described in chapter 2.11ii). Note the apparent increase in potency of 
compounds shown compared to A C Inhibition of SDF1-mediated migration in Jurkat cells by 
FC131 and novel antagonists (refer to section 2.12). Curves shown are representative examples 
of 3 independent experiments, error bars show SEM. 
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Table 11. Summary of IC50 values for FC131 and novel pentapeptide compounds  
Name Structure RBA IC50 (µM) Migration assay IC50 (µM) 
FC131 cyclo[tyr-arg-arg-nal-gly] 0.60 0.08 
CCIC15 cyclo[tyr-FTA-arg-nal-gly] 0.96 9.93 
CCIC29 cyclo[tyr-arg-FTA-nal-gly] 16.18 > 100 
CCIC30 cyclo[FTA-arg-arg-nal-gly] 0.30 not tested 
CCIC36 cyclo[tyr-arg-arg-FTA-gly] > 100 not tested 
Radioligand binding assay data refers to data collected using method B described in chapter 
2.12ii. Migration assay data refers to data collected using protocol described in section 2.13. 
Compounds CCIC30 and CCIC36 were not tested in for their inhibition of migration due to a lack 
of available compound for the assay. N=3. Radioligand binding assay (RBA); Fluorotriazole (FTA). 
  
resulted in the poorest affinity for CXCR4, whereas substitution at C2 or C5 
(CCIC30 and CCIC15) showed the greatest potency in CXCR4 antagonism. It was 
therefore decided that these 2 compounds would be selected for further 
development as potential PET tracers by radiolabelling with 18F. While the 
affinity of the ion-chelated CCIC16 T140 compound was higher than either 
CCIC15 or CCIC30, the potential for a more improved pharmacokinetic profile 
due to their cyclisation was anticipated, and so the novel compounds CCIC15 
and CCIC30 were selected for further development as 18F-radiolabelled PET 
tracers. 
 
3.33 - Validation of [18F]CCIC15 in vitro and in vivo  
Following radiolabelling of [18F]CCIC15, an initial experiment was required to 
determine the CXCR4 specificity of the radiotracer. To this end, the uptake of 
0.37 MBq of [18F]CCIC15 into U87.CD4 and U87.CD4. CXCR4 cell lines in vitro was 
investigated as described in section 2.13. As figure 37A shows, uptake of 
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[18F]CCIC15 into U87.CD4.CXCR4 cells was on average 2-fold higher than in 
U87.CD4 cells at 60 minutes, suggesting CXCR4-dependent uptake. In 
confirmation, 15 minutes pre-incubation with 20 µM FC131 as a competitive 
inhibitor prevented this increase in uptake, confirming that uptake of 
[18F]CCIC15 occurs in a CXCR4-specific manner.  
 
Following this promising development, the potential of [18F]CCIC15 was further 
investigated in its first in vivo experiment; unfortunately at this point in the 
programme there was an interruption in the use of imaging facilities following 
the closure of Biological Imaging Centre at Imperial College London, and the only 
in vivo studies that could take place at this time were biodistribution 
experiments.  Biodistribution was conducted with U87.CD4.CXCR4 tumour-
bearing mice at 60 minutes post-injection of 3.7 MBq [18F]CCIC15 (n=3), as 
described in section 2.15iii. As can be seen in figure 37B, there was no 
detectable CXCR4-dependent uptake of [18F]CCIC15 in the tumour, as there was 
no difference in tracer uptake within the tumour compared to muscle. The most 
notable sites of [18F]CCIC15 accumulation were instead seen within the 
gallbladder, duodenum and urine of the animals, suggesting clearance of the 
tracer from the blood through hepatic and urinary routes of excretion. Given the 
lack of tumour uptake of [18F]CCIC15, the in vivo experiments were curtailed in 
order to reduce the number of animal subjects used unnecessarily; it was 
considered possible that the potency of CCIC15 antagonism for CXCR4 may not 
have been sufficient to allow CXCR4-dependent uptake in vivo. 
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Figure 37. In vitro and in vivo uptake of [18F]CCIC15 at 60 minutes 
A Example of uptake of U87.CD4 and U87.CD4.CXCR4 cells with 0.37 MBq [18F]CCIC15 at 60 
minutes (n=3), as described in section 2.13. Cells were pre-treated for 15 mins with either 20 µM 
FC131 or inhibitor-naive media. B Biodistribution of 3.7 MBq [
18
F]CCIC15 in BALB/c nu/nu mice 
bearing U87.CD4.CXCR4 tumours at 60 min post-injection (n=3) as described in 2.15iii. Error bars 
show SEM; ** signifies P≤0.01. 
 
3.34 - Validation of [18F]CCIC30 in vitro and in vivo  
Given that CCIC30 had shown a higher affinity for CXCR4 than CCIC15, it was 
hoped that [18F]CCIC30 might also show potential as a CXCR4-targeting 
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radiotracer. Indeed, the mean difference in tracer uptake at 60 minutes was 2-
fold higher in U87.CD4 cells than in U87.CD4.CXCR4 cells in vitro (using the 
protocol described in section 2.13), the accumulation of which could be blocked 
by pre-treatment with 20 µM FC131 as a competitive inhibitor (figure 38), 
suggesting that uptake of [18F]CCIC30 was specific to CXCR4 expression.  
 
Figure 38. In vitro uptake of [18F]CCIC30 at 60 minutes 
U87.CD4 and U87.CD4.CXCR4 cells were incubated for 60 minutes with 0.37 MBq [18F]CCIC30 
following a 15 minute pre-treatment with either 20 µCi FC131 or untreated media, as dexribed in 
section 2.13. Figure shown is an example of 3 independent experiments. Error bars show SEM ; * 
signifies P≤0.05, ** signifies P≤0.01.  
 
As a result of these promising in vitro findings, in vivo PET imaging experiments 
were planned (using the Genysis4 benchtop scanner that was now available; 
refer to section 2.15ii for protocol; n =3). Initial experiments appeared to show a 
degree of promise, as the U87.CD4.CXCR4 tumour was visible against 
background uptake, especially at early time-points within the scan (figure 39). 
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Furthermore, biodistribution data (using the protocol described in section 
2.15iii; n=3) showed a 3-fold difference in [18F]CCIC30 uptake in the 
U87.CD4.CXCR4 tumour compared to the muscle, even at 60 minutes (figure 40). 
However, expansion of the experiment to include U87.CD4 tumour-bearing mice 
showed no difference in uptake between the two tumour groups at any time-
point, and the time-activity curves (TACs) of radioactivity uptake in the tumour 
did not reflect the typical upward slope expected of TACs depicting radiotracer 
accumulation (such as seen for 68Ga-CCIC16, figure 29C), but rather a downward 
slope from 5 minutes indicative of tracer washout. As with the results observed 
for [18F]CCIC15, there was no significant difference in the biodistribution of 
[18F]CCIC30 in U87.CD4 and U87.CD4.CXCR4 tumours at 60 minutes post-
injection (figure 40). Biodistribution data for in vivo uptake of [18F]CCIC30 also 
showed that the vast quantity of radioactivity was present within the urine, with 
additional sites of uptake at the liver and gallbladder, consistent with a 
predominantly urinary route of excretion.  
 
It was initially considered that the reason for the this discouraging lack of CXCR4-
dependent uptake in tumours might have been as a result of rapid tracer 
metabolism, in a similar manner to that seen for [18F]CCIC7 (figure 31). Thus to 
rule out metabolism as a cause, a limited metabolism experiment was carried 
out at 2 time-points (n=1) in order to gain an insight into the stability of the 
compound in vivo. It was found that [18F]CCIC30 was extremely stable in the 
plasma, liver, and urine samples of the mice tested (figure 41), with very little
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Figure 39. Dynamic PET imaging of 1.1 MBq [
18
f]CCIC30 in U87.CD4 and U87.CD4.CXCR4 xenografts. Representative PET images in BALB/c nu/nu mouse bearing 
U87.CD4.CXCR4 tumour following 1.1 MBq [18F]CCIC30 injection at A between 5 and 30 minutes and B at 60 minutes post-injection (refer to section 2.15ii). Transverse 
(left), coronal (middle) and sagittal (right) fields of view shown. Position of U87.CD4.CXCR4 tumour indicated by arrow. G Time-activity curve (TAC) of [18F]CCIC30 uptake in 
tumours. H Standardised uptake value (SUV) at 60 minutes in tumours. I AUC values for tumours during 60 minute scan. Error bars show SEM (n=3). 
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Figure 40. Biodistribution of 1.1MBq [18F]CCIC30 in BALB/c nu/nu mice bearing U87.CD4 or U87.CD4.CXCR4 tumours at 60 min post-injection  
A Tracer uptake in selected tissues B Tumour-to-muscle ratio and C tumour-to-blood ratio of U87.CD4 and U87.CD4.CXCR4 tumours, as calculated from biodistribution 
data. Error bars show SEM (n=3). Refer to section 2.15iii.
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evidence of tracer metabolism within the plasma, liver or urine even as late as 
60 minutes post-injection (92%, 88% and 85%, respectively); thus it seemed that 
[18F]CCIC30 was considerably serum stable. Despite this, the tracer showed 
extremely poor pharmacokinetics due to rapid clearance from the blood to the 
urine, which likely affected the ability of the tracer to accumulate in CXCR4-
expressing tumours.   
 
 
Figure 41. HPLC traces showing parent compound and metabolite peaks in liver and plasma 
extracts of BALB/c mice following 30 and 60 minute inoculation of 3.7 MBq [
18
F]CCIC30. 
Radiochromatograms from acetonitrile extracts from mouse plasma and homogenised liver 
samples at the indicated time points (n=1). Refer to section 2.16. 
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3.35 - Overview of pentapeptide tracers [18F]CCIC7, [18F]CCIC15 and 
[18F]CCIC30  
 
None of the pentapeptide radiotracers investigated in this project (i.e. 
[18F]CCIC7, [18F]CCIC15 or [18F]CCIC30), were successful in identifying CXCR4 
expressing tumours in vivo. When the in vivo biodistribution data for the three 
novel pentapeptide tracers are compared (table 12 and 13; refer to section 
2.15iii) it can be seen that despite their similarities in structure (as shown 
previously in figure 12 and table 10), the biodistribution of each tracer at 60 
minutes were quite different. While the uptake of [18F]CCIC7 was rapidly 
confined to the hepatic excretory pathway, hepatic uptake of [18F]CCIC30 was 
comparatively low. [18F]CCIC15 showed tracer uptake in the gallbladder and 
liver, but not the duodenum and jejunum as observed with [18F]CCIC7, implying 
slower hepatic clearance. All tracers showed considerable renal/urinary 
excretion, yet no other to the same degree as [18F]CCIC30, where uptake at 60 
minutes was primarily confined. None of these tracers showed any appreciable 
uptake in endogenous sites of CXCR4 expression, such as the lung, spleen and 
bone.  
 
Of [18F]CCIC15 and [18F]CCIC30, which were both assessed for their ability to 
identify U87 glioblastoma tumours of differing CXCR4 expression, neither 
showed high uptake in U87.CD4.CXCR4 tumours at 60 minutes. However, while 
[18F]CCIC15 failed to accumulate in the tumour above background levels, 
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[18F]CCIC30 fared slightly better, with a maximum 3.2-fold difference in uptake 
between U87.CD4.CXCR4 tumours and muscle (table 13). However, as was 
previously described, in U87.CD4 tumours the fold-difference was still 2-fold, 
and not significantly different. Thus it seems that what [18F]CCIC30 uptake there 
was in the tumour was not specific to CXCR4 expression. Thus the investigation 
into the effectiveness of pentapeptide antagonists as PET tracers was, in this 
instance, extremely disappointing; suggested reasons for this lack of success are 
outlined in chapter 5.  
 
Table 12. Biodistribution of [18F]CCIC7, [18F]CCIC15 and [18F]CCIC30 in selected tissues of 
BALB/c nu/nu mice in vivo at 60 minutes post-injection (refer to section 2.15iii; n=4, 3 and 3, 
respectively) 
 
Mean biodistribution at 60 minutes (%ID/g ± SEM) 
 
[18F]CCIC7 [18F]CCIC15 [18F]CCIC30 
Blood 1.298 ± 0.573 0.457 ± 0.214 0.171 ± 0.053 
Heart 0.681 ± 0.164 0.349 ± 0.096 0.368 ± 0.053 
Lung 0.943 ± 0.208 1.756 ± 0.336 0.870 ± 0.138 
Liver 0.943 ± 0.208 2.914 ± 0.161 6.341 ± 0.776 
Gallbladder 7.923 ± 1.758 27.193 ± 8.878 6.007 ± 0.779 
Stomach 4.367 ± 1.988 0.672 ± 0.002 0.533 ± 0.220 
Duodenum 37.249 ± 11.970 64.508 ± 17.050 1.291 ± 0.138 
Jejunum 24.191 ± 15.444 1.127 ± 0.180 0.473 ± 0.069 
Caecum 0.373 ± 0.108 0.215 ± 0.030 0.147 ± 0.019 
Colon 0.329 ± 0.081 0.917 ± 0.560 0.380 ± 0.127 
Spleen 0.468 ± 0.125 0.402 ± 0.082 0.340 ± 0.043 
Kidney 3.413 ± 1.301 0.990 ± 0.395 1.839 ± 0.155 
Muscle 0.296 ± 0.118 0.375 ± 0.188 0.317 ± 0.111 
Bone 0.442 ± 0.153 0.809 ± 0.127 0.825 ± 0.207 
Brain 0.117 ± 0.0254 0.097 ± 0.014 0.132 ± 0.026 
Urine 57.490 ± 13.595 170.956 ± 38.326 236.819 ± 49.012 
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Table 13. Biodistribution of [
18
F]CCIC15 and [
18
F]CCIC30 in U87.CD4.CXCR4 tumour-bearing 
BALB/c nu/nu mice at 60 minutes post-injection (n=3). Refer to section 2.15iii.  
 
U87.CD4.CXCR4 tumour uptake ± SEM 
 
(%ID/g) (Tumour/muscle) (Tumour/Blood) 
[18F]CCIC15 0.315 ± 0.018 1.155 ± 0.626 0.633 ± 0.199 
[18F]CCIC30 0.596 ± 0.012 3.219 ± 0.722 1.230 ± 0.395 
 
3.4 - Modification of small molecular antagonists 
It1t and AMD3465 
 
3.41 - Design of novel isothiourea antagonist library  
 
While the [68Ga]-CCIC16 tracer described in chapter 3.2 has enabled 
identification of CXCR4-expressing tumours in vivo, peptidic compounds such as 
CCIC16 bear a number of disadvantages against many non-peptide compounds. 
Such problems include a vulnerability to metabolism and low bioavailability 
(Craik et al., 2013). Cyclicisation to produce cyclic pentapeptides was hoped to 
reduce the extent of these inherent flaws, although as chapters 3.1 and 3.3 
show, our own investigations into the development of such radiotracers were 
largely unsuccessful. Thus it was decided to look to alternative compound 
classes that might also show specificity for CXCR4, but without the drawbacks 
associated with peptides.  
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One potential group is the isothiourea CXCR4 antagonists (described in chapter 
1.5), which have shown extremely high potency for CXCR4. Furthermore, very 
little in the way of development has been undertaken with these compounds, 
with only one main article reporting the structure-activity relationship of these 
derivatives (Thoma et al., 2008). There is therefore substantial grounds for hope 
that the current lead compound, It1t, may not yet be fully optimised, and 
therefore that the process of introducing functional groups for radiolabelling 
with 18F might improve or maintain the potency of It1t for CXCR4. The 
development of 18F-labelled It1t analogues might also be aided by the recent 
publication of the crystal structure of CXCR4 (Wu et al., 2010), with co-
crystallisation of It1t, allowing determination of the likely binding sites. It1t 
interacts with CXCR4 at numerous sites within its structure, however one the 
most promising sites for functionalization is at one of the cyclohexane groups,  
which is less integral to CXCR4 binding than many other locations on the 
molecule (Wu et al., 2010).  
 
Through utilisation of a number of different techniques, a compound library of 
It1t derivatives was designed (table 14), bearing functional groups that could 
allow radiolabelling with 18F. A number of methods for the integration of a 
fluoride-containing group into the vicinity of this ring structure were attempted; 
One approach was the substitution of the cyclohexane group for an alternative 
ring structure, such as an ortho-, meta- or para-fluorophenyl group (giving rise to 
the compounds GG343, CCIC8 and GG345), or a piperidine-ethyl-fluoride ring 
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It1t 
GG343 
CCIC8 
GG345 
CCIC27 
GG337 
GG338 GG366 
GG248 
Name Name Structure Structure Name Structure 
Table 14. Structure of novel It1t-derived analogues. 
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(giving rise to GG366). Other modifications included the substitution of 
cyclohexane for a piperidine-para-fluorobenzyl group (as is the case for CCIC27), 
or for ipso-cyclohexyl-triazol-ethyl-fluoride (creating GG337). More drastic 
alterations were made by the removal of the ring structure altogether, through 
substitution with isopropyl-triazol-ethyl-fluoride (such as in the case of GG338), 
or alternatively with PEG2-triazol-ethyl-fluoride, giving rise to GG248. This library 
represents a varied and experimental approach to optimisation of the 
functionalisation of It1t for use as a PET radiotracer. 
 
3.42 - Assessment of novel isothiourea library antagonism of CXCR4 
As with the pentapeptide compounds described in chapter 3.3, initial attempts 
to assess the affinity of It1t antagonists for CXCR4 were hampered by the 
unexpectedly high IC50 values yielded with the initial competitive radioligand 
binding assay protocol used (protocol A, see chapter 2.11i). Given that the 
expected IC50 value for the lead compound It1t was expected to be in the region 
of 8 nM (Thoma et al., 2008), an observed value of > 100 µM, over 12,000-fold 
higher than expected, gave considerable cause for concern (figure 42A). 
Fortunately, modification of the radioligand binding assay protocol to method B 
(described in chapter 2.11ii) resulted in a mean IC50 value of 1.5 nM being 
obtained (figure 42B), in line with expectations, and so the novel It1t-derived 
compounds displayed in table 14 were assessed using the same method. A 
considerable range in potencies was observed, from the nM- to the mM-scale; 
most notable among these were CCIC8, GG345 and 366, with IC50 values of 34.4  
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Figure 42. In vitro assessment of isothiourea novel antagonist library for antagonism of CXCR4 
Inhibition of radioligand binding by novel antagonist using A protocol A (chapter 2.11i) and          
B protocol B (chapter 2.11ii). C Inhibition of Jurkat cell migration by novel antagonist compounds 
(refer to chapter 2.12). Curves shown are representative of at least 2 independent experiments, 
error bars show SEM.  
A 
-12 -10 -8 -6 -4 -2
0
20
40
60
80
100
120
It1t
Log [M]
B
o
u
n
d
1
2
5
I-
S
D
F
1
(%
 m
a
x
)
C 
B 
-12 -10 -8 -6 -4 -2
0
20
40
60
80
100
120
It1t
GG343
CCIC8
GG345
GG366
CCIC27
GG337
GG338
GG248
Log [M]
B
o
u
n
d
1
2
5
I-
S
D
F
1
 (
%
)
-12 -10 -8 -6 -4 -2
0
20
40
60
80
100
120
It1t
GG343
CCIC8
GG345
GG366
GG337
GG338
GG248
CCIC27
Log [M]
M
ig
ra
ti
o
n
 (
%
)
184 
 
Table 15. Comparative table of novel It1t analogue antagonism as judged by inhibition of 
radioligand binding and migration. 
 
Radioligand binding assay Migration assay  
Compound IC50 (µM) n IC50 (µM) n 
It1t 0.002 3 0.045 3 
GG343 > 100 2 > 100 2 
CCIC8 0.034 3 0.242 3 
GG345 0.108 2 0.987 3 
GG366 0.396 3 9.130 2 
CCIC27 1.263 2 15.730 3 
GG337 4.645 2 58.130 3 
GG338 > 100 2 74.050 3 
GG248 > 100 3 > 100 3 
 
N refers to the number of independent experiments. 
 
nM, 107.5 nM and 361.1 nM, respectively. Of low potency were CCIC27 and 
G337, with values of 1.3 µM and 4.6 µM, respectively, whereas GG343, GG338 
and GG248 showed very little affinity for CXCR4 whatsoever (figure 42B and 
table 15).  
 
Similar potencies were observed with the compounds’ inhibition of SDF1-
mediated migration in Jurkat cells (according to the protocol described in section 
2.12), with the reference compound It1t showing the greatest antagonism at 45 
nM, followed by the fluorobenzoylated CCIC8 and GG345 with 987.0 nM and 
242.0 nM, respectively. Low potency was observed with GG366, CCIC27 and 
GG337 with 9.1 µM, 15.7 µM and 58.1 µM, respectively, and again, little to no 
antagonism by GG338, GG343 and GG248. The binding affinity of the 
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compounds to the CXCR4 receptor is therefore directly proportional to their 
ability to inhibit SDF1-induced migration. With the highest potencies for CXCR4 
shown by the novel antagonists CCIC8 and GG345, these compounds would 
appear to show the greatest potential for radiolabelling with 18F. Unfortunately 
there was insufficient time remaining on the project to make progress in this 
regard, although plans for future experiments are discussed in chapter 4. 
 
3.43 - Functionalisation of cyclam AMD3465 
 
In addition to the isothiourea-derived compounds, there are also many other 
small molecular categories of compounds that may be used to inhibit CXCR4-
dependent signalling processes (outlined in chapter 3.3). Of these classes, the 
monocyclam AMD3465 has perhaps shown the most potential for use in PET 
imaging (De Silva et al., 2011), although the only method of functionalisation 
assessed so far is the chelation of 64Cu within the cyclam core. It is possible that 
alternative approaches towards functionalisation might bear advantages; among 
the possible alterations to AMD3465 structure is the substitution of the pyridine 
ring for a dimethylamine fluorophenyl group, a novel compound named DB011 
(figure 43). In contrast to the previously reported [64Cu]AMD3465, the proposed 
radionuclide is a covalently bound 18F, which bears a number of advantages over 
64Cu when used in PET imaging (as explained previously in chapter 1.5). 
Furthermore, the use of covalent bonding rather than chelation at the cyclam 
may help to promote specificity of the tracer, as transchelation of radionuclides 
186 
 
can be associated with nonspecific uptake into non-target organs (Tolmachev 
and Stone-Elander, 2010).  
 
Figure 43. Structures of AMD3465 and novel derivative DB011 
 
Assessment of AMD3465 and the derived DB011 using in vitro assays compared 
their respective potencies for the CXCR4 receptor through inhibition of ligand 
binding and subsequent migration. The results were promising, with very little 
difference in potency observed between the two compounds (see figure 44 and 
table 16), with half-maximal inhibitory concentrations observed at 89.8 and 
111.3 nM, respectively (using the protocol described in section 2.11ii). IC50 
values for the inhibition of SDF1-dorected migration (using the protocol 
described in 2.12) by AMD3465 and DB011 were similarly alike at 79.9 and 
226.6 nM, respectively. These observations strongly suggest that the 
modification of AMD3465 to incorporate a fluoride atom in this manner should 
have little-to-no effect upon the affinity of the tracer for CXCR4, with respect to 
the unmodified AMD3465. The potency of DB011 for CXCR4 is therefore high, 
and would benefit from further development towards radiolabelling with the 18F 
radionuclide. Unfortunately, there was insufficient time remaining to investigate 
AMD3465 DB011 
187 
 
this more fully within the project, however the compound certainly shows 
promise for future investigations. 
 
Figure 44. In vitro antagonism of CXCR4 by AMD3465 and novel derivative DB011 
A Radioligand binding assay using protocol A (chapter 2.11ii). B Inhibition of SDF1-induced 
migration of Jurkat cells (refer to section 2.12). Curves shown are representative of at least 2 
independent experiments, error bars show SEM.  
Table 16. In vitro antagonism of CXCR4 by AMD3465 and novel derivative DB011 
 
Radioligand binding assay Migration assay  
Compound IC50 (nM) n IC50 (nM) n 
AMD3465 89.8 3 79.9 3 
DB011 111.3 3 226.6 2 
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Chapter Four - Discussion 
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CXCR4 is a chemokine receptor that has been strongly implicated in the 
progression of cancer, and may be a potential biomarker of tumour 
aggressiveness and patient prognosis. The work presented here details the 
approaches made to functionalising a variety of classes of CXCR4 antagonist for 
use as novel PET tracers; these antagonist types included a T140 14mer peptide, 
numerous peptidomimetic cyclic pentapeptides, various isothioureas, and a 
monocyclam.  At least one example of every group of novel antagonists showed 
potent antagonism of ligand binding and inhibited migration in CXCR4-
expressing cellular models, highlighting their potential for use for in vivo imaging 
applications. Several of these candidates were assessed for their ability to 
successfully identify tumours of high CXCR4 expression in vivo. This aim was 
addressed most completely with the novel 14mer peptide tracer [68Ga]-CCIC16, 
which enabled the identification of tumours expressing high levels of CXCR4 
expression from those expressing lower levels of CXCR4. This achievement and 
several others will now be discussed, along with the challenges and potential 
solutions.  
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4.1 - On the assessment of CXCR4 expression, and cellular 
models 
 
Initial attempts to validate the novel CXCR4-targeting radiotracer [18F]CCIC7 
were impeded by uncertainty regarding the suitability of HCT116 and A549 as 
cellular models of high and low CXCR4 expression, respectively. As outlined 
previously, it was rationalised that the antibody ab2074 was likely subject to a 
degree of nonspecific binding, as predictions of differential CXCR4 expression in 
HCT116 and A549 cells were not supported by qRT-PCR or flow cytometric 
analysis. In contrast, data collected by western blot using the UMB2 clone anti-
CXCR4 antibody used in subsequent experiments showed considerably improved 
agreement with these alternative methods of CXCR4 expression analysis. 
Furthermore, observations of the increased expression in U87.CD4.CXCR4 
compared to U87.CD4 cells predicted by the UMB2 clone antibody were 
supported by increased in vitro uptake of the novel radiotracers [68Ga]-CCIC16, 
[18F]CCIC15 and [18F]CCIC30. These observations point to UMB2 as the most 
suitable antibody for the assessment of CXCR4 expression, and thus that the 
conclusions derived from its use are correct (i.e. that the isogenic U87.CD4 and 
U87.CD4.CXCR4 cell lines represent low and high CXCR4 expression, 
respectively). 
 
Antibodies to GPCRs such as CXCR4 are notoriously unreliable, resulting in cross-
reactivity against related GPCR family members (Michel et al., 2009). More 
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specifically, there is evidence that many antibodies to CXCR4 used in published 
studies are far from optimal, with cross-reactivity against its closest family 
member, CXCR7, as well as the observation of unexpected cellular localisation 
patterns, suggesting non-specificity and leading to erroneous conclusions 
(Fischer et al., 2008). However, in this same publication, Fischer et al postulated 
that the UMB2 clone antibody to CXCR4 was highly specific, in contrast to the 
other antibodies assessed, strongly supporting this study’s favourable 
assessment of its validity.  
 
As such, the results presented in this study appear to confirm that the 
U87.CD4.CXCR4 cell line reliably expresses at least 5-fold more CXCR4 than the 
isogenic U87.CD4 cell line, and higher expression even than Jurkat cells, a known 
expresser of CXCR4 (Hesselgesser et al., 1998). This is in accordance with 
previous reports of the cell lines’ expression profiles (Endres et al., 1996, 
Nimmagadda et al., 2010). This finding, in combination with the observation that 
U87.CD.CXCR4 cells also exhibit significantly more effective wound-closure than 
the CXCR4-negative cell line, confirms that a biologically functional CXCR4 
receptor is overexpressed and therefore that the cell lines are appropriate 
models of differential CXCR4 expression for the development of CXCR4-specific 
radiotracers.  
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4.2 - [68Ga]-CCIC16 validation and HSP90 inhibition 
 
Of all the novel antagonists assessed within this study for use in PET imaging, the 
NO2A-conjugated TN14003 analogue CCIC16 was the most characterised, 
showing potent inhibition of radioligand binding as well as SDF1-directed 
migration. Like many other described CXCR4 antagonists, cationic chelation 
resulted in an increased affinity of CCIC16 for CXCR4 (Demmer et al., 2011, 
Gourni et al., 2011, Hennrich et al., 2012, Gerlach et al., 2003). This 
phenomenon may be explained by the interaction of the metal cations with key 
amino residues of CXCR4 that mediate ligand binding. Mutational analysis of 
CXCR4 has identified Asp262 as being exclusively responsible for the increase in 
CXCR4 binding potency observed as a result of cation chelation to AMD3100 
(Gerlach et al., 2003). Furthermore, analysis of the crystal structure of CXCR4 
when co-crystallised with the peptide antagonist CVX15 has resulted in the 
identification of a number of interactions between CVX15 and CXCR4 (Wu et al., 
2010); as the 16-mer CVX15 shares many characteristics with the 14-mer 
antagonist CCIC16, the proposed interactions of a metal ion-chelated CCIC16 
with CXCR4 are outlined in figure 44. It is possible that the cation is able to 
interact with the electronegative aspartate residues of CXCR4, such as either 
Asp187 or Asp262, enabling higher affinity binding of the cation-chelated CCIC16 
than the unchelated peptide. Future work involving co-crystallisation or 
mutational analysis could confirm the veracity of this hypothesis. 
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The observation that Ga-CCIC16 reliably inhibited CXCR4 binding and function at 
very low concentrations identified it as a candidate for radiolabelling, following  
The observation that Ga-CCIC16 reliably inhibited CXCR4 binding and function at low 
concentrations identified it as a candidate for radiolabelling, following which it was 
found that [68Ga]-CCIC16 bound to in vitro cultures of U87 glioblastoma cells in a 
CXCR4-specific manner. Further investigation in vivo showed that tracer uptake 
in U87.CD4.CXCR4 tumours was 2.1-fold higher than in U87.CD4 tumours, 
CXCR4 
receptor 
Figure 45. Proposed interactions of metal-chelated CCIC16 with CXCR4 
Interactions show  by dashed lines. Suggested hypothetical interactions betwee  chelated 
cation (M) and CXCR4 shown in magenta (?1 and ?2). Adapted from (Wu et al., 2010) and 
(Gerlach et al., 2003). 
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closely reflecting the mean difference in CXCR4 expression between in vivo 
tumour samples, supporting the stance that uptake is specific to CXCR4 
expression levels. The discrepancy in CXCR4 expression fold-differences of the in 
vitro cultures versus the same cell lines growing as tumours in vivo is likely to be 
as a result of a number of factors; primarily that the maintenance of transgene 
expression is likely to be adversely affected by the lack of G418 selection 
pressure in vivo (Kaufman et al., 2008). In addition, CXCR4 expression could  be 
introduced to tumours via other cellular components of the tumour, such as 
infiltrating immunocytes which are widely acknowledged to express CXCR4 (Sica 
et al., 2006); this could account for the CXCR4 expression observed in U87.CD4 
tumours in vivo, where no in vitro expression had been noted.  
 
The potential of [68Ga]-CCIC16 as a radiotracer for the PET imaging of CXCR4-
expressing tumours was further highlighted by signal-to-background uptake 
values and stability in systemic circulation in vivo that enabled an improved 
biodistribution of [68Ga]-CCIC16 in comparison to the previously assessed 
[18F]CCIC7. Also of note is the time-dependent accumulation of radiotracer in the 
bone and spleen, where CXCR4 has previously been reported to be expressed 
(Shao et al., 2011, Federsppiel et al., 1993), suggesting the potential for CXCR4-
dependent uptake in other tissues. The above information paints a picture of 
[68Ga]-CCIC16 as a CXCR4-specific PET radiotracer, with a high affinity for CXCR4 
and potency of subsequent signalling-mechanisms.  
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Despite these features, [68Ga]-CCIC16 exhibits a number of limitations in 
comparison to previously developed radiotracers targeting CXCR4. For example, 
overall tracer uptake in CXCR4-expressing tumours is low at 3.7%ID/ml, 
considerably lower than the 12-102%ID/g range reported for some of the 64Cu-
labelled small-molecular antagonists (Nimmagadda et al., 2010, Weiss et al., 
2011, De Silva et al., 2011). However, 68Ga can be considered a more desirable 
radionuclide due to its high proportion of radioactivity decay by positron 
emission as well the ability for rapid radiolabelling in the absence of cyclotron 
facilities, as the radionuclide is produced instead using cost-effective 
Germanium-Gallium generators.  
 
Furthermore, in contrast to many T140-derived analogues that have been 
functionalised for use in PET imaging (Jacobson et al., 2010, Jacobson et al., 
2011), there was no evidence of high red blood cell uptake interfering with the 
ability of the radiotracer’s ability to accumulate in CXCR4-expressing tumours, 
which considerably simplifies the process of image interpretation. The only 
other reported radiotracers for CXCR4 that have been labelled with 68Ga show 
comparable levels of tumour uptake to [68Ga]-CCIC16, and yet they have not 
validated their results in tumours of low CXCR4 expression (Demmer et al., 2011, 
Gourni et al., 2011), so conclusions of their specificity to CXCR4 cannot be 
confidently made. The data presented with respect to [68Ga]-CCIC16 therefore 
succeeded in the primary aim of the project, which was to develop potent 
antagonists to CXCR4 which could be used as a PET tracer for the detection of 
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CXCR4 in cancer, and represents a competitive addition to the current range of 
available radiotracers for the detection of CXCR4 expression in cancer.  
 
While [68Ga]-CCIC16 proved adept at identifying U87.CD4.CXCR4 tumours from 
U87.CD4 tumours, the use of the tracer to attempt to noninvasively identify a 
17AAG-induced reduction in CXCR4 expression in vivo failed for a number of 
reasons. Firstly, 48 hours daily treatment 80 mg/kg 17AAG resulted in an entirely 
unexpected 2-fold increase in CXCR4 expression, rather than a decrease. 
Secondly, this increase in CXCR4 expression was variable between tumour 
samples, and so the increase observed was not statistically significant. It is not 
likely that the inability to observe a reduction in CXCR4 expression was as a 
result of unsatisfactory HSP90 inhibition, as treatment was marked by a clear 
increase in HSP70 expression. The dose and formulation used is also equivalent 
to that which has been administered in previous published studies to induce 
significant reductions in HSP90 client proteins (Rodrigues et al., 2012, Bagatell et 
al., 2000). Thus the lack of observed reduction in CXCR4 expression is not 
thought to be related to the dosing formulation or regimens. 
 
Given that the CXCR4 protein expressed by U87.CD4.CXCR4 cells is the product 
of transfection with a cDNA sequence to CXCR4 rather than endogenous CXCR4 
protein (Bjorndal et al., 1997), it is possible that high turnover of CXCR4 
expression where CXCR4 expression is driven by a promoter may mask CXCR4 
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degradation as a result of HSP90 inhibition by 17AAG. In support of this 
suggestion, it has previously been reported that cells overexpressing transgenic 
CXCR4 was less susceptible to indirect HSP90 inhibition by histone deacetylase 
inhibitors than cells which expressed CXCR4 endogenously (Mandawat et al., 
2010). It is therefore possible that the U87.CD4.CXCR4 cell line was an 
unsuitable cellular model for the assessment of 17AAG-induced reductions in 
CXCR4 expression. Future work using a tumorigenic cell line of high endogenous 
expression may better illuminate the potential of [68Ga]-CCIC16 in identifying 
changes in CXCR4 expression in response to treatment. The tracer may also be 
suitable for further investigation in alternative applications. For example, 
increases in CXCR4 expression has been described in tumours developing 
resistance to various cancer therapies (Singh et al., 2010, Kioi et al., 2010, 
Dubrovska et al., 2012b); as a result, CXCR4 antagonism is being investigated as 
a sensitiser to therapy. With this in mind, tracers targeting CXCR4 such as [68Ga]-
CCIC16 might be capable of identifying tumours that are developing resistance, 
and therefore indicating situations where CXCR4-targeted therapy may be 
worthwhile pursuing. 
 
4.3 - IC50 determination of cyclic pentapeptide antagonists, 
and structure-activity relationships 
 
The cyclopentapeptide CCIC7 (cyclo[tyr-fluorobenzyl hydroxy arg-arg-nal-gly]) 
was designed with reference to previous observations that the arg2 of FC131 
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(cyclo[tyr-arg-arg-nal-gly]) was less important to the structure-activity 
relationship of lead compound FC131 than other amino residues (Tamamura et 
al., 2005a). However, inhibition of CXCR4-directed migration by the inhibitor was 
not potent, with its half-maximal concentration for the inhibition of migration 
higher than 10 µM. In vivo, tumour uptake of [18F]CCIC7 was hampered by poor 
pharmacokinetics at 60 minutes as well as rapid metabolism into more 
hydrophilic metabolites; even at 5 minutes post-injection the plasma-circulating 
tracer was widely present in  a metabolised form, suggesting that the compound 
was extremely metabolically unstable. In the light of the overall failure of CCIC7 
to adequately target CXCR4, the structure of the current lead compound FC131 
was revisited in order to develop the novel antagonists CCIC15, CCIC29, CCIC30, 
and CCIC36. In developing these compounds, the assumption that arg2 
represented the most favourable site for functionalisation was discarded, as 
CCIC7 failed to show the high potency for CXCR4 and the in vivo stability 
required for use as a PET tracer.  
 
Assessment of the structure-activity affinity of the novel cyclopentapeptide 
antagonists for CXCR4 was impeded by the lack of consistency shown by the 
radioligand binding assay method A (referred to in chapter 2.11i) between 
CXCR4 antagonists of different structural classes. While the small-molecular 
cyclam AMD3100 and T140-derived TC14012 inhibited radioligand binding with 
high potency, reference compounds for other classes of CXCR4 antagonist 
exhibited half-maximal inhibition of SDF1 binding at concentrations hundreds or 
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even thousands of fold higher than expected from published studies (including 
FC131, representing cyclic pentapeptides (Inokuchi et al., 2011, Ueda et al., 
2008), and It1t, representing isothioureas (Thoma et al., 2008). There appeared 
no obvious reason for the problems; the protocol was based upon a previously 
reported method (Jacobson et al., 2012), and was consistent with many 
recommendations for good practice in radioligand binding assays (Bylund and 
Toews, 1993).  
 
After considerable optimisation by trial and error, an alternative protocol was 
settled upon (method B, chapter 2.11ii), and showed a considerable 
improvement in the observed IC50 values of pentapeptide- and isothiourea-
derived CXCR4 antagonists. While an observed IC50 of 600 nM for FC131 is 5-fold 
higher than has been previously reported in a radioligand binding assay 
(Inokuchi et al., 2011), it is worthwhile bearing in mind that with differences in 
method and in cell line that some discrepancies are to be expected. 
Nonetheless, the measurement obtained using the new protocol B reflects at 
least a 30-fold reduction in observed IC50 value for FC131 within the project, and 
is likely to represent a more accurate estimation of its affinity for CXCR4. The 
precise reason for the discrepancy in measured half-maximal concentrations is 
not confidently known, however monovalent and divalent cations have been 
associated in some cases with changes in agonist affinity (Tsai and Lefkowitz, 
1978, Reith and Coffey, 1993). Any changes in SDF1 radioligand binding at CXCR4 
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would ultimately have secondary effects upon the perceived potency of the 
antagonist being assessed.   
 
Using the radioligand binding assay method B, it was found that CCIC30 
(cyclo[tyr-FTA-arg-nal-gly]) was the most potent of the novel pentapeptide 
library investigated in this report. This is consistent with the findings of a 
recently published review, which finds that the Tyr1 is a relatively dispensible 
component of the pharmacophore (Mungalpara et al., 2013). The fluorotriazole 
functional group of CCIC30 is very electronegative, and may allow hydrogen 
bonding to Tyr45 of CXCR4, where the hydroxyl group Tyr1 of FC131 would 
ordinarily interact (Yoshikawa et al., 2012) - see figure 45 for proposed 
interactions of FC131 with CXCR4.  The electronegativity of the fluorotriazole 
may also help to explain the reasonably potent affinity of CCIC15 (cyclo[tyr-FTA-
arg-nal-gly]) for CXCR4; FC131’s polar Arg2  residue is likely well-served by 
replacement with FTA and may help to preserve interactions with CXCR4. Arg3-
fluorotriazole substitution to create a relatively ineffectual CCIC29 (cyclo[tyr-arg-
FTA-nal-gly]) is consistent with the suggested indispensibility of Arg3 as an 
anchor to CXCR4 (Tamamura et al., 2002). Conversely, the least potent of the 
pentapeptide library assayed, CCIC36 (cyclo[tyr-arg-arg-FTA-gly]), replaced the 
hydrophobic naphthylalanine residue with charged FTA, which likely prevents 
the proposed pi-stacking arrangement of His203 with the aromatic ring 
(Mungalpara et al., 2013).  
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Figure 46. Proposed interactions of pentapeptide antagonist FC131 with CXCR4 
Interactions shown as dashed line. Bold amino groups reflect binding positions of CXCR4 
receptor structure. H20 in blue denotes water molecules indicated by crystal structure.  Adapted 
from docking experiments (Yoshikawa et al., 2012). 
  
With the structure-activity relationship of cyclic pentapeptides elucidated, 
further development of a compound more suitable for use as a PET radiotracer 
can be considered. While glycine has not been substituted within this project, 
and glycine does not form part of the pharmacophore of T140, previous 
research has shown that the steric arrangement of glycine in cyclopentapeptides 
is vital for the preservation of affinity for CXCR4, and has so far only successfully 
been replaced with D-alanine (Ueda et al., 2007). For this reason, 
functionalisation at this residue is unlikely to yield satisfactory results. With all 
these findings in mind it can be seen that the structure of FC131 does not allow 
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much scope for functionalisation without compromising potency for CXCR4; 
although numerous studies have systematically substituted amino residues, few 
approach the potency of FC131. However, substitution of key residues in the 
peptide backbone with isosteric amidine groups has been shown to drastically 
improve the inhibitory capabilities of pentapeptide antagonists (Inokuchi et al., 
2011).  In this investigation, CCIC30 has been shown to inhibit radioligand 
binding at lower concentrations than FC131, and so reflects a useful stepping 
stone towards derivitisation of pentapeptides as a radiotracer. Future progress 
with the pentapeptide class of CXCR4 antagonists may potentially come from 
exploring the use of isosteric peptidomimetic bonds in CCIC30-related 
derivatives. 
 
Future work in the development of pentapeptide radiotracers should involve 
steps to improve the poor in vivo pharmacokinetics which were observed with 
tracers [18F]CCIC7, [18F]CCIC15 and [18F]CCIC30, leading to poor tracer uptake at 
CXCR4-expressing tumour. Peptide drugs are notorious for proteolytic instability, 
and so further investigation into the biostability of cyclic pentapeptide 
antagonists with human liver microsomes would be a useful and clinically 
relevant approach for the precise determination of locations susceptible to 
degradation (Asha and Vidyavathi, 2010). While the terminal amino residues of 
many 14-mer T140 derivatives are marked by their vulnerability to degradation 
by the liver (Tamamura et al., 2003), it is not currently clear whether 
pentapeptide derivatives  are similarly affected.  [18F]CCIC7 was subject to 
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extremely rapid metabolism in vivo that precipitated the poor tumour uptake of 
radiotracer at 60 minutes; further analysis to confirm whether degradation 
occurs at the pentapeptide backbone or the amino acid side chains is necessary. 
 
In contrast, [18F]CCIC30 was found to be metabolically stable, and yet was 
rapidly cleared from circulation via the kidneys. Renal clearance is complex and 
therefore can be difficult to predict, however a number of drug qualities are 
associated with rapid clearance rates, including hydrophilicity and ionic state. 
[18F]CCIC30 exhibited a LogD of -2.30, and the presence of positively charged 
arginine residues may contribute to a physiochemical phenotype that is prone to 
secretion at the proximal tubule, perhaps by the organic cation transporter 
(OCT) (Feng et al., 2010). The possibility of this could be investigated by 
competition with cimetidine in a drug-drug interaction (DDI) study. Positive 
identification of elimination via the transporter would initiate a redesign of the 
compound to reduce the potency of the antagonist as a substrate.  
 
4.4 - Potential of small molecular inhibitors of CXCR4 
 
While the development of novel small molecular CXCR4 antagonists based on 
isothiourea and monocyclam compounds progressed only a small distance 
before the end of the project, it is possible to begin to make tentative 
conclusions regarding the structure-activity relationships of the isothioureas. 
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The greatest potential for CXCR4 antagonism appears to be shown by those 
compounds with the least modifications to the structure of the lead compound, 
It1t; the highest potential is indicated within CCIC8 and GG345 – compounds 
almost identical to It1t except for the substitution of one of the cyclohexane 
rings for a fluorophenyl ring. An exception to this apparent rule is GG343, an 
almost entirely inactive fluorobenzoylated derivative of It1t that was fluorinated 
at the adjacent ring carbon to the thiourea linking group, rather than the more 
medial placement of the fluorine within CCIC8 and GG345 (table 14). This vast 
difference in potency for CXCR4 with only very minor differences in structure 
may possibly be explained with reference to the interactions between It1t and 
CXCR4; as shown in figure 46, it can be seen that for It1t the nearby urea forms a 
hydrogen bond with Asp97 of CXCR4. The presence of an electronegative fluorine 
atom at the adjacent carbon of the benzene ring may prevent the protonation of 
the urea group and hence formation of the hydrogen bond between the urea 
and the hydroxyl group of the aspartate residue.  
 
In contrast, with the exception of GG343, by far the least potent compounds 
assayed were GG338 and GG248, which are notable for the fact that both of 
these compounds are missing the second ring group that is typical of It1t and the 
other novel antagonists assayed. This strongly suggests that the presence of a 
ring structure (whether cyclohexane or benzene-derived) is vital to the potency 
of these compounds for CXCR4. In the case of GG248, it is possible that the 
presence of electronegative oxygen and nitrogen atoms might interfere with the 
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formation of hydrophobic interactions that would otherwise form between the 
ring structure of the It1t analogues and the arginine 183 and isoleucine 185 of 
the CXCR4 receptor (refer to figure 46). With GG338, the ring structure 
responsible for these hydrophic interactions is simply absent. Alternatively, it 
may be that the reduced rigidity of these non-cyclic functional groups may 
impede interaction of the It1t analogues at the binding site of CXCR4. The 
explanations above are to some degree supported by the compounds GG366, 
CCIC27 and GG337, which show a more moderate affinity for CXCR4 than the 
more potent It1t, CCIC8 and GG345 compounds. It is possible that larger 
molecular size causes steric hindrance, and higher electronegativity within the 
functional groups may reduce the hydrophobic interactions that aid the binding 
of isothioureas to the CXCR4 binding pocket.  
 
Figure 47. Conclusions on the interactions between It1t and CXCR4, as determined by co-
crystallisation 
Derived from information reported in (Wu et al., 2010).  A Molecular modelling as illustrated by 
Schrödinger software; hydrogen bonds depicted with yellow dotted lines. B Diagrammatic 
representation of It1t-CXCR4 interactions; thin dashed line denote hydrophobic interactions, 
thick dashed lines denote salt bridges and hydrogen bonds. Figures reproduced with permission  
(George, 2013). 
A B 
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With the observation that CCIC8 and GG345 showed the highest potency for 
CXCR4, and therefore the greatest chance of successful development into a PET 
imaging radiotracer, the next step in the development process would therefore 
be the [18F] radiolabelling of the compounds, however as of yet this step has not 
been completed. A reason for the lack of development in this regard is that the 
synthetic process that would enable the radiolabelling of these compounds has 
only very recently been described (Lee et al., 2012) and the use of such a novel 
approach therefore required considerable optimisation, and could not be 
achieved by the associated radiochemists in time for the project’s completion. 
However, the effort in perfecting this approach would likely be well-spent, as 
the compounds show a considerable degree of promise in terms of potency for 
CXCR4. Despite the limited progress of the current developments of the 
isothiourea compounds at present, the investigation discussed here reflects a 
considerable advancement in the development of the compounds for PET 
imaging, as to date there no published research exploring the functionalization 
of isothiourea compounds for radiolabelling. 
 
Lastly, substitution of the AMD3465 pyridine ring for a dimethylamine 
fluorophenyl group created the novel monocyclam antagonist DB011, which 
showed a potency very similar to that of AMD3465 in both radioligand binding 
and migration experiments, showing that derivatives of AMD3465 can 
potentially be radiolabelled with 18F whilst retaining a high degree of affinity for 
CXCR4. Radiolabelled [18F]DB011 shows considerable promise for development 
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as a radiotracer, as the most successful novel CXCR4-targeting radiotracer so far 
was also derived from AMD3465, and showed highest uptake of all measured 
tissues in CXCR4-expressing tumours with an exceptionally high target-to-
background ratio (De Silva et al., 2011). If similar characteristics were to be 
shown by [18F]DB011 in future developments this would reflect an extremely 
competitive addition to the current repertoire of CXCR4-specific radiotracers, as 
the tracer could be expected to bear a number of advantages over the 
previously described [64Cu]AMD3465: Firstly, the use of the more desirable 18F 
would allow images with a greater degree of resolution and with a lower dose of 
ionising radiation to the patient. Secondly, the incorporation of the radionuclide 
through covalent conjugation rather than chelation prevents the occurrence of 
radionuclide transchelation from the CXCR4 antagonist, reducing the likelihood 
of nonspecific uptake of radioactivity in non-target tissues (Boswell et al., 2004).  
 
One characteristic that both the novel isothiourea and AMD3465 derivative 
antagonists share is that they are small molecular compounds; that it to say that 
they are not in any way peptidic in nature. Small molecular compounds such as 
these have a significant advantage over non-peptidic drugs in that they show a 
higher degree of ‘druglikeness’ - the collective observation that many approved 
drugs share the same 5 characteristics, known as the Lipinski rule of 5 (Leeson, 
2012). These include the preferences for a molecular weight of less than 500, a 
LogP value of less than 5, and less than 5 electron donating groups, or 10 
electron accepting groups. Furthermore, as non-peptidic compounds, there is 
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potential for high bioavailability of the compounds in vivo due to a reduced 
vulnerability to metabolism, as shown by previous studies (Thoma et al., 2008). 
It is useful to note that the lead compounds It1t and AMD3465 pass all of these 
criteria (along with the most potent novel antagonist derivatives, CCIC8, GG345 
and DB011), whereas the compounds T140 and FC131 fail on one or more 
counts (table 17). This indicates that the small molecular CXCR4 antagonists may 
show improved characteristics in vivo, and may therefore be more effective than 
the peptidic CXCR4-targeting radiotracers developed thus far. 
Table 17. Comparative table of example CXCR4 antagonists adherence to the ‘Rule of 5’ 
Compound < 500 kDa ?  < 5 EDG ? < 10 EAG ? LogP < 5 ? 
T140 × × × 
FC131 × ×  
It1t    
AMD3465    
 
kDa (kiloDaltons) ; EDG (electron-donating groups) ; EAG (electron-accepting groups) ; LogP (Log 
partition coefficient) ;  signifies compound has passed the indicated criterion, × signifies 
compound has failed indicated criterion. 
 
The most potent small molecular antagonists, CCIC8, GG345 and DB011, clearly 
show potential and would therefore benefit from further research, including but 
not necessarily limited to their radiosynthesis, assessment with in vitro uptake 
assay, and imaging, biodistribution and metabolism experiments in vivo. These 
experiments would go some way toward determination of their suitability as 
CXCR4-specific radiotracers for the detection of cancer. 
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4.5 - Conclusions  
 
The emergence of CXCR4 as a biomarker for disease progression in cancer 
precedes the necessary development of diagnostic tools for its detection in vivo. 
Positron emission tomography with a sensitive radiolabelled probe specific to 
CXCR4 protein would enable rapid noninvasive assessment of the tumour which 
could be applicable to a physician’s judgement of patient prognosis and 
subsequent treatment options. The present study has explored modifications to 
a wide range of available antagonists to CXCR4 to determine their suitability as 
radiotracers of CXCR4 expression.  
 
Most notably, [68Ga]-CCIC16, a novel radiolabelled derivative of the 14mer 
antagonist T140, was found to be a potent inhibitor of SDF1 binding and 
migration in CXCR4 expressing cell lines, and could accumulate in tumours in a 
CXCR4-specific manner, with further evidence of tracer uptake in tissues of high 
CXCR4 expression, including the spleen and bone. [68Ga]-CCIC16 uptake showed 
a favourable target-to-background ratio, and sufficient serum stability to enable 
imaging of the tracer uptake at 60 minutes post-injection. In contrast to many 
previously reported CXCR4-targeting PET radiotracers in development, the 
identification of CXCR4-positive tumours [68Ga]-CCIC16 was not dependent upon 
blockade of non-specific binding by unlabelled antagonist. The tracer also takes 
advantage of several convenient properties of the 68Ga radionuclide, including a 
favourably short half-life, with a high rate of radioactive decay by positron 
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emission, as well as a relatively inexpensive and accessible mode of generation. 
[68Ga]-CCIC16 therefore represents an original contribution to the field of CXCR4 
molecular imaging. 
 
An additional aim of the present study was to determine whether changes in 
CXCR4 expression induced by HSP90 inhibition could be detected using a novel 
radiotracer. An HSP90 inhibitor, 17AAG, was shown to downregulate CXCR4 
expression in treated cells in vitro, which could be identified by the radiotracer 
[68Ga]-CCIC16. Unfortunately, the tracer did not identify untreated from treated 
tumours in vivo, possibly as a result of high receptor turnover by promoter-
driven expression in U87.CD4.CXCR4 cells, masking the effects of CXCR4 protein 
degradation. Future work inhibiting HSP90 function in tumours derived from 
cells expressing CXCR4 endogenously would enable the limitations of this study 
to be overcome, and to confirm whether [68Ga]-CCIC16 detection of CXCR4 
expression could be used to identify response to HSP90-inhibiting therapy. 
 
The present study also investigated functionalisation of the potent pentapeptide 
CXCR4 antagonist, FC131, with limited degrees of success. Substitution of Arg2 
with a fluorobenzyl PEG2 linker to create CCIC7 considerably reduced the affinity 
of the pentapeptide for CXCR4, and in vivo assessment of the radiolabelled 
[18F]CCIC7 was hampered by extremely rapid metabolic degradation of the 
tracer. In a different approach, the effect of substituting a fluorotriazole 
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functional group in various positions of the pentapeptide structure was 
investigated, and found to be extremely well-tolerated at Tyr1 (giving rise to 
CCIC30), and moderately so at Arg2 (resulting in CCIC15). However, in vivo 
assessment of [18F]CCIC30 and [18F]CCIC15 showed that neither radiotracer 
could identify tumours of varying CXCR4 expression; in contrast to [18F]CCIC7, 
[18F]CCIC30 was found to be metabolically very stable, with low systemic 
presence as a result of extremely rapid kidney clearance. The work described 
represents a continuation of developments to optimise pentapeptide 
antagonists for use as radiotracers, and suggests future work to improve 
pharmacokinetics in vivo, including comprehensive analysis of metabolic stability 
and renal clearance.  
 
Lastly, the project explored the functionalisation of a number of potent small 
molecular antagonists of CXCR4, including the monocyclam AMD3465 and 
isothiourea It1t. Substitution of the AMD3465 pyridine ring for a dimethyl 
fluorophenyl group gave rise to the monocyclam compound DB011, while 
functionalisation of the isothiourea It1t by substitution of the cyclohexane group 
with meta- and para-fluorophenyl groups yielded CCIC8 and GG345, 
respectively; all three of these novel antagonists showed excellent affinity for 
CXCR4. While not yet fully developed, the compounds DB011, CCIC8 and GG345 
are ideal candiadates for further investigation as 18F-labelled radiotracers for 
CXCR4 expression, and their development so far represents advances in 
understanding of small molecular structure-activity relationships with CXCR4, 
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and is the first reported attempt to functionalise the little-explored isothiourea-
derived antagonists as radiotracers. Small molecular antagonists such as 
isothiourea and monocyclams show considerable potential as radiotracers as 
they show increased druglikeness compared to either the 14mer peptide or 
cyclopentapeptide antagonists of CXCR4, and may therefore show improved in 
vivo characteristics. 
 
The findings discussed in this report confirm CXCR4 expression as a viable target 
for the molecular imaging of cancer, and presents novel information on the 
structure-activity relationships of a wide variety of antagonists with CXCR4. With 
further development, novel tracers to CXCR4 such as [68Ga]-CCIC16 may enable 
selective imaging of primary tumours prone to progession and metastases, and 
tumours showing signs of resistance to therapy. 
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